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Given the marked personal, social and economic impacts, depressive disorder creates 
significant demands on individuals, health service providers and society as a whole. 
Antidepressant drugs remain the mainstay of treatment for depression for most people 
in contact with healthcare services and the last 20 years have seen dramatic changes in 
antidepressant prescription patterns. Initially, there was an increase in the use of the 
selective serotonin reuptake inhibitors (SSRIs) and subsequently, other novel 
antidepressant agents with different pharmacological mechanisms entered the market. 
Given the range of choices, clinicians must decide about which is the most 
appropriate intervention for their patients. To this end, knowledge regarding the 
relative cost-effectiveness and cost-utility of individual antidepressants is important. 
Therefore, in this thesis, a systematic review was first conducted to assess 
methodological approaches in economic evaluations of pharmacological treatments 
using database analyses. Based on the National Health Insurance Research Database 
in Taiwan, a cost analysis was conducted to identify which demographic and clinical 
characteristics are associated with healthcare costs of patients with depression. 
Compared to patients prescribed SSRIs, those prescribed older antidepressants had 
lower total and psychiatric costs, while patients prescribed serotonin norepinephrine 
reuptake inhibitors (SNRIs), and other newer antidepressants had higher total and 
psychiatric costs. The baseline comorbidities of cardiovascular diseases (CVD) and 
headache were also associated with healthcare costs over the 12-month period. To 
further assess the longer-term economic impacts, a set of database outcome statuses 
(sustained treatment-free status, continuous treatment, and late re-contact) were then 
applied to explore factors associated with outcome status following initial treatments 
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and to examine healthcare costs over the following three years by outcome status. The 
results showed the initial outcome status could exert an impact on total healthcare 
costs in the second and third years after commencing treatments. Finally, 
cost-effectiveness and cost-utility were compared between different categories of 
antidepressant treatments and also to test whether and how the presence of CVD, the 
most prevalent comorbid physical illness in this cohort, affects these results. The 
results showed that SSRIs are more cost-effective than tricyclic antidepressants and 
SNRIs regardless of comorbid CVD. There are various limitations to be considered in 
these analyses, including the limited scope of costs, the lack of clinical information, 
and the adoption of utility scores from previous studies. Further efforts to elucidate 
the relationship between depression treatments, costs and outcomes for longer period 
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Chapter 1. Introduction 
 
1.1. Aims and objectives 
 
The overall aim of this thesis is to apply methods of economic evaluation to assess 
costs, treatment outcomes, and cost-effectiveness of pharmacological treatment for 
patients with depression in Taiwan. 
 
The specific objectives are: 
 To describe the epidemiology of depressive disorders and to summarise existing 
literature on the treatment and consequences of depressive disorders. 
 To undertake a systematic review of published economic evaluations of 
pharmacological treatments for patients with depression to identify existing 
methods and any gaps in the current knowledge. 
 To identify and critically appraise study designs, outcome measures and methods 
of economic evaluation for pharmacological treatments of depression in 
naturalistic settings. 
 To identify and develop appropriate methods for estimating treatment outcomes 
and cost-effectiveness of pharmacological treatments of depression using a 
database analysis. 
 To report the treatment costs of depression and to identify patient characteristics 
(demographic and clinical, including physical comorbidities) associated with 
these costs. 
 To assess the impact of treatment outcomes on future service use and costs. 
 To conduct a cost-effectiveness and cost-utility analysis of pharmacological 
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treatment for depression with a particular focus on the impact of physical 
comorbidities. 
 
1.2. What is depression? 
 
Depression is characterised by low mood, lack of interest, and a range of associated 
emotional, cognitive, physical and behavioural symptoms. The identification of major 
depressive disorder (MDD) is based not only on its severity but also on persistence, 
the presence of other symptoms (e.g. change in appetite and sleep), and the degree of 
functional and social impairment (NICE, 2010). Mood usually remains low 
throughout the course of each day in patients with MDD. However, mood may vary 
diurnally for some people, with gradual improvement throughout the day; for others, 
mood may be reactive to positive events, but these elevations in mood are not 
sustained. Typical behavioural/physical symptoms include irritability, social 
withdrawal, and exacerbation of pre-existing pains, a lack of libido, fatigue and 
diminished activity (Gerber et al., 1992). While there can be reduced sleep and 
appetite, for some people sleep and appetite are increased. A loss of enjoyment or 
interest in everyday life is common, as is suicidal ideation, actual suicide attempts or 
completed suicides. Cognitive changes include reduced concentration, negative 
thoughts about oneself, one’s past and the future, mental slowing and rumination 
(Cassano and Fava, 2002). In sum, MDD exists when a persistent low mood is 
accompanied by a range of other symptoms; the number and combination needed to 




Onset and course 
 
Although the first episode of MDD may occur at any time from early childhood 
through to old age, the majority of people have their first episode during early 
adulthood but another substantial proportion of people have their first episode in 
childhood or adolescence (Fava and Kendler, 2000; Zisook et al., 2007). Individuals 
may experience a range of symptoms in the months prior to the full illness, including 
anxiety and milder depressive symptoms; others may develop severe depressive 
illness rapidly, not uncommonly following a stressful life event (Brown et al., 2010). 
Somatic symptoms may sometimes dominate the clinical picture, leading the clinician 
to first investigate possible underlying physical illness until mood changes become 
obvious. Although depression is highly prevalent in clinical settings, patients may 
tend to report somatic symptoms rather than emotional sufferings. Besides, the 
presence of somatic symptoms with depression may not increase the recognition or 
treatment of depression by physicians (Williams et al., 2003). 
 
Regarding course of illness, a meta-analysis (221 patients from 19 trials) showed that 
20% of untreated patients with MDD improved within four to eight weeks, and 50% 
improved within six months; the authors also estimated that 60% of responders to 
placebo and 30% of responders to antidepressants may experience spontaneous 
resolution of symptoms if untreated (Posternak and Miller, 2001). An earlier study 
followed up 114 patients with untreated depression for six months and found that the 
mean duration of an episode was six months, with 50% remission by 25 weeks 
(Coryell et al., 1994). When treated by psychiatrists with antidepressants, another 
study showed that the median time to recovery for MDD patients was three months, 
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with 26% recovering within one month, 63% within three months, 85% within one 
year, and 88% within two years (Furukawa et al., 2000). Further studies following 
patients with depression treated in general practice settings reported a 67.5% rate of 
recovery during the first six months (Bottomley et al., 2010).  
 
Despite a relatively high rate of initial recovery, incomplete recovery and relapse are 
common for patients with depression in the longer-term follow-up. An earlier study 
showed that only 30% of recovered patients remained in recovery and symptom-free 
during a one-year follow-up (Keller and Shapiro, 1981). The WHO study of mental 
disorders (15 centres, 14 countries) also found that 50% of patients still had a 
diagnosis of depression after one year (Simon et al., 2002). Evidence suggested that at 
least 10% of depressed patients suffer from persistent or chronic depression (Kessler 
et al., 2003). Following the first episode of MDD, at least 50% of people would have 
at least one more episode and, after the second and third episodes, the risk of further 
relapse rises to 70% and 90%, respectively (Kupfer, 1991). People with early onset 
depression and depression occurring in old age have a significantly increased 
vulnerability to relapse (Giles et al., 1989; Mitchell and Subramaniam, 2005). Early 
onset depression seems to imply a genetic influence on disease course and findings 
related to old age depression may underline the importance of assessing other risk 
factors related to patients' age. Therefore, while the outlook for people with a first 
episode seems favourable, the likelihood of recurrent episodes over the long term can 
be high with many patients experiencing depressive symptoms and functional 




Disability and mortality 
 
Globally, depression is a major cause of disability. In 1990, it was the fourth most 
common cause of disability-adjusted life years (DALYs) in the world, and it is 
projected to become the second most common cause by 2020 (World Bank, 1993). It 
was previously estimated that about 1.5 million DALYs were lost each year in 
Western countries due to depression (Murray et al., 1994). A dose-response 
relationship between depression severity and the extent of disability has also been 
proposed (Ormel and Costa e Silva, 1995 ). In patients essentially disability free at 
baseline, depressive illness resulted in a 1.5-fold (at three months) and a 1.8-fold (at 
12 months) increase in risk of onset of physical disability, after controlling for 
physical disease severity. Depressive illness also resulted in a 2.2-fold (at three 
months) and a 23-fold (at 12 months) increase in risk of onset of social disability 
(Ormel et al., 1999).  
 
There are major impacts of depression on social as well as occupational functioning 
(Hirschfeld et al., 2000; Kessler et al., 1999a). Social impairments include reduced 
ability to communicate and sustain relationships. Emotional, motivational and 
cognitive effects of the illness can substantially reduce a person’s ability to work 
effectively, with losses in personal and family income as well as lost contributions to 
society in terms of his/her employment skills and tax revenues. Wider social effects 
may include greater dependence upon welfare benefits. For example, depressed 
workers in the USA reported 1.5-3.2 more work-absence days per month compared to 
people who were not depressed (Kessler et al., 1999a), while in the European Study of 
the Epidemiology of Mental Disorders, depressed workers had three to four times 
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more work-loss days per month (Alonso et al., 2004a). Notwithstanding the impact of 
absenteeism, the greatest cost associated with MDD results from presenteeism or 
reduced productivity while at work (Lerner and Henke, 2008). Taken together, MDD 
is among the most costly of all health problems to employers in terms of work 
absence and productivity loss (Hilton et al., 2010). 
 
Depression can exacerbate the pain, distress and disability associated with physical 
health problems. More specifically, depression combined with chronic physical health 
problems incrementally worsens health compared with physical disease alone or even 
combinations of physical diseases (Moussavi et al., 2007). For a range of physical 
health problems, findings suggest an increased risk of death in the presence of 
comorbid depression (Cassano and Fava, 2002). For instance, depression is associated 
with an 80% increased risk, both of the development of coronary heart disease and of 
subsequent mortality in established disease (Nicholson et al., 2006). The relationship 
between depression and chronic physical disorders will be discussed in more detail in 
Section 1.4. 
 
Although with substantial variation between countries, suicide is another important 
issue that accounts for nearly 1% of all deaths in the general population, with around 
two-thirds of this figure occurring in individuals with depression (Sartorius, 2001). 
Having depression leads to a more than four times risk of suicide than for the general 
population, and the difference is nearly 20-fold in the most severely ill (Bostwick and 
Pankratz, 2000). The National Comorbidity Survey in the USA found that patients 
with MDD had an odds ratio of 11 for suicide ideation and of 9.6 for suicide plans 
(Kessler et al., 1999b; Kessler et al., 1994). Overall, the actual lifetime risk of suicide 
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in MDD may be estimated at between 3.4% and 6% (Nierenberg et al., 2001). In 
addition, the National Comorbidity Study reported a lifetime prevalence of at least 
one comorbid disorder in 74% of patients with depression, including anxiety disorders 
(58%) and substance use disorders (39%) (Kessler et al., 1996). Depression is also 
frequently prevalent in patients with schizophrenia and other psychiatric disorders 
(Enns et al., 2001). It is noteworthy that comorbidity with other mental disorders such 




With disparities attributable to the method of assessment and real differences between 
countries, estimates of the proportion of people who are likely to experience 
depression in their lifetime vary widely between studies and settings, but the best 
estimates may lie between about four and 10% for MDD, and between about 2.5 and 
5% for dysthymia (Waraich et al., 2004). Prevalence rates have consistently been 
found to be between 1.5 and 2.5 times higher in women than men (Waraich et al., 
2004). 
 
The prevalence of MDD varies widely across different cultures (Andrade et al., 2003; 
Weissman et al., 1996). In the 1980s, the lifetime prevalence of MDD as determined 
by the Diagnostic Interview Schedule (DIS) ranged from 1.1% in Taiwan to 19% in 
Beirut (Hwu et al., 1996; Weissman et al., 1996). In the 2000s, the estimated lifetime 
prevalence of MDD increased in most countries, but considerable cross-national 
variability in the lifetime prevalence of MDD still existed (Andrade et al., 2003; 
Kessler et al., 2003; Weissman et al., 1996). For example, the International 
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Consortium of Psychiatric Epidemiology (ICPE) representing 10 countries reported 
lifetime prevalence rates of MDD from 3% in Japan to 16.9% in the USA (Andrade et 
al., 2003). Over the past decades, lower prevalence rates of MDD have been reported 
among Asian countries in several cross-national surveys. For example, a more recent 
survey (conducted between 2003 and 2005), the Taiwan Psychiatric Morbidity Survey 
(TPMS) (Liao et al., 2012), reported a 1.2% life-time prevalence rate for MDD in a 
nationally representative sample of 10,135 adult individuals using a face-to-face 
interview with the paper version of the World Mental Health Survey of the WHO 
Composite International Diagnostic Interview (WMH-CIDI) (Kessler and Ustun, 
2004). 
 
Apart from the significantly lower prevalence of MDD as a disease entity in Asian 
countries than in the West, the prevalence rates of individual MDD symptoms have 
been reported to be lower in Taiwan and Korea, than in the USA when comparing the 
nationally representative samples of TPMS, the Korean Epidemiologic Catchment 
Area Study and the National Comorbidity Survey (Chang et al., 2008; Liao et al., 
2012). There are a range of explanations for the lower prevalence of MDD in 
non-Western countries. One school of thought is that the diagnostic threshold of 
MDD (e.g. DSM) may be higher as people in these non-Western countries may not 
show positive responses to individual symptoms of MDD as often as Westerners do 
and the administration of identical diagnostic measures may identify different levels 
of depression across cultures (Simon et al., 2002). For instance, individuals with 
MDD in Taiwan reported more lost workdays, ranging from 5.8 for no impairment to 
mild impairment to 61.3 for those with severe impairment. Their counterparts in the 
US study had figures of 2.1 and 53.5 respectively (Liao et al., 2012). Similarly, 
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Koreans diagnosed with MDD also showed more work impairment than Americans 
with MDD in their nationally representative samples (Chang et al., 2008). Although 
lost workdays can be influenced by labour market conditions, the finding that the 
severity and the associated functional impairments of MDD diagnosed using the same 
diagnostic measures may be greater in these Asian countries warrants further research 
(Chang et al., 2008; Liao et al., 2012). 
 
Cultural stoicism has been used to explain the lower prevalence of MDD in the 
Taiwanese population; when a Western-designed structured diagnostic interview is 
applied to people who tend to repress their feelings, the culturally determined 
‘response bias’ may lead to a lower estimate of the prevalence of emotional problems 
(Compton et al., 1991). Usually, cultural stoicism refers to a relatively high tolerance 
for or denial of emotional sufferings in these cultures (Hwu et al., 1996). This 
hypothesis is supported by the finding that greater acculturation is associated with a 
greater tendency to report persistent and impairing depressive episodes among 
Chinese people living in Australia (Parker et al., 2005). This stoicism in Taiwanese 
adults may be also reflected in the much lower percentage of help-seeking behaviours; 
only 20% of patients with MDD in a nationally representative sample sought help 
(mental health, general medical, health care, human services, or 
complementary/alternative medicine) in the previous year (Liao et al., 2012), 
compared to 57.3% in the USA (Kessler et al., 2003). After stratification by severity, 
the percentages of MDD cases ever seeking professional help in the TPMS (0% for 
mild severity and 21.7% for moderate severity or above) remained much lower than in 
the US study (35.2% for mild severity and 54.6-70.5% for moderate severity or above) 
(Kessler et al., 2003). Consistently, based on claims data from the National Health 
 27 
Insurance system in Taiwan, the one-year prevalence of treated MDD was found to be 
only 0.35% (Chien et al., 2004). In addition, the percentage of MDD cases (68.9%) 
who reported low perceived need as the reason for not seeking professional help in 
TPMS was higher than the 25.9% reported in the US National Comorbidity 
Survey-Replication (Mojtabai et al., 2011). The tendency that low prevalence of 
diagnosed MDD accompanied by low help-seeking behaviour is found not only in 
Taiwan but also in China, Korea and Japan (Chang et al., 2008; Lee et al., 2007; 
Naganuma et al., 2006), which poses a great challenge regarding depression treatment 
for policy-makers, health providers and society in these countries.  
 
1.3. Pharmacotherapy of depression 
 
Although pharmacological, psychological, and case management interventions are all 
recommended, antidepressant drugs remain the mainstay of treatment for depression 
(NICE, 2009). The last 20 years have seen dramatic change in antidepressant 
prescription patterns all over the world. Initially, there was an increase in the use of 
the selective serotonin reuptake inhibitors (SSRIs), which produced a progressive rise 
in total drug expenditures for antidepressants (Barbui et al., 2001; Lexchin et al., 
2003). Other novel antidepressant agents with different pharmacological mechanisms 
have also entered the market over the past decades. 
 
The placebo effect in trials of psychiatric medications is a concern. Sometimes the 
placebo effect is so large that specific pharmacological effects can be hard to identify. 
There can also be suspicion of publication bias, especially in pharmaceutical company 
funded trials (Lexchin et al., 2003; Melander et al., 2003). In general, antidepressants 
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for depression may offer little or no advantage over placebo for patients with 
subthreshold depressive symptoms or mild depression, who often improve 
spontaneously or respond well to non-specific measures such as emotional support 
and education. However, the evidence does support the efficacy of pharmacological 
treatments with more severe and persistent depression. Systematic reviews using 
meta-analyses suggest that antidepressant drugs, when considered individually or by 
class, are more effective than placebo in the treatment of MDD (Gartlehner et al., 
2008; NICE, 2004). SSRIs are considered to be safer in overdose than tricyclic 
antidepressants (TCAs) and are generally better tolerated than antidepressants from 
other classes. SSRIs are recommended as first-line pharmacological treatment of 
moderate to severe depression in England and Wales (NICE, 2004), and are now the 
most commonly prescribed antidepressants in many countries (including Taiwan, see 
Table 4.1). However, there are still concerns over side effects, which potentially limit 
patients' adherence. SSRIs as a class are associated with headache and gastrointestinal 
symptoms, and a relative higher propensity than other antidepressants to cause 
hyponatraemia and sexual dysfunction. TCAs tend to be associated with 
anticholinergic side effects and a higher likelihood than other antidepressants to cause 
adverse cardiovascular effects including hypotension, tachycardia and corrected QT 
interval (QTc) prolongation. Venlafaxine (a serotonin norepinephrine reuptake 
inhibitor (SNRI)) may be reported to be better tolerated than TCAs but side effects 
like nausea and headache are not uncommon; withdrawal symptoms when stopping 
venlafaxine abruptly sometimes occur. Some of the common antidepressant side 
effects, such as nausea, tend to resolve within the first week of treatment whereas 
others, such as anticholinergic effects and, in some patients, sexual dysfunction, may 
persist. 
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Antidepressant treatment has been reported to be associated with an increased risk of 
suicide, particularly in adolescents and young adults, leading to the recommendation 
that patients should be warned of this potential adverse effect during the early weeks 
of treatment. All antidepressants have been implicated in this risk. Although the 
relative risk of developing suicidal thoughts and acts may be elevated above placebo 
rates in some patient groups, the absolute risk remains very small and is similar 
between all antidepressants (Schneeweiss et al., 2010). Overall, evidence suggests that 
the most effective way to prevent suicidal thoughts and acts is still to treat depression 
(Gibbons et al., 2012). 
 
Despite major developments in the management of depressive disorder, in clinical 
practice, incomplete, or lack of, response to treatment continues to be problematic. 
Many studies have demonstrated that approximately one-third of patients treated for 
depression do not respond satisfactorily to first-line pharmacotherapy. Follow-up 
observations reveal that a considerable number of patients have a poor prognosis and 
as many as 20% remain unwell two years after the onset of illness (Keller et al., 1986). 
Even after multiple treatments, up to 10% of patients remain depressed (Nierenberg 
and Amsterdam, 1990). A number of studies suggest that between 10 and 20% of 
patients with depression have a long-term poor outcome (Lee and Murray, 1988; 
Winokur et al., 1993). Recent evidence has emphasised that clinicians should be 
aware that clinical improvement starts immediately after commencing treatment; early 
improvement is a strong predictor of eventual response which is unlikely if no 
improvement is evident after four weeks of treatment (Anderson et al., 2008; 
Posternak and Zimmerman, 2005). At the present time, there are a variety of strategies 
for improving efficacy following initial non-response, including dose escalation, 
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switching to another antidepressant, and combining the antidepressant with another 
antidepressant, a second drug such as lithium, a second generation antipsychotic drug 
or thyroid hormones. Adjunctive use of psychological therapies, particularly cognitive 
behavioural therapy (CBT), is also supported.  
 
An untreated depressive episode typically lasts about six months (Angst and Preisig, 
1995; Solomon et al., 1997) and, in view of the high recurrence rate if antidepressant 
medication is stopped immediately after response, it is recommended that 
antidepressant treatment is continued for a minimum of six months after remission of 
MDD and the same dose of antidepressant is used in this continuation phase. It is also 
recommended that patients with recurrent MDD should continue to receive 
maintenance treatment (NICE, 2004). There is evidence that patients with residual 
symptoms are at increasing risk of relapse of MDD and the current practice aims to 
achieve remission to prevent future relapses. 
 
Pharmacotherapy of depression in Taiwan 
 
Health care in Taiwan is organised through a government administered system, which 
provides national health insurance (NHI) to all the population. Citizens are eligible to 
receive comprehensive medical care, including preventive health services, clinical 
care, hospitalisation, residential care, and social rehabilitation. Taiwan launched this 
compulsory single-payer NHI programme on 1 March 1995. In 2003, there were 21.9 
million (the population in Taiwan is about 23 million) individuals enrolled in the NHI 
– a coverage rate of 96%. The NHI contracted with 17,022 medical institutions, which 
constituted 93.8% of medical institutions nationwide. Nearly all Taiwanese citizens 
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seek care through NHI (Chan et al., 2006). By the end of 2005, approximately 22.7 
million individuals had been enrolled in Taiwan’s NHI program - a coverage rate of 
98% (Wu et al., 2012). 
 
Unlike other healthcare systems which emphasise ‘gatekeeper’ roles, the insured 
individual in Taiwan can freely access any type of health provider, including clinics 
or medical centres, general practitioners or specialists, within the public or private 
sector. For people living in the mountainous areas and off-shore islands, the NHI 
provides extra funds for an integrated system to deliver primary care and some 
aspects of specialty care; co-payments are waived in those areas. There is usually no 
waiting line. It normally takes about two weeks to receive major surgery at the 
location of a patient’s choice. One of the consequences of such easy accessibility to 
specialists is that the gatekeeper role of family physicians is relatively weak in Taiwan. 
Having limited gatekeeping means there is no check on whether Taiwanese people use 
specialty services appropriately. Indeed, the reported average number of outpatient 
department visits is 14 times per year per person in Taiwan which is higher than that 
in most of countries with well-established referral systems (Wu et al., 2010). To 
promote a referral system and to decrease non-essential outpatient visits, a 
‘non-referral co-payment policy’ has been in operation since July 2005. If insured 
individuals directly access outpatient services in hospitals without a referral, they 
have to pay an extra 60% on top of the normal co-payment charge in local hospitals 
and 70% in regional hospitals and medical centres (Lu and Chiang, 2011). However, 
the out-of-pocket payment is still affordable with study results showing that this 
‘non-referral co-payment policy’ fails to reduce the demand for health care. 
Taiwanese people still prefer to have direct access to larger-sized hospitals and 
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specialist cares (Chen et al., 2012).  
 
All antidepressants can be prescribed by general practitioners or specialists to any 
insured patient. However, SSRIs and other new antidepressants are only reimbursed 
for officially approved indications. The Bureau of National Health Insurance sample 
and audit the claims for unnecessary use or fraudulent claims. Before the launch of 
NHI on 1 March 1995, the available antidepressants in Taiwan included amitriptyline, 
dothiepin, doxepin, imipramine, maprotiline, melitracen/flupentixol, fluoxetine, 
moclobemide and trazodone and two months after the launch, citalopram was 
introduced and reimbursed. By the end of 1997, clomipramine, fluvoxamine, 
paroxetine and sertraline had also been reimbursed. Venlafaxine has been reimbursed 
since 1 February 1999, mirtazapine since 1 April 2002, bupropion since 1 January 
2003, milnacipran since 1 May 2004, escitalopram since 1 February 2005, and 
duloxetine since 1 December 2005 (Wu et al., 2012). 
 
A study using a database of random sample of 145,304 adults provided by the 
National Health Insurance Research Database (NHIRD) in 2004 reported that 
one-year prevalence of antidepressant use in Taiwan was 4.3%. Among those with 
antidepressant use, 21.1% received them for neurotic depression, 17.6% for anxiety, 
14.6% for MDD, 5.4% for depressive disorder not elsewhere classified and 2.6% for 
adjustment reactions. Regarding non-psychiatric medical conditions, the highest 
proportions of antidepressant use were for diseases of the genitourinary system, 
musculoskeletal system and connective tissue (Kuo et al., 2011). Antidepressants, like 
TCAs have an anticholinergic effect (Sawynok et al., 2001) that acts on bladder 
muscarinic receptors, which helps to relax the bladder muscle and contraction of the 
 33 
detrusor, resulting in relief of the symptoms of urgency, frequency, and incontinence 
(Hunsballe and Djurhuus, 2001). There was also high use of antidepressants for 
diseases of the musculoskeletal system and connective tissue. These conditions may 
be variations of the diagnosis of fibromyalgia, which is characterised by the 
symptoms of widespread musculoskeletal pain, persistent fatigue, and non-refreshing 
sleep (Longley, 2006). Furthermore, a large proportion of antidepressant use in 
non-psychiatric disorders may be for their analgesic properties (Atkinson et al., 1999; 
Atkinson et al., 1998; Sawynok et al., 2001). Of diseases of the circulatory system, 
antidepressants are used most frequently for those with hypertension and hypertensive 
heart disease. Their use may be due to depression and anxiety being present in more 
than 50% of patients with hypertension, and combining an antidepressant with 
antihypertensive therapy seems to be of benefit (Vasiuk Iu et al., 2004). 
Antidepressants were also used for diseases of the nervous system and sense organs, 
including mononeuritis, vertiginous syndrome, and migraine for pain relief or 
vestibular balance (Adly et al., 1992; d'Amato et al., 1999). There are some 
hypotheses that using antidepressants may be beneficial in treating dizziness or 
vertigo (Blakley, 1999; Swartz and Longwell, 2005).  
 
In another recent study examining all incident antidepressant use based on the NHIRD 
in Taiwan from 2000 to 2009 (Wu et al., 2012), 53.9% of subjects with mood 
disorders were found to be prescribed SSRIs, 19.3% TCAs, 17.4% trazodone, 11.3% 
other new agents (bupropion, duloxetine, milnacipran, mirtazapine and venlafaxine) 
and 4.6% moclobemide (MAOIs). For these cases of mood disorders, the average 
number of antidepressant prescriptions in the first-year of treatment ranged from 3.2 
to 4.0 across antidepressant classes. In addition, the trend of incident antidepressant 
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use due to mood disorders in Taiwan was shown to increase from around four to five 
per 1,000 population from 2000-2005 and then to decrease to 3.5 per 1,000 population 
in 2009. There are a range of explanations for the decrease in incident use of 
antidepressants. The public concern about safety issues with antidepressant use may 
be important, as US data suggest (Libby et al., 2009; Olfson et al., 2008). Yet given 
the growing body of evidence of the effectiveness of antidepressants for chronic pain 
(Attal et al., 2006; Chou and Huffman, 2007; Chou et al., 2007; Evers et al., 2009; 
Hauser et al., 2010), the decline of antidepressant use for chronic pain was less 
obvious, remaining as the most common single non-psychiatric indication for 
antidepressant prescription in Taiwan (Wu et al., 2012).  
 
1.4. Comorbidities of depression 
 
The presence of comorbid chronic physical disorders is an important issue in the 
treatment of depression. Egede (2007) studied the one-year prevalence of depression 
in 10,500 patients with chronic diseases compared with healthy controls in the USA 
and found that those with chronic disease were almost three times more likely to be 
depressed (Egede, 2007). Compared to healthy controls, rates for depression were 
double in diabetes, hypertension, coronary artery disease and heart failure, and three 
times in end-stage renal failure, chronic obstructive pulmonary disease (COPD) and 
cerebrovascular disease (these comorbidities were also considered in the analyses of 
this thesis). In a WHO study of the one-year prevalence of depression among 245,400 
patients in 60 countries, Moussavi et al. (2007) reported that those with two or more 
chronic physical health problems experienced a prevalence of depression of 23%, 
whereas in healthy controls the rate was only 3.2% (Moussavi et al., 2007). Similar 
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findings are also reported in the WHO World Mental Health Survey (Von Korff et al., 
2009). 
 
Physical illness has been shown to be a risk factor for the development of depression. 
Patten (2001) studied people who were free of depression at baseline in a large 
population-based cohort (n = 11,859); after two years, 3.5% of this group had 
developed MDD and physical illness was a risk factor (OR = 2.5, 95% CI: 1.3-4.6) 
(Patten, 2001). The risk was similar for a wide range of physical health problems, 
namely hypertension, asthma, arthritis and rheumatism, back pain, diabetes, heart 
disease and chronic bronchitis. In a Dutch cohort study of 4,664 participants who had 
never had depressive disorder, 2.7% of the population developed depression after one 
year and the presence of two out of three illnesses (migraine, respiratory problems or 
abdominal problems) predicted the later development of depressive disorder (Smit et 
al., 2004). 
 
There are several ways in which a chronic physical health problem can cause 
depression. First, the number of different ailments a person experiences is directly 
proportional to the prevalence of depression. Dworkin and colleagues (1990) showed 
that patients with a single ailment had no increased risk of depression, those with two 
ailments had double the risk, and those with three or more had five times the risk 
(Dworkin et al., 1990). Second, chronic physical health problems carry the risk of 
disability and this can be very depressing. For example, researchers in the UK (Prince 
et al., 1997) demonstrated in a survey with over 65-year-old people (n = 654) that 
impairment, disability and handicap were strongly associated with depression; the 
adjusted odds ratio for depression in the most handicapped quartile compared with the 
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least was 24.2 (95% CI, 8.8-66.6). Ormel and colleagues (1997) showed similar 
findings in Holland (Ormel et al., 1997). Third, there are physical changes in some 
diseases that may underlie the development of depression, such as changes in the 
allostatic load. The term, allostasis, refers to the ability of the body to adapt to 
stressful conditions. Life stress, tissue damage and degenerative illness all increase 
allostatic load and can induce inflammatory changes which can then result in 
peripheral sensitisation of sensory neurons and activation of central pain pathways 
(Rittner et al., 2003). Taken together, there are a number of ways that depression and 
physical health problems interact with one another (Katon, 2003). For example, 
depression is associated with risk factors such as sedentary lifestyle, which are also 
risk factors for physical health problems. In addition, depression can be linked with 
poorer self-management of chronic physical health problems, which increases the 
burden of the disease. Moreover, the functional impairment associated with physical 
illness, as well as indirect pathophysiological factors (for example, increased cytokine 
levels or other inflammatory factors) may increase the risk of developing and 
worsening depression.  
 
Depression can also precede a new episode of a physical health problem. Systematic 
reviews of 11 prospective cohort studies in healthy populations have shown that 
depression predicts later development of coronary heart disease (OR 1.18 to 5.4, 
median = 2.05) (Hemingway and Marmot, 1999; Nicholson et al., 2006). Nielsen and 
colleagues (1989) reported the occurrence of a depressive episode before an episode 
of myocardial infarction (Nielsen et al., 1989). Depression is also shown to be an 
independent risk factor in stroke (Everson et al., 1998; Larson et al., 2001; Ohira et al., 
2001). The hypothesis is that the increases in proinflammatory cytokines and 
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adrenocortical reactivity in depression may lead to atherosclerosis, and with it 
increased risk for both stroke and coronary artery disease (Wichers and Maes, 2002). 
Besides, in prospective population-based cohort studies, depression has been shown to 
predict the later development of colorectal cancer (Kroenke et al., 2005), back pain 
(Larson et al., 2004) and multiple sclerosis (Grant et al., 1989), and although 
inconsistent, there is some evidence that depression may precede the onset of type 2 
diabetes (Prince et al., 2007). Depression may also increase the likelihood of a person 
developing a physical disease by the immune changes including changes in immune 
cell classes with an increase in white cell counts and a relative increase in neutrophils, 
increases in measures of immune activation, and a suppression of mitogen-induced 
lymphocyte proliferation with a reduction in natural killer cells (Irwin, 1999).  
 
It is believed that depression may lead to a shorter life expectancy (Evans et al., 2005) 
and, therefore, treatment might be expected to prolong life. For example, depressed 
patients were found to be three times more likely to be non-compliant with treatment 
recommendations than non-depressed patients, suggesting that there may be real 
advantages to treating depression among the physically ill (DiMatteo et al., 2000). 
Indeed, van Melle and colleagues (2004) reported a more than double greater risk of 
death with comorbid depression in people with heart disease (van Melle et al., 2004). 
However, the studies required to demonstrate the impact of treating depression on 
prolonging life in the physically ill have not been carried out because they would 
require long follow-up periods accompanied by prolonged treatment of depression 
with a control group not in receipt of such treatment. While randomised trials on the 
treatment of depression may report beneficial effects on outcome measures of 
depression, they often fail to show much effect on the physical illness including heart 
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disease (Berkman et al., 2003; Glassman et al., 2002) or diabetes (Katon et al., 2006; 
Williams et al., 2004). On the basis of a meta-analysis, Gilbody and colleagues (2006) 
conclude that while depression can be treated effectively by collaborative care there 
does not appear to be consistent evidence that such treatment improves physical 
outcomes (Gilbody et al., 2006). 
 
There are other studies which have though found that treatment for depression has 
beneficial effects other than those on depression itself. Simon and colleagues (2005) 
showed improvements in social and emotional functioning, and disability, in a mixed 
group of people with chronic physical health problems (Simon et al., 2005); Mohr and 
colleagues (2007) demonstrated improvements in both disability and fatigue with 
CBT for depression in patients with multiple sclerosis (Mohr et al., 2007); Lin and 
colleagues (2003) showed that treatment of depression in patients with arthritis 
resulted in improved arthritis-related pain, functional outcomes, and better general 
health status and overall quality of life (Lin et al., 2003). Based on those studies, it 
seems that, in addition to reducing depressive symptoms, the treatment of depression 
is effective in reducing functional disability (Von Korff et al., 2009). 
 
1.5. Costs of depression 
 
Depression is among the most disabling illnesses in the world, and accounts for 9.6% 
of all years lived with disability (YLDs) (Vos et al., 2012). There is now widespread 
recognition of the significant burden that depression imposes on people and their 
carers, health services and communities throughout the world. Due to its high 
prevalence and treatment costs, its role as a key risk factor for suicide (Knapp and 
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Ilson, 2002), as well as its large impact on workplace productivity, depression places 
an enormous burden on both the healthcare system and the wider society.  
 
Thomas and Morris (2003) estimated the total cost of depression (including costs for 
primary and secondary care, and indirect costs of lost working days (morbidity) and 
lost life years (mortality)) in adults in England in 2000 (Thomas and Morris, 2003). 
That study found that the direct treatment costs were £370 million, of which 84% was 
attributable to antidepressant medication; the indirect costs of depression were 
estimated to be far greater: Total morbidity costs were £8 billion and mortality costs 
were £562 million. More recently, a review was conducted to estimate mental health 
costs, including for depression, in England (McCrone et al., 2008). That indicated that 
the total cost of services for depression in England in 2007 was £1.7 billion, while lost 
employment increased the figures to £7.5 billion. By 2026, these figures were 
projected to be £3 billion and £12.2 billion, respectively. In contrast to the study by 
Thomas and Morris (2003) (Thomas and Morris, 2003), medication costs accounted 
for only 1% of total service costs while inpatient and outpatient care accounted for 
over 50% (psychiatric inpatients 10%; non-psychiatric inpatients 17%) (McCrone et 
al., 2008). In the USA, an earlier study showed that the total costs of depression in 
1990 were estimated to be US$44 billion, with absenteeism and productivity costs 
accounting for US$24 billion (Greenberg et al., 1993). A Canadian study in 1998 
estimated the total mental health burden to be $14.4 billion, placing mental health 
problems among the costliest conditions (Stephens and Joubert, 2001). One of the key 
findings from the cost-of-illness literature is that the indirect costs of depression far 
outweigh the health service costs. Thomas and Morris (2003) suggested that the effect 
on lost employment and productivity is 23 times larger than the costs for the health 
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service (Thomas and Morris, 2003). Based on UK labour market survey data, Almond 
and Healey (2003) estimated that individuals with self-reported depression/anxiety 
were three times more likely to be absent from work (equivalent to 15 days per year) 
than those without problems of depression/anxiety (Almond and Healey, 2003). A US 
study also suggested that depression is a major cause of reduced productivity while at 
work (Kessler et al., 2001). This reduced workplace productivity is unlikely to be 
adequately measured by absenteeism rates and further emphasises the ‘hidden costs’ 
of depression (Knapp, 2003). Other intangible costs of depression include the impact 
on the quality of life of people with depression and their carers. Indeed, the 
cost-of-illness calculations show that depression imposes a significant burden on 
people, family members, the healthcare system and on the broader economy. It is 
therefore important that efficient use of healthcare resources is made, to maximise 
health benefits for people with depression. 
 
Cost of depression in Taiwan 
 
The economic burden of depression depends on a number of factors, including its 
prevalence and treatment rates, as well as its debilitating nature. Over time, changes in 
any of these factors are likely to affect the estimated burden of illness (Greenberg et 
al., 2003). A study from nearly 20 years ago showed that the total cost of affective 
disorders (including bipolar disorder and major depression) in Taiwan in 1994 was 
US$1.4 billion, 25% of which were direct costs (Yeh et al., 1999). These figures were 
based on a bottom-up approach that surveyed more than 100 individuals and 
generated costs from these individual level data.  
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More recently, a top-down approach was used to measure the burden of depression 
among adults over the age of 15 years in Taiwan for the three years 2000-2002 (Chan 
et al., 2006). Medical claims were characterised in claims data as depression-related 
using International Classification of Diseases, Ninth Revision codes (ICD-9) 
296.00-296.99 (affective psychoses, including: manic disorders, major depressive 
disorders, bipolar affective disorders, atypical manic or depressive disorders, other 
manic-depressive psychosis, unspecified or other specified affective psychoses), 311 
(depressive disorders, not elsewhere classified), and 300.4 (neurotic depression). The 
prevalence data for depression and rates of depression were taken from an estimation 
by the Social and Economic Burden of Depression study in the Asia-Pacific Region 
(Sartorius, 2004), with participants including Taiwan, China, the Philippines, 
Singapore, Thailand, Malaysia, and Pakistan. The results showed that in Taiwan, total 
national health care expenditures in 2000-2002 were around US$9 billion for each 
year. The direct medical costs of depression in 2000, 2001, and 2002 were estimated 
to be US$93 million, US$117 million, and US$140 million, respectively. Medication 
use was found to be an important contributor to health care expenditures for 
depression in Taiwan, accounting for 49.0%, 48.3%, and 48.4% of costs in 2000-2002 
(Chan et al., 2006). Together with the studies showing that antidepressant use in 
Taiwan doubled from 1997 to 2004 (Chien et al., 2007a) as well as the increase in the 
annual treated incidence of MDD from 1.89 per 1000 in 1997 to 2.58 per 1000 in 
2003 (Chien et al., 2007b), the burden of depression treatment in Taiwan has been 









In health care, evidence based decision-making is becoming an established part of 
modern clinical practice. It is increasingly common in many countries for evidence on 
the clinical effectiveness of interventions to be accompanied by an economic 
evaluation, in which the costs of the treatments are analysed alongside the effects. 
There are reasons why economic evaluations are increasingly carried out alongside 
clinical evaluations in health care. For example, in the UK, a report by the King's 
Fund estimated that mental health services have received a large increase in funding 
in recent years (McCrone et al., 2008) and yet resources remain inherently limited. At 
any one time there are a maximum number of mental health professionals working in 
the system, a limited number of inpatient beds available, a restricted budget for 
psychotropic medication and as yet no evidence whatsoever of any limit to demand. 
The benefit of the alternative foregone is what economists call 'opportunity cost' 
(Rutherford, 1995). Every decision to fund a service or treat a patient in a resource 
constrained healthcare system has to be associated with a loss elsewhere and it is this 
loss, or opportunity cost, that is a key focus of economics. 
 
Economic evaluation is concerned with the efficient allocation of available resources 
between alternative uses (Rutherford, 1995). As the people, equipment, and facilities 
of health care are scarce, economics can provide a useful framework in which the 
possible alternative uses of the available resources can be compared. In this way, 
economic evaluation seeks to maximise outcomes from available resources. There are 
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a range of approaches that can be taken to conducting an economic evaluation. These 




A principle of economic evaluation is that it should be comparative, since it is 
concerned with the allocation of scarce resources that could be used for a number of 
different purposes. Consequently, all economic evaluations should involve the 
comparison of at least two groups. The choice of the comparator, e.g. treatment as 
usual or a head-to-head comparison is very important since it will influence the size of 
the difference in costs and effects. In an economic evaluation, the ideal comparator 




The evaluation must establish the perspective that it will take and determine which 
costs will be included and which costs excluded. An evaluation can take a narrow 
perspective, including only the cost of the intervention or programme under 
evaluation, or a wide cost perspective in which the costs of the programme and other 
health care cost, family costs and resources consumed in other sectors are included 
(Drummond et al., 1997; Gold et al., 1996a). For instance, an evaluation of a health 
care programme taking a wide perspective could include health care costs alongside 
resources consumed in other sectors such as social services, the criminal justice sector 
and education. A societal perspective would also include out-of-pocket costs to 
families, such as the costs of transport to hospital and the costs of time taken by 
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An economic evaluation needs good quality evidence on the costs of the resources 
used by the treatment and comparator groups. The perspective will help guide the 
researcher in identifying which costs should be included. It may also be necessary to 
review the literature on the services used being evaluated and to discuss relevant 
services with service users and clinicians. There exist a number of approaches for 
measuring these resources including service use questionnaires and the examination 
of patient records. Once information on service use has been collected, unit costs are 
applied to each piece of service use information and total costs are calculated. In 
economic evaluations, it is common to collect information on use of all resources, 
including apparently unrelated resources, rather than just resources that are associated 




The choice of effectiveness or outcome measure is directly related to the method of 
economic evaluation chosen and these issues are further explored later. Disease- or 
condition-specific outcomes are often used in evaluations of healthcare programmes. 
However, in many cases the consequences of an intervention are multi-dimensional 
and it is difficult to capture these complexities in a single outcome measure (Brazier 
et al., 2007a). Therefore, multiple secondary outcome measures are often used besides 
the primary outcome measure in economic evaluations. Furthermore, economists have 
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another concern: economic evaluations should aid decision-makers who want to 
maximise the healthcare benefits from available budgets across different disease areas. 
Thus, the measure of outcomes should ideally allow the comparison of treatments 
across a range of diseases and conditions, which is very difficult if every disease area 
uses a different outcome measure. This has led to the development of generic outcome 
measure such as the quality-adjusted life-year (QALY). The QALY approach provides 
a single index that combines information both on the length and quality of life 
(Brazier et al., 2007a). It is though evident that QALYs may not be able to capture all 
the benefits of a healthcare intervention (Knapp, 2007). For example, an improvement 
in the health of a patient may impact on the health of their caregiver as well. While 
some of these impacts can be captured in the analysis, it would not always be possible 
to capture all benefits of an intervention in a single index. A fuller discussion of the 




Study design is the means by which data on the costs and outcomes of the two courses 
of action are collected. Data can be collected within a range of study designs and 
ideally data should be collected in a way that minimises bias. Possible study designs 
include randomised controlled trials, observational designs and decision modelling. 
These designs are examined in detail in Chapter 3. 
 
Method of economic evaluation 
 
Data on the costs and effects of the treatment and comparator group are formally 
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compared in a number of ways. Different methods of economic evaluation vary in the 
valuation of outcomes. The most commonly employed methods are discussed below 
and summarised in Table 1.1.
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Table 1.1 Methods of economic evaluation 





Money Single disease-specific 
measure 








Money None; assumed equal 
Cost-benefit analysis Money Money 
 
In a cost-effectiveness analysis, costs are considered alongside disease-specific 
outcomes. A cost-effectiveness analysis can be undertaken using the disease specific 
outcome measures that are collected as measures of effectiveness for the clinical 
evaluation and so the results may be more easily presented to clinicians and/or 
decision-makers. In health care evaluations, the incremental costs and effects of the 
treatment over the comparator are determined and used as the basis for analysis. The 
incremental cost-effectiveness ratio (ICER) is the ratio of differences in costs between 
intervention and comparison groups and the differences in outcomes. This kind of 
economic evaluation is limited by the narrow focus on a single measure of outcome. 
There can be difficulties in evaluating treatments that impact on more than one 
outcome and problems in attempting to compare the results of evaluations across 
disease groups where outcomes have been measured using different measures. 
Cost-effectiveness analysis does though remain a widely used technique especially 
when a decision-maker is considering a limited range of options within a given field 
(Drummond et al., 1997). 
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A cost-utility analysis is similar to a cost-effectiveness analysis but it considers costs 
alongside a utility based outcome measure, usually QALYs. The advantage of cost 
utility analysis is that the results can be compared across different disease areas, 
although criticisms of the use of generic measures to generate QALYs in mental 
health populations should be borne in mind when designing or appraising a 
cost-utility analysis (Chisholm et al., 1997). 
 
In a cost-consequences analysis, costs are presented alongside a range of outcomes. 
Costs and outcomes are not formally combined in this analysis. Cost-consequences 
analysis is a useful approach when little is known on the subject, or when it is difficult 
to identify an adequate primary outcome measure for a cost-effectiveness analysis. 
 
Outcomes are assumed to be, or have been proven to be, equal in a cost-minimisation 
analysis. Since outcomes are the same, the decision is made on the relative costs of 
the intervention and comparator. Cost-minimisation analysis is rarely appropriate 
because there is almost always statistical uncertainty around any measurement of 
outcomes (Briggs and O'Brien, 2001). 
 
In a cost-benefit analysis, outcomes are translated into monetary values so that the 
analysis is able to make a direct comparison of the outcomes and costs. The advantage 
of cost-benefit analysis is that it allows the comparison of different interventions or 
programmes not only across health care, but also other areas, making it broader in 
scope and potential useful (Sugden and Williams, 1978). The main disadvantage is the 
difficulty of assigning monetary outcomes to outcome measures. 
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1.7. Structure of the thesis 
 
In this Chapter, the background to depressive disorders including its prevalence, 
course, pharmacological treatments and physical comorbidities has been examined. 
Some information relating specifically to Taiwan has also been provided. A range of 
methods of economic evaluations have been summarised. 
 
The second chapter contains a systematic review of published economic evaluations 
in antidepressant treatments and aims to identify existing methods of economic 
evaluations in this area and any gaps in the current knowledge. Using the results of 
the review, useful evaluation approaches for subsequent analyses in this thesis have 
been identified. 
 
Chapters 3 and 5 are a critical appraisal for methods of economic evaluation, study 
designs, and outcome measures. In Chapter 3, the study design and methods of 
economic evaluations are discussed. In Chapter 5, appropriate outcome measures for 
cost-effectiveness analysis for antidepressant treatments are considered. 
 
Chapters 4, 6 and 7 report the results of the application of these methods. In Chapter 4, 
the results of an economic evaluation of treatment costs for patients with depression 
and the associated factors including comorbid cardiovascular diseases and pain 
disorders are reported. In Chapter 6, an economic evaluation involving impacts of 
initial treatment outcomes on service use and costs within the following three years is 
reported. In Chapter 7, the results of a cost effectiveness (utility) analysis of 
antidepressants treatments with a particular focus on comorbid cardiovascular 
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diseases are reported. 
 
Finally, Chapter 8 summarises major findings from previous chapters and discusses 
limitations, strengths, and implications of studies in this thesis.
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Chapter 2. Systematic review of economic evaluations of antidepressant 
treatments: evidence from database analyses and prospective studies 
 
This chapter reports results from a systematic review of economic evaluations of 
antidepressant treatments in patients with depression. The focus is on comparisons 
between prospective studies and database analyses. The specific purposes are: first, to 
inform the methodological approach taken in the subsequent evaluation and second, to 
place the results in context. In terms of methods, the review provides information on 
the approach needed for the most appropriate outcome measure for an evaluation in 





An economic evaluation should be preceded by a review of the published literature. 
The investigator designing the economic evaluation may then use the information 
gathered in the review and measure costs in a similar manner, or choose to use the 
same outcome measure so as to make useful comparisons between the results of the 
evaluation and existing evidence. Furthermore, the review helps to identify gaps in the 
knowledge in the existing literature. The investigator might therefore use a specific 
method to explore a particular question. 
 
The prospect of making meaningful comparisons and of identifying gaps in the 
existing knowledge is linked to the above-mentioned second purpose of a systematic 
review, i.e. to place the results of the evaluation once completed in the context of what 
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is already known on the subject. It is also important to note that economic evaluations 
are particularly context specific. For example, studies carried out in the USA may not 
be very informative for study design in Taiwan or the UK. Therefore, a systematic 
review may provide an opportunity to compare results from different settings and 
inform study designs in a specific setting.  
 
In Chapter 1, an initial exploration of the literature suggested that depression is a 
severe and pervasive disorder. Unipolar depressive disorder was the fourth leading 
cause of burden among all diseases in 2002 and its impact will continue to grow in 
future decades (Mathers and Loncar, 2006). Given its marked personal, social and 
economic impacts, depressive disorder creates significant demands on individuals, 
health service providers and society as a whole. Although pharmacological, 
psychological and case management interventions are all recommended, 
antidepressant drugs remain the mainstay of treatment for depression for most people 
in contact with healthcare services (NICE, 2009), which may be partly due to a 
shortage of therapists in some countries. The last 20 years have seen dramatic changes 
in antidepressant prescription patterns. Initially, there was an increase in the use of the 
selective serotonin reuptake inhibitors (SSRIs), which resulted in a progressive rise in 
total drug expenditures for antidepressants (Barbui et al., 2001; Eccles et al., 1999). 
Subsequently, other novel antidepressant agents with different pharmacological 
mechanisms entered the market. Given the range of choices, clinicians must decide 
about which is the most appropriate intervention for their patients (Simon et al., 
1996).  
 
To this end, knowledge regarding the relative cost-effectiveness of individual 
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antidepressants is important, especially for policy makers. In contrast to the 
substantial evidence on efficacy and tolerability of antidepressant treatments from 
randomised controlled trials (RCTs), data specifically addressing cost-effectiveness in 
real-world settings are scarce (Brunoni et al., 2009; Montgomery et al., 2005). At the 
same time, the clinical meaning of the statistical differences in the efficacy or 
tolerability in RCTs remains uncertain (Cipriani et al., 2005; Cipriani et al., 2009) 
because study settings and populations of RCTs are principally protocol-driven and 
operate strict inclusion and exclusion criteria. This limited level of external validity 
makes it difficult to generalise results to the context of routine medical practice.  
 
Given the gap in knowledge from real-world settings, database analyses using 
information from actual clinical practice might provide valuable insights into 
depression treatments for more heterogeneous populations to complement evidence 
from controlled trials. These studies can utilise large administrative databases such as 
medical claims that capture patients’ resource utilisation. However, the 
methodological approaches employed in economic evaluations using database 
analyses have been diverse and there have been few reviews of their strengths and 
limitations. The aim of this review is to systematically assess methodological 
approaches used in retrospective database analyses of the cost-effectiveness of 
antidepressant agents in depression treatment. For comparative purposes, economic 










Studies were identified through a Medline, PsycInfo, and Embase electronic search 
performed with no limits in language but with limits to human studies ranging from 
the year 1999 to 3 September 2010. Three sets of keywords included: cost or cost 
effectiveness or cost benefit or cost utility or cost consequence or comparative 
effectiveness; antidepressant; depression or depress$ or major depressive disorder. 
Reference lists of included papers and previous reviews were hand-searched for 
published reports missed by the electronic search. Unpublished studies/grey literature 




A structured form was designed to record the eligibility of the initially identified 
papers from the electronic search for inclusion in the final review. All located papers 
were first screened by reviewing the titles. The review was initially performed by the 
student with a subsequent check by the first supervisor to identify potentially relevant 
studies. When it was not clear whether a particular study should be included, the full 
paper was reviewed to ensure eligibility. No limitation on the age of study subjects 
was applied. Articles had to meet the following criteria to be included in the review: 
 Comparative analysis of alternative antidepressant treatments (or 
antidepressant versus placebo) for depressive disorders. 
 Studies undertaken based on a database analysis, an RCT (either 
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conventional or pragmatic), or a naturalistic observational study. 
 Economic evaluations, including cost analysis, cost-effectiveness analysis, 
cost-benefit analysis, cost-utility analysis, and cost-consequence analysis. 




A structured form was used for the extraction of information on the year of 
publication, study design, study perspective, length of follow-up, country and setting 
of the study, antidepressants compared, sample size, study inclusion/exclusion criteria 
(including patient age, diagnosis, and certain comorbidities), measurements of 
baseline disease severity (e.g., number of comorbid physical or mental disorders, 
emergency room visits, or hospitalisation before the index date), methods of 
economic evaluation, and funding sources. Additional information on study results 





The outcomes of interest included total healthcare costs, healthcare costs plus indirect 
costs, compliance with treatment, hospitalisation rates, and change in clinical 
symptoms/or quality of life measurements. Results were compared and classified 
according to study designs, i.e., retrospective database analyses, conventional RCTs, 
and pragmatic RCTs plus naturalistic observational studies. A key difference between 
pragmatic RCTs and conventional ones is that the former aim to keep exclusion 
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criteria to a minimum and may often recruit a group of patients with more 
heterogeneous features - a common feature of patients with mental disorders in 
routine practice settings - than those included in conventional RCTs which usually 




A breakdown of inclusion and exclusion is given in the Quality of Reporting on 
Meta-analyses standards (QUOROM) diagram (Moher et al., 1999) in Figure 2.1.  
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As seen in Figure 2.1, the electronic search yielded 4417 studies but an initial review 
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of titles led to the exclusion of 4220 because (A) they did not focus on depression 
treatment, they were not comparative analyses of alternative antidepressants (or 
antidepressant versus placebo), or they did not include costs. For the remaining 197, 
the abstracts were reviewed to identify potentially relevant papers and a further 143 
excluded mainly because (B) on closer examination they were found not to be 
economic evaluations, or they were not based on one of the designated study designs 
to be covered by this review. For the remaining 54, the full papers were reviewed and 
a further 17 excluded because (C) they were not economic evaluations based on a 
database analyses, an RCT, or a naturalistic observational study. Then, (D) reference 
lists of included papers and previous reviews were hand-searched and another three 
studies were identified, thus 40 papers were included in the final review: 28 
retrospective database analyses and 12 prospective studies. 
 
In assessing the quality of economic evaluations of mental health interventions in a 
previous review, Evers et al. (1997) identified a number of common weaknesses in 
study design, including short follow-up periods and lack of justification of sample 
sizes (Evers et al., 1997). In a more recent review of cost-effectiveness of treatments 
for depression, Barrett et al. (2005) highlighted specific difficulties in synthesising 
evidence from various economic evaluations because of the use of different outcome 
scales and different perspectives across studies (Barrett et al., 2005). This is often a 
concern because there has not been a universal outcome scale used for economic 
evaluations even for the same disease entity, e.g., depressive disorders. This is partly 
attributable to mental disorders having impacts on multiple dimensions, but even for 
the same dimensions there are often a number of possible outcome measures to use. 
The key characteristics of the included papers are summarised in Tables 2.1 and 2.2. 
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Follow-up periods for five RCTs were less than or equal to 24 weeks. Fifteen studies 
lasted for six months and the remaining 19 studies for at least 12 months. The 
effectiveness of the treatments was recorded using nearly 20 different outcome 
measures, including treatment persistence and hospitalisation. Only four studies used 
a primary outcome measure of quality of life. Most studies used process or service 
outcomes instead of clinical outcomes. While indirect costs including productivity 
losses may occur as a result of impaired working ability, only 16 papers considered a 
broad perspective of costs and the remainder (n=24) considered only costs to 
healthcare systems. Two of the included studies were carried out in multinational 
settings; another eight studies were from individual European countries, one from 
India, and the remainder (n=29) from North America (Tables 2.1 and 2.2). 
 
Findings from retrospective database analyses 
 
Characteristics and methodological approaches of studies based on database 
analyses 
 
Most included database analyses were carried out in the United States or Canada, with 
one exception which used primary care data from the United Kingdom (Wade et al., 
2010) (Table 2.1). The study populations were mostly adults aged 18 years or above 
(some of them recruited only working-age adults), with the exception of three studies 
focusing on elderly populations (Tournier et al., 2009; Wu et al., 2008a; Wu et al., 
2008b). The majority of these analyses adopted a similar methodology, based on the 
identification of patients who had a paid insurance claim that indicated a diagnosis of 
a depressive disorder and treatment with antidepressants. Diagnoses of a depressive 
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disorder included major depressive disorder and dysthymic disorder (or neurotic 
depression) in most studies; several studies recruited only subjects with major 
depressive disorder and one study focused exclusively on subjects with severe 
depression (Wade et al., 2010). Another three studies recruited subjects with a 
diagnosis of either depression or anxiety disorder (Sheehan et al., 2004; Sheehan et al., 
2005; Sheehan et al., 2008) while the others also included subjects with a diagnosis of 
bipolar depression (Griffiths et al., 1999; Sullivan et al., 2000) or bipolar disorder 
(Ackerman et al., 2002). In these studies, the impact of ‘pure’ depression would be 
difficult to estimate due to the recruit of mixed populations.  
 
The most often used proxies for baseline clinical characteristics were number of 
concomitant disease states and baseline healthcare utilisation, e.g. the number of 
emergency room visits or hospitalisations before the index date. An intention-to-treat 
(ITT) principle was applied in most cases and patients were assigned to a drug cohort 
on the basis of their initial prescription, with resource utilisation data over a specified 
study period after the first prescription analysed and compared between drug cohorts. 
Compared to an RCT, more sophisticated statistical methods would be needed in 
database analyses to address the likely systematic differences in the baseline 
characteristics across subjects from different drug cohorts due to the non-random 
assignment of treatments. The most commonly used methods in the reviewed studies 
to account for such differences have been regression modelling. More recently, 
methods based on propensity scores have been proposed to reduce or eliminate the 
effects of confounding in observational studies (Austin, 2011) but only one study was 
found to use a propensity score-adjusted method (Wade et al., 2010) in this systematic 
review. The propensity score was defined to be the probability of treatment 
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assignment conditional on observed baseline characteristics. Conditional on the 
propensity score, the distribution of measured baseline covariates was similar between 
subjects receiving different interventions. Therefore, under certain assumptions, 
conditioning on the propensity score allows one to obtain unbiased estimates of 
average treatment effects. Four different propensity score methods are often used for 
removing the effects of confounding when estimating the effects of treatment on 
outcomes: propensity score matching, stratification (or sub-classification) on the 
propensity score, inverse probability of treatment weighting using the propensity 
score, and covariate adjustment using the propensity score (Austin and Mamdani, 
2006; Austin, 2011). 
  
A healthcare perspective for costing was adopted in all studies, although some of them 
also took into consideration out-of-pocket payments by patients including copayments, 
coinsurance, and/or deductibles (Table 2.1). Among the 28 database studies, seven 
were cost analyses, and the remaining 21 were cost-consequence analyses where costs 
were reported alongside a range of outcome measures. Treatment persistence, odds of 
hospitalisation, and guideline adherence were the most frequently used outcome 
measures (although from an economic point of view service use such as inpatient 
stays is more correctly seen as an input rather than an outcome). Study periods ranged 
from six to 24 months. Of the 28 included studies, 23 were funded by pharmaceutical 
companies. In one of the two studies funded by government agencies (Ackerman et al., 
2002; Tournier et al., 2009), the authors provided consultancy services to the 
pharmaceutical industry (Tournier et al., 2009). In a further two studies in which 
funding sources were not stated, the authors either provided consultancy services to 
the pharmaceutical industry (Sheehan et al., 2005) or were employees of the 
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pharmaceutical companies (Poret et al., 2001). Only one study declared no conflicts 
of interest (Chung, 2005) (Table 2.1). It is thus important to interpret these results 
taking into consideration competing interests as it is reasonable that pharmaceutical 
companies may tend to publish favourable results. 
 
Economic evaluations comparing antidepressants using database designs 
 
Four studies were primarily designed to compare escitalopram with other 
antidepressants. Escitalopram was shown to have better treatment persistence and 
lower total healthcare costs compared to other SSRI/SNRIs in a large sample of adult 
patients (Wu et al., 2008b; Wu et al., 2009). In another study which included severely 
depressed adult patients, there were significantly fewer hospitalisations per patient in 
the escitalopram versus venlafaxine or generic SSRI groups and the total annual 
healthcare expenditure per patient was lower in the escitalopram group compared to 
venlafaxine but similar between escitalopram and generic SSRIs (Wade et al., 2010). 
Escitalopram was shown to have better treatment persistence, a lower hospitalisation 
rate, and lower total healthcare costs than citalopram in a geriatric population (Wu et 
al., 2008a). These studies were funded by the same pharmaceutical company and 
escitalopram was the antidepressant of interest in all of them. 
 
In a comparison between venlafaxine XR (a form of extended-release venlafaxine) 
and SSRIs (citalopram, fluoxetine, paroxetine, and sertraline), better treatment 
persistence was found for the former but total direct medical costs were comparable 
(Monfared et al., 2006). Patients prescribed with venlafaxine were reported to have 
lower odds of hospitalisation for non-mental-health reasons than those prescribed with 
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SSRIs, while total healthcare costs were similar between the two groups. However, 
some other studies failed to demonstrate differences in treatment persistence between 
venlafaxine XR and SSRIs (Wan et al., 2002a, b). Two cost analyses with similar 
study designs revealed that total medical expenditures were generally similar among 
patients receiving venlafaxine, SSRIs, or TCAs as a second-line therapy for 
depression (Griffiths et al., 1999; Sullivan et al., 2000). Another study comparing 
healthcare costs of patients who switched antidepressants versus those who did not 
found that switchers had higher total healthcare costs than non-switchers. For patients 
switching from an SSRI to venlafaxine, mean medical cost reductions offset higher 
pharmacy costs of venlafaxine after the switch, and for those switching from 
venlafaxine to an SSRI, mean medical and pharmacy costs declined after the switch 
(Khandker et al., 2008). Each of the above studies was again funded by the same 
pharmaceutical company. Another study, funded by a government agency (Tournier et 
al., 2009), showed similar treatment persistence and costs for medical service 
utilisation and psychiatric hospitalisation between venlafaxine (n=1937) and SSRIs 
(n=8186). 
 
There were 12 database analyses included in the review that used TCAs as a 
comparator treatment. One study showed that patients treated with SSRIs were more 
likely to meet treatment duration recommendations than those treated with TCAs, and 
among compliant patients the mean total healthcare costs were lower for SSRIs 
(Baker et al., 2001). SSRIs were shown in a bivariate probit model to reduce patients 
discontinuing pharmacotherapy compared to TCAs, but total healthcare charges were 
similar between the two groups (Dobrez et al., 2000). Despite comparable total 
healthcare expenditures between treatment groups, SSRI users were shown to have 
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higher depression-related service expenditures but lower non-depression-related 
service expenditures than TCA users (Sullivan et al., 2000). It was further revealed by 
Baker et al. (Baker et al., 2001) that among patients compliant with treatment duration 
recommendations, non-depression-related costs were lower for those prescribed 
SSRIs than for those prescribed TCAs (Baker et al., 2001). There was also evidence 
suggesting that SSRIs reduced overall outpatient visits and the use of other 
prescription drugs, but resulted in increased utilisation of services for depression, 
which then cancelled out the potential cost advantage of SSRIs over TCAs (Chung, 
2005). Although speculative, SSRIs were shown to be associated with reduced 
non-depression-related expenditures which may be due to lower use of other 
prescriptions for depression-related somatic symptoms and better engagement in 
depression treatment. 
 
Compared to patients prescribed TCAs, fluoxetine patients were shown to be half as 
likely to be hospitalised (Croghan et al., 2000) and to have lower total healthcare costs 
(McCombs et al., 1999). Similarly, citalopram was reported to result in better 
treatment persistence and lower total healthcare costs than the TCA amitriptyline 
(Sclar et al., 1999). Lower nursing home and other costs were found in a comparison 
of sertraline versus TCAs (McCombs et al., 1999), but another study revealed a 
similar likelihood of hospitalisation for patients initially prescribed sertraline and 
TCAs (Croghan et al., 2000). In a study comparing bupropion SR (noradrenaline 
dopamine reuptake inhibitor) with other antidepressants, total healthcare costs were 
shown to be lower for patients treated with bupropion SR than for those treated with 
TCAs and in comparison with bupropion SR, patients initiating therapy with sertraline 
had significantly higher mental health payments (Poret et al., 2001).  
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Turning to comparisons between different SSRIs, the results were largely mixed. A 
head-to-head comparison favoured sertraline in having lower depression-related costs 
than citalopram (McLaughlin et al., 2004), but a contradictory finding emerged in 
another study favouring citalopram in having lower total and depression-related 
healthcare costs (Sclar et al., 1999). Likewise, sertraline was shown to have lower 
total and depression-related costs than fluoxetine in one study (Berndt et al., 2000), 
but in another study, fluoxetine was shown to have better treatment persistence than 
sertraline and paroxetine while total healthcare costs were similar between 
antidepressant groups (Polsky et al., 2002; Russell et al., 1999) as were total 
healthcare costs in another study (Crown et al., 2001). One study examined the 
‘cost-persistence ratio’ in a comparison of SSRIs (Tournier et al., 2009). Persistence 
was considered as an indicator of effectiveness because premature discontinuation is 
often a consequence of treatment failure related to adverse effects, or absence of 
clinical benefits; non-persistence was defined as treatment duration of less than 180 
days in a follow-up period of 12 months. Paroxetine was shown to have the most 
favourable results (lower cost-persistence ratio), but fluoxetine was considered the 
best choice in terms of incremental cost-persistence ratio (the difference in costs 
between the two treatments divided by the difference in outcomes - frequency of 
persistent treatments - between the two treatments). 
 
Beyond comparisons between different antidepressants, one study of patients with 
major depressive disorder revealed significantly higher total healthcare costs for those 
not receiving any initial psychotropic medications compared to either those treated 
with TCAs or SSRIs (Optenberg et al., 2002). Further research compared the same 
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antidepressant compounds with different release patterns. Paroxetine CR was shown 
to have better treatment persistence and lower medical costs relative to paroxetine 
immediate release (IR) (Sheehan et al., 2004). Elsewhere, compared to other SSRIs 
(including paroxetine IR) as a group, paroxetine CR was also shown to have lower 
medical costs (Sheehan et al., 2005). Several studies principally focused on hospital 
charges (Ackerman et al., 2002; Croghan et al., 2000). In one of them, initial use of 
heterocyclic agents was shown to be associated with higher hospital charges than 
monoamine oxidase inhibitors (MAOIs), SSRIs and venlafaxine, despite the major 
cost drivers being other more expensive procedures, e.g. electro-convulsive therapy, 
rather than choices of antidepressant treatments (Ackerman et al., 2002). The 
remaining study defined all antidepressants launched after 2002 as ‘third-generation 
antidepressants’ (bupropion XL, duloxetine, venlafaxine XR, escitalopram, paroxetine 
CR) and reported that newer generation antidepressants were associated with lower 
total medical costs (excluding pharmacy costs), lower odds of all-cause 
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Findings from economic evaluations comparing antidepressants using 




Findings from conventional RCTs were also reviewed. Four of the six conventional 
RCTs included were head-to-head cost-effectiveness comparisons between 
antidepressant treatments for patients with major depressive disorder. Three of these 
compared the cost-effectiveness of escitalopram with duloxetine (for those aged 18-65)  
(Wade et al., 2008), citalopram (18-65) (Fantino et al., 2007), and venlafaxine (18-85) 
(Fernandez et al., 2005), respectively. The results revealed that escitalopram appeared 
as a dominant strategy compared to either duloxetine or citalopram and it had similar 
effectiveness but lower costs compared with venlafaxine. The other head-to-head 
comparison examined the cost-effectiveness of mirtazapine versus paroxetine and 
suggested that mirtazapine may be a more cost-effective treatment choice (Romeo et 
al., 2004).  
 
In the remaining conventional RCTs, fluoxetine was compared to placebo or 
psychological treatment for the management of common mental disorders in adults 
(Patel et al., 2003) and major depressive disorder in adolescents (Domino et al., 2008). 
Fluoxetine was shown to be more cost-effective than placebo and psychological 
treatment over both the short term (two months) and long term (12 months) in the 
former study (Patel et al., 2003) and in the latter one, fluoxetine was more 
cost-effective than placebo treatment when the threshold of $100,000 per 
quality-adjusted life year (QALY) was applied (Domino et al., 2008). 
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With the exception of one study which adopted a healthcare payer perspective with a 
societal perspective considered in a sensitivity analysis (Fernandez et al., 2005), all 
the conventional RCTs estimated costs from a broader societal perspective, either 
healthcare with loss of productivity costs (Fantino et al., 2007; Romeo et al., 2004; 
Wade et al., 2008) or healthcare with patient and/or family costs (Patel et al., 2003). 
The outcome measures used in these conventional RCTs included the Sheehan 
Disability Scale score (SDS), Children’s Depression Rating Scale-Revised, 
Montgomery-Asberg Depression Rating Scales Self-reported (MADRS-S), EQ-5D (a 
health-related quality of life measure), 17-item Hamilton Depression Rating Scale 
(HDRS-17), remission, and psychiatric morbidity rated by the Clinical Interview 
Schedule, Revised (CISR total score). Study periods ranged from eight to 24 weeks, 
with the exception of Patel et al (Patel et al., 2003) which measured and compared 
cost-effectiveness over 12 months (Table 2.2).  
 
Pragmatic RCTs and naturalistic observational studies 
 
Compared to conventional RCTs, pragmatic RCTs aim to inform decisions about 
clinical practice by testing effectiveness with relatively unselected participants and 
under flexible conditions. There were five pragmatic RCTs and one naturalistic 
observational study included in this review (Table 2.2). From a societal perspective, 
imipramine (a TCA) was shown to be a more cost-effective treatment than fluoxetine 
in a six-month randomised prospective naturalistic study as the similar level of 
effectiveness was counteracted by lower total costs for the imipramine group 
(Serrano-Blanco et al., 2006a). Imipramine was also found to dominate fluoxetine (i.e. 




The remaining three pragmatic RCTs adopted a healthcare payer perspective. One of 
them compared TCAs, SSRIs and the modified TCA lofepramine as first choice of 
treatment for depressive disorder in primary care, and revealed no significant 
differences between the antidepressants in either outcomes or costs during the 12 
months of follow up. The cost-effectiveness acceptability curves suggested that SSRIs 
were likely to be the most cost-effective option although the probability of this did not 
rise above 0.6 (Peveler et al., 2005). In a sample of depressed patients in primary care, 
randomisation to fluoxetine or a TCA (desipramine or imipramine) led to similar 
clinical outcomes and overall treatment costs for 24 months (Simon et al., 1999). 
Using the number of hospitalisation-free days as the effectiveness measure, one 
pragmatic RCT compared groups defined by initial use of antidepressants 
(amitriptyline, citalopram, and fluoxetine) and revealed no differences in either 
depression treatment costs or effectiveness over the period of six months (Hosák L et 
al., 2000). 
 
From a societal perspective, the only non-randomised prospective six-month 
follow-up naturalistic study showed that fluoxetine dominated paroxetine and 
citalopram and had a high probability of being more cost-effective than sertraline 
(Serrano-Blanco et al., 2006b). Overall, half of the included pragmatic RCTs and the 
naturalistic observational study adopted the healthcare payer perspective while the 
others estimated costs from a broader societal perspective. The outcome measures in 
these studies included the EQ-5D, MADRS, depression-free weeks, 
hospitalisation-free days, HDRS score, the Medical Outcomes Study SF-36 Health 
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Survey (SF-36), the anxiety and depression subscales of the Hopkins Symptom 
Checklist (SCL), and remission. The study periods ranged from six to 24 months 




Summary of main results comparing database analyses and prospective studies 
 
Based on the available evidence from both database analyses and conventional RCTs, 
depressed patients prescribed escitalopram had lower total healthcare costs than those 
prescribed other SSRIs, and escitalopram appeared more effective in terms of 
treatment persistence and clinical symptom measures like Montgomery-Asberg 
Depression Rating Scales Self-reported (MADRS-S). Compared to venlafaxine, patients 
prescribed escitalopram in some studies had lower total healthcare costs. The validity 
of applying these results to depressed patients with anxiety disorder has not been 
established. 
 
In database analyses, patients using TCAs generally had comparable healthcare costs 
to those using SSRIs, while in some studies, higher non-depression related costs and 
lower depression related costs were found for TCA users. Other database studies 
reported that SSRI users had greater treatment persistence and lower total healthcare 
costs than TCA users. Different results emerged from prospective studies. From a 
healthcare payer perspective, patients prescribed TCAs were shown to have 
comparable costs and clinical outcomes to SSRI users in pragmatic RCTs (Hosák L et 
al., 2000; Peveler et al., 2005; Simon et al., 1999). However, from a societal 
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perspective, TCA users in pragmatic RCTs, had similar or even better outcomes but 
lower total costs than SSRI users (Serrano-Blanco et al., 2006a; Serrano-Blanco et al., 
2009).  
 
Without randomisation, the above results comparing TCAs with SSRIs in database 
analyses may reflect physician choice based on heterogeneous presentations of 
depressed patients that could not be captured by demographic factors or proxy 
variables for disease severity used in the included studies. The findings that TCA 
users had higher non-depression-related costs and lower depression-related costs than 
SSRI users also implied that in real-world settings, patients prescribed TCAs are 
probably different from SSRI users in terms of clinical features of depression or 
comorbid physical illnesses. When randomisation was applied in a pragmatic RCT, 
TCA users were shown to have equal or better outcomes than SSRI users and total 
costs were found to be equal or even lower for patients prescribed TCAs. It is also 
worth noting that the cost-effectiveness advantage of TCAs over SSRIs revealed in 
the pragmatic RCTs (but not in the database analyses) may not be driven by the lower 
drug acquisition costs of TCAs considering that the wider societal cost perspective in 
the pragmatic RCTs would mean the contribution of drug acquisition costs to total 
costs is very low. Therefore, the cost-effectiveness differentials between TCAs and 
SSRIs among these studies are likely to be driven by other factors that warrant further 
research.  
 
Strengths and limitations of economic evaluations using database analyses 
 
Database analyses can supplement RCTs to inform decision-making in actual clinical 
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practice, as conventional RCTs may not accurately reflect the real-world 
cost-effectiveness of competing antidepressant treatments (Crown, 2000). Appropriate 
allocation of scarce resources among competing choices is a fundamental policy 
concern. Economic evaluations conducted within the context of conventional RCTs 
may not be sufficient to inform decision-making, considering that individual 
behaviour in conventional RCTs is controlled through a strict, protocol-driven 
environment. In light of these considerations, more flexible study designs are 
employed in pragmatic RCTs to measure cost-effectiveness in a situation closer to the 
real-world settings. Despite that, the randomisation procedure makes physician choice 
and other important factors influencing initial choice of antidepressant treatment in 
real-world settings unobservable. 
 
Economic evaluations based on RCTs may be underpowered. The sample size of an 
RCT is usually calculated according to clinical rather than economic criteria, and a 
much larger sample may be needed to determine the significance of economic 
outcomes (Briggs, 2000). Although modeling and other methods have been widely 
used in recent economic evaluations, these approaches rely heavily on assumptions 
that may not be easily testable. By contrast, retrospective database analyses using 
routine administrative data can offer quick access to large samples of patients in 
naturalistic settings. Besides the advantages of lower research costs and larger sample 
sizes than RCTs, database analyses potentially assess economic outcomes over longer 
periods of follow-up and from more heterogeneous populations, and hence are 
capable of supplementing RCTs to inform decision-making.  
 
Despite these strengths, several limitations should be borne in mind when interpreting 
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results from database analyses. Lack of clinical data on effectiveness is clearly a 
major issue. Many database analyses in this review focus on comparisons of costs. 
Among studies comparing costs and outcomes simultaneously, persistence of 
treatment and rate of hospitalisation are frequently used as proxies for clinical 
effectiveness. There are concerns regarding the use of these proxies; for example, 
poor outcome tends to be assumed for individuals who discontinue their index 
antidepressants without taking into consideration fast responders or patients with 
milder disease severity. The use of hospitalisation rate as an effectiveness index may 
be problematic as it is also a resource measure (and hence potentially included in the 
measurement of cost). Also, use of hospitalisation is influenced by its supply. Efforts 
to develop alternative methods for obtaining effectiveness measurements have been 
noted in the literature, such as the application of expert panels to estimate health 
values (as an effectiveness index) of alternative treatment patterns (Watkins et al., 
2009). In that study, a panel of 13 clinical experts made a series of utility ratings for a 
range of clinical profiles before any new treatment, three months later with no new 
treatment and three months after initiating various common treatments. Clearly, 
further efforts should be made to incorporate newer approaches to effectiveness 
measurement in administrative database analyses. 
 
Compared to the more recent RCTs, database analyses usually adopt a narrower 
definition of costs, do not include services outside the health area, and so are unlikely 
to adequately detect the impact of treatment on loss of productivity and employment 
and other areas that may contribute substantially to the overall costs of depression 
(Thomas and Morris, 2003; Wang et al., 2003). 
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There are also biases to be considered in database analyses. Confounding or selection 
bias due to nonrandomised study design is clearly important. For example, a patient’s 
medical and social history, disease severity, and a physician’s characteristics may 
influence both the initial choice of antidepressant and the subsequent outcome. To 
address this heterogeneity issue, strategies including matching (Sheehan et al., 2004) 
and the use of propensity score techniques (Wade et al., 2010) have been used. 
Furthermore, the reverse causality between medical care utilisation and drug choice 
can be minimised through defining the drug choice at baseline and estimating 
utilisation during the following period. While this limits potential attempts to compare 
treatment effects in a counterfactual scenario using database analyses, it also is 
cognizant of the real-world situations in which physician preferences and 
heterogeneity of clinical presentations influence both antidepressant choice and 
cost-effectiveness outcomes for a patient with depression.  
 
Publication/sponsorship bias would be another major concern as complex statistical 
analyses could leave the results open to a degree of subjectivity. Since 23 out of the 28 
database analyses included in this review were sponsored by the pharmaceutical 
industry and another three studies had authors affiliated with pharmaceutical 
companies, the potential for overestimation of effect due to sponsorship should be 
kept in mind, especially when no company has apparently published data that indicate 
their compound to be less cost-effective than a rival. Of course, this consideration 
applies to many randomised trials too. 
 
In this review, the antidepressant of interest was usually new or just available in the 
months leading up to the study, while the comparator drugs were mostly well 
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established and continuously available. Many physicians might not be able to 
prescribe newer antidepressants in the beginning of the study period and might have 
had inadequate time to gain sufficient experience with them. Some of them might 
preferentially prescribe newer antidepressants to those patients refractory to previous 
treatment, a tendency that has been called ‘channeling’ or ‘allocation bias’ (Egberts 
AC et al., 1997). However, the reverse might also be true, if not more common, i.e. to 
prescribe newer antidepressants to patients with milder disease to gain more clinical 
experience while the perceived mild side effects would not harm patients. For 
example, patients who are able to work may be prescribed newer agents because these 
drugs are perceived as less disruptive and more tolerable. The timing of studies 
therefore might affect the economic outcomes presented due to the different intervals 
from the launch dates of competing antidepressants. 
 
Furthermore, diagnostic heterogeneity in the studied populations was noted (Table 
2.1). These differences may act as confounders when assessing the relative 
cost-effectiveness of the various antidepressants. 
 
Although most of the included database analyses adopted an intention-to-treat (ITT) 
design, this approach may not be directly transferrable from the analysis of RCTs 
where it was originally used. The most important aim of ITT is to maintain treatment 
groups that are similar apart from random variation. In database analyses, patients are 
of course not randomised to treatments and the possibility for selection bias must be 
addressed by statistical methods other than ITT analysis. Furthermore, the second 
fundamental idea behind ITT is to reduce bias that might be introduced by excluding 
patients who did not complete the originally assigned course of therapy from the 
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analyses (Gillings D and Koch G, 1991). Yet, most database analyses excluded those 
not continuously enrolled in the insurance programme during the study period, hence 
bringing in possible bias. 
 
With the exception of one study from the United Kingdom (Wade et al., 2010), all the 
database analyses are from the United States or Canada and so all studies are from 
Western developed countries. Generalisability of effectiveness and cost data across 
different countries might not be straightforward. Not only do prescribing costs differ 
dramatically between settings, but also healthcare systems are organised in very 
different ways. Differences are certainly evident when comparing high- to low- and 
middle-income countries (Dixon et al., 2006; Knapp et al., 2006). Moreover, many of 
the included studies are based on private insurance databases in which the subjects 
might be healthier, with different socioeconomic characteristics, or provided with 
different antidepressant choices compared to people with public insurance or no 
insurance (Chung, 2005; McCombs et al., 1999). Future research is needed from 
developing countries and covering different insurance systems, as well as a wider 
range of populations. 
 
Cost-effectiveness data for populations with different characteristics/comorbidity are 
not available. Despite studies comparing the characteristics across subjects initially 
treated with individual antidepressants, there have been no cost-effectiveness 
comparisons of individual antidepressant treatments across specific populations with 






This review suggests database analyses are an important source of evidence of the 
potential cost-effectiveness of alternative antidepressant treatments. Even though 
database analyses are susceptible to bias and confounding, they have the advantage of 
being based on observations from real-world practice. Given the limited external 
validity of RCTs, database analyses using data from actual clinical practice can 
usefully contribute to our understanding of the economic outcomes of alternative 
antidepressant treatments. Prospective and retrospective studies have their own 
strengths and limitations. It is essential to assess economic outcomes across a broad 
range of contexts using a range of study designs, and only findings that are consistent 
across a number of study designs and healthcare settings should be accepted with 
confidence. 
 
Specific implications for the methods of database analyses for this thesis 
 
To date, few economic evaluations based on database studies have evaluated costs and 
outcomes simultaneously and the outcome measures used in previous studies are not 
able to directly represent targets of clinical treatment, like remission. Future economic 
evaluations should aim to identify more suitable outcome measures which could 
reflect clinical practice and to evaluate costs and outcomes simultaneously using 
appropriate methods of economic evaluation.  
 
This review has found that head to head comparisons between individual 
antidepressants more commonly use RCTs while comparisons between whole 
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categories (e.g. SSRIs vs. TCAs) are more prevalent in database analyses. However, 
few studies have compared more than two categories of antidepressants at the same 
time while physicians need to choose between various antidepressants given the range 
of categories. Therefore, economic evaluations comparing multiple categories of 
antidepressants in the depression treatment are needed. Furthermore, in order to make 
comparisons across disease areas, generic outcome measures should be incorporated 
into future economic evaluations if comparisons are to be made with interventions in 
other clinical areas. 
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Chapter 3. Study design and economic evaluation methods 
 
The purpose of this chapter is to consider the suitability of different study designs, 
and methods used in economic evaluations for comparing antidepressant treatments. 
Given the focus on database analyses in this thesis, strengths and limitations of 
different study designs and economic evaluations for the proposed analyses in this 
specific study context are also discussed.  
 




Given the focus in this study on the ‘real-world’ cost-effectiveness of antidepressant 
treatments, an observational study design was chosen. There are several observational 
designs which can be defined as follows (Centre of Reviews and Dissemination, 
2001).  
 
 Cohort study: A comparison of costs and outcomes is made between participants 
who have received an intervention and those who have not. 
 Case-control study: Participants with and without a given outcome are identified 
and exposure to a given intervention is compared. Costs are compared by 
exposure and outcome status. 
 Cross-sectional study: The relationships between a disease, costs, and other 
variables of interest (e.g. demographic and clinical) are examined in a defined 
population at a particular time. 
 Before-after study: The comparison is made between costs and outcomes before 
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and after an intervention is implemented. 
 Case series study: A description of cost and outcomes of a number of cases who 
received an intervention. 
 
Black (1996) identified circumstances in which non-randomised approaches may be 
appropriate, or even preferred, to randomised studies because of the nature of a study 
(Black, 1996). First, experimentation is unnecessary if the effect of the intervention is 
believed to be so strong that the likelihood of unknown confounding factors affecting 
the results is too small to warrant attention. Second, experimentation may be 
inappropriate in cases where it would be impossible to recruit sufficient numbers to 
measure a rare outcome including one that takes place in the future, or to determine 
the impact of uncommon adverse events. Neither is considered to be a concern here as 
outcome of depressive illness is likely to be influenced by multiple factors and the 
ailment and its treatments both can have a short-term effect as well as longer-term 
consequences. 
 
Third, randomised controlled trials (RCTs) may be inappropriate where randomisation 
itself impacts upon the effectiveness of the intervention. It is suggested that this would 
be the case where the intervention requires the subject's active participation, which 
would depend on their beliefs and preferences (Black, 1996). This will certainly be a 
concern here because individual patient's active participation is important for 
antidepressant treatments. The attrition rate of antidepressant treatments is high in 
both trials and naturalistic settings. The adherence is usually poorer in ‘real-world’ 
situations than in trials. For example, attrition rates in the first three months of 
treatment can be as high as 52% in naturalistic settings (Lin et al., 1995; Maddox et 
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al., 1994). Such poor adherence to antidepressants may reduce the effectiveness of 
treatment (Demyttenaere et al., 2008). As patients’ beliefs about the cause of 
depression and preferences towards antidepressants can influence both adherence and 
outcome, randomisation precludes patients' participation in decision-making which 
may impact the effectiveness of the intervention. Additionally, experimentation may 
be impossible when key personnel involved in the delivery of the intervention are 
unwilling to participate in an RCT. Physicians may tend to prescribe to patients 
different antidepressants other than the allocated ones when this is allowed. In a 
previous cost-utility study, a higher proportion of patients randomised to TCAs were 
in fact prescribed a different class of antidepressants than those randomised to SSRIs 
(TCA: 42% vs. SSRI: 16%) and physician preference was the stated cause for over 
half of these cases who did not receive the allocated treatment (Kendrick et al., 2006). 
Therefore, it is not always appropriate to assume that physicians would prescribe 
antidepressants randomly to their patients.  
 
Experimentation may also be inadequate if there is only limited scope for the results 
to be generalisable to other settings. Black (1996) notes that the more complex the 
intervention, the lower the external validity. For example, the results noted in trials 
undertaken with well-trained enthusiastic professionals in teaching hospitals may not 
be replicable elsewhere. Since depression is a highly prevalent disease and usually 
treated in routine practice settings, it is not likely that the treatment and resources 
provided in trials could be replicated in everyday practice.  
 
Finally, strict inclusion and exclusion criteria in RCTs often mean that trials include 
only a small proportion of the patients that are treated in usual practice. Although 
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these limitations of RCTs can be overcome to some extent through modifying study 
protocols, e.g. pragmatic RCTs, with randomisation maintained, an economic 
evaluation based on an observational study design for a total-population sample can 
be helpful to supplement results from clinical trials and to answer real-world 
cost-effectiveness questions that are of interest to policy makers. However, it should 
be kept in mind when interpreting results from observational studies that lack of 
randomised comparisons can be a limitation. 
 
It is useful to make a distinction between efficacy and effectiveness trials (Table 3.1). 
Efficacy trials take place under strict conditions regarding the treatments received by 
the intervention and control groups and seek to prove that the intervention works, i.e. 
to prove the effect of the treatment relative to the a control in the ideal situation where 
all persons fully comply with the treatment regime (Everitt, 1995). Effectiveness 
studies, sometimes called pragmatic trials, are observational and seek to demonstrate 
whether an intervention works in real-world settings (Hotopf, 2002).  
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Table 3.1. Differences between efficacy and effectiveness trials 
 Efficacy trials Effectiveness trials 
Aim To establish the efficacy 
and safety of a specific 
clinical intervention 
To establish the 
effectiveness of approved 
treatments, interventions, 
programmes or policies 
Timing Prior to the intervention 
being introduced 
Post-implementation 




Strict, tending to exclude 
patients with co-morbid 
disorders 
Limited, in order to 
maximise external validity 
Comparator Placebo, active control or 
treatment as usual 
Active comparator or 
treatment as usual 
Blinding Patients, staff and 




Research protocol Strictly defined Designed to be closely 
aligned to treatment as 
usual 
Outcomes Clinical parameters such 
as symptom rating scales 
Single primary outcome 
measure with multiple 
secondary outcomes 
including costs 
Adapted from Tansella et al. (2006) 
 
Observational studies, designed to be closely aligned to routinely delivered care, can 
have better external validity and generalisability. However, despite the fact that 
observational studies may provide information regarding whether an intervention 
works in real-world settings, caution should be borne in mind when interpreting 
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results because allocation to the treatment groups is not generally randomised and any 
results may be subject to confounding. Thus it is very challenging to differentiate 
between groups in terms of outcomes due to unobserved factors (Everitt, 1995) and 
oftentimes, more complex statistical methods are needed in analysing results from 
observational studies. 
 
3.2. National Health Insurance Research Database (NHIRD) 
 
This study uses data from the National Health Insurance Research Database (NHIRD) 
in Taiwan. National Health Insurance (NHI) in Taiwan is a single-payer compulsory 
social insurance plan that centralises the disbursement of healthcare funds and 
guarantees equal access to health care for all citizens. With a coverage rate of over 
98% (Wu et al., 2012), nearly all Taiwanese citizens sought care through NHI (Chan 
et al., 2006). The enrolled person is issued an NHI card, which serves as an 
identification card to access the medical system. The NHIRD provides information of 
insured residents’ health care utilisation (medical contacts and procedures/treatments), 
expenditure, demographic characteristics of users, and practicing features of 
physicians (e.g. physician specialties and types of hospitals in which the physicians 
work). Clinical diagnoses are coded in the NHIRD according to the International 
Classification of Diseases, 9
th
 revision, clinical modification (ICD-9-CM).  
 
The main registration and claims datasets maintained in the NHIRD are as follows 
(Hsiao et al., 2007): 
(i) Registry for beneficiaries: Registry for beneficiaries allows follow-up and 
identification of insured persons. Data elements include date of birth, gender, and 
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unit/type of enrolment. A unique identification code is assigned to each person 
insured and precautions are taken to safeguard the confidentiality of individually 
identifiable information.  
(ii) Registry for contracted medical facilities and medical personnel: This 
includes two separate files containing data on the NHI’s practicing healthcare 
facilities and professionals. The type and location of the facilities and the 
demographic information of the healthcare professionals are specified.  
(iii) Outpatient visits: There are two subsets of databases providing information 
on outpatient visits, which are the ‘ambulatory care expenditures by visits’ and the 
‘details of ambulatory care orders’. The outpatient visit database is an encounter 
form-based dataset with date of each visit, diagnosis codes, type of providers, health 
professionals, and service costs.  
(iv) Inpatient visits: Two subsets of databases provide information on inpatient 
visits, which are the ‘inpatient expenditures by admission’ and the ‘details of inpatient 
care orders’. The inpatient visit database is also an encounter form-based data set with 
date of each admission, diagnosis codes, procedure codes, type of providers, health 
professionals, and service costs. 
(v) Pharmacy database: This includes all relevant information of prescription 
drugs dispensed by contracted pharmacies in NHI in Taiwan. Pharmacy identifier, 
prescribing date, dosage, prescription duration in days, prescribing physician, 
dispensing pharmacist and cost of prescription drugs are all included. 
 
To ensure the accuracy of disease diagnosis in the NHIRD, the Bureau of National 
Health Insurance (BNHI) in Taiwan has randomly reviewed medical charts of 1/100 
ambulatory and 1/20 inpatient claims on a regular basis (Wang et al., 2013). 
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Furthermore, the high validity of the diagnostic data from the NHIRD has been 
reported (Cheng et al., 2011), although future studies to further validate diagnoses of 
specific mental disorders may still be needed. Regarding the quality of service use 
data, agreement between self-reported utilisation and the insurance claims of the 
NHIRD was shown to be good in the general population in Taiwan (Yu et al., 2009). 
Data from the NHIRD can be considered as representative of the total population 
sample that encompasses the entire range of clinical diversity of depression and the 
contexts of clinical contacts, e.g. outpatient or inpatient settings. During the past 
decade, there have been a large number of published studies based on the NHIRD in 
Taiwan (see Chapter 1). 
 
Study cohort details 
 
The cohort is defined as all subjects in the NHIRD receiving at least one 
antidepressant prescription for treatment of major depressive disorders (MDD; 
ICD-9-CM codes: 296.2x, 296.3x) or other depressive disorders (ICD-9-CM codes: 
311.xx, 300.4x) in 2003. The index date is defined as the date in 2003 on which the 
subject is first identified in NHIRD. A dataset containing all NHI information of the 
subject in the preceding one year and the three years following the index date was 
then established. Only data on adult subjects (aged 18 or over on the index date) are 
included in the analyses of this thesis.  
 
Demographic and clinical data  
 
Demographic and clinical data, including age, gender, physician specialty, clinical 
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setting (inpatient, outpatient and emergency departments), types of depression (MDD, 
other depression) and choice of antidepressants on the index date were extracted. 
Subjects were further divided into groups of newly diagnosed and pre-existing 
depression (non-newly diagnosed depression). Subjects with newly diagnosed 
depression were defined as people who had not received antidepressant treatment or a 
depression diagnosis in the twelve months prior to the index date. Limitations of the 
definition of newly diagnosed depression include mis-categorising patients who had 
been treated for depression at an earlier time, e.g. two years ago. 
 
Categories of antidepressants included selective serotonin reuptake inhibitors (SSRIs), 
serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants 
(TCAs), other older antidepressants (maprotiline, moclobemide, and trazodone), other 
newer agents (bupropion and mirtazapine) and multiple use of antidepressants at the 




Data on comorbid mental disorders, physical disorders and painful physical symptoms 
during the twelve months before the index date were extracted. These variables 
indicated presence or non-presence of the comorbidities. The included comorbid 
disorders are listed in Tables 3.2, 3.3 and 3.4.  
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Table 3.2. Comorbid mental disorders extracted from NHIRD 
Category ICD-9-CM 
Schizophrenia 295 
Other psychotic disorder 297.0-297.3, 297.8-297.9, 298.1-298.4,  
298.8-298.9 
Transient psychotic disorder 293.81, 293.82 
Paranoid personality disorder 301.0 
Substance induced mental disorder 303-305 
Alcohol induced mental disorder 291 
Drug induced mental disorder 292 
Bipolar spectrum disorder  296.0-296.1, 296.4, 296.6-296.7, 296.80, 
296.81, 296.89 
Dementia and related disorder  290, 291.2, 292.82, 294.1, 294.8, 331 
Generalised anxiety disorder 300.02 
Obsessive-compulsive disorders 300.3 
Panic disorder without agoraphobia 300.01 
Phobic disorder 300.2 
Post-traumatic stress disorder 309.81 
Acute reaction to stress 308 
Sleeping disorder 307.42, 307.44-307.47, 347, 780.52, 
780.54, 780.59 




Table 3.3. Comorbid physical disorders extracted from NHIRD 
Category ICD-9-CM 
Cardiovascular diseases 306.2, 394-398, 402, 410-417, 420-429, 
431, 434, 436, 437, 746 
Chronic obstructive pulmonary disease 490-494, 496 
Diabetes Mellitus 250 
Hyperlipidemia 272 
Hypertension 401-405, 416.0, 416.8, 437.2, 459.1, 
459.3, 642 
Renal disease  250.4, 403, 404, 581.9, 582-588, 593.9, 
646.2, 753.11, 753.15 
Stroke  431, 434, 436 
Cancer 140-208 
Epilepsy 333.2、345 
Irritable bowel syndrome 564.1 




Table 3.4. Painful physical symptoms extracted from NHIRD 
Category ICD-9-CM 
Joint (OA, RA, Gout/other, other joint 
disease, TMJ) 
274.0-274.9, 524.62, 712-716, 
718-719 
Back 720-724 
Muscle (myositis, sprain, synovitis/ 
tendinitis) 
840-848, 729.1, 905.7 
GU/gastritis 531-535、787.1、V127.1 
Functional GI disorder 564.1, 564.5, 564.8, 564.9 
Abdominal pain  789.0 
Headache/migraine or dizziness 307.81, 346, 386, 780.4, 784.0 
CAD/angina or chest pain  413, 786.50, 786.51, 786.59 
Other pain (trigeminal, causalgia, 
phantom limb etc.)  
 
307.80, 307.89, 379.91, 388.70, 350.1, 

















Service use and cost data 
 
Service use data extracted from the NHIRD included contacts with outpatient services, 
emergency department attendances, and days in hospital (for all reasons). Medication 
data included prescriptions for all medications but only antidepressant medications 
were specifically identified and analysed in this study. All medication costs were 
included in the analyses. Service use data for the preceding year (baseline period) and 
three years following the index date were extracted. The percentage of patients with at 
least one contact and the mean number of service contacts was reported. The database 
contains actual expenditure data and no unit costs were separately defined. The 
assumption used here is that expenditure data represents ‘costs’. Annual expenditures 
were calculated from the actual claims data, were categorised as psychiatric and 
non-psychiatric expenditures (depending on physician specialty of the service contact) 
and were converted using purchasing power parity (PPP) conversion rates from New 
Taiwan Dollars (NTD) to international dollars (World Economic Outlook (WEO) 
data). 
 
3.3. Analysis of cost differences and variations 
 
Differences in total costs over twelve months between antidepressant groups were 
initially compared using ANOVA followed by multivariable regression models. Cost 
data are usually skewed because a small number of individuals in the sample may 
incur high costs (e.g. prolonged inpatient stays). Transformation is a way of 
addressing this but the focus on the arithmetic mean cost is usually preferred and so 
transformation may not be advisable (Thompson and Barber, 2000). Skewed data can 
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also cause problems for multivariable analyses as the assumptions of standard 
ordinary least-squares (OLS) linear regression (e.g. normally distributed residuals or 
homoscedasticity) may be violated. These problems are not though so great when 
sample sizes are large. In studies where randomisation is not used, multivariable 
analysis is important for assessing the effect of a specific factor in costs due to the 
need to control for confounding factors. Therefore, multivariable approaches are 
employed for the cost analysis in this thesis with the results presented in Chapter 4. 
 
Introduced by Nelder and Wedderburn (1972), the generalised linear model (GLM) 
synthesises the techniques used to analyse continuous and discrete data into a unified 
framework (Drummond et al., 1997). This model allows a generalisation of the 
response distribution to other members of the exponential family, including gamma, 
inverse Gaussian, and binomial distributions. Also, a description of the variance as a 
function of the mean has been introduced as a method of modelling cost data (Blough 
et al., 1999; Manning and Mullahy, 2001). The gamma distribution has been found to 
be often appropriate for cost analyses given the assumption that data have a constant 
coefficient of variation, which is frequently the case with cost data. The gamma model 
may incorporate a reciprocal, log or identity link. In a GLM, the regression equation 
is called the ‘linear predictor’ but this linear predictor is not equated with the expected 
cost, as in multiple regression with the raw data, but via ‘link function’. For example, 
there can be models in which the natural logarithm of the expected costs is equated 
with the linear predictor (Dunn et al., 2003). The log link is also commonly used 
when analysing cost data, because it guarantees non-negative outcomes and has a 
close connection to the logarithmic transformation of data (Myers et al., 2001). 
Evidence has suggested that healthcare resource use and expenditure data frequently 
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have a log-normal or gamma distribution and the existing studies using GLM for cost 
analysis have focused on the latter (Manning and Mullahy, 2001). This GLM 
approach has been commonly used in analyses of economic cost data (Chong et al., 
2013; Desai et al., 2013; Sabes-Figuera et al., 2012). Given the characteristic 
properties of cost data mentioned above, cost analyses in this thesis were conducted 
by using GLM with a log link and gamma variance function. 
 
3.4. Analysis of cost and outcome 
 
Incremental analysis of costs and outcomes 
 
The most common approach of combining the costs and outcomes in healthcare 
research is incremental analysis (Drummond et al., 1997; NICE, 2008). In incremental 
analysis, the additional or incremental costs of the programme are compared to the 
additional or incremental outcomes. Consider a new intervention for a health problem 
which is compared to standard treatment, with costs and outcomes measured. 










Figure 3.1. Cost-effectiveness plane 
 
 
The new intervention could cost less than the standard treatment and result in better 
outcomes. In this situation the intervention is said to ‘dominate’ standard treatment 
and is the preferred choice. The new intervention could cost more than the standard 
treatment and result in worse outcomes. In this situation, the new intervention is said 
to be ‘dominated’ by standard treatment and should not be recommended. The new 
intervention could cost more than the standard treatment and result in better outcomes. 
In this situation, there is a trade-off to be made. The decision-maker should be 
presented with information regarding the incremental cost per incremental unit 
improvement in outcome in the form of an incremental cost-effectiveness ratio and 
then the decision maker would need to make a value judgement regarding the 
intervention. Finally, the new intervention could cost less than the standard treatment 
and results in worse outcomes. In this situation, there is again a value judgement to be 
made – are sufficient costs saved to justify the worse outcomes attained? 
 
When non-dominant situations occur (i.e. South West and North East quadrants) then 
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decision makers need to refer to the incremental cost-effectiveness ratio (ICER) 
defined as the difference in costs between the two options divided by the difference in 
outcomes. The ICER can be judged against a maximum willingness to pay for 
improvements in outcome. This willingness to pay for improvements in outcome is 
often referred to as the ceiling ratio and frequently depicted as λ (Figure 3.2). If the 
ICER is less than the ceiling ratio (i.e. it falls below the λ line) then the new 
intervention is considered to represent good value for money. If the ICER is greater 
than the ceiling ratio (falls above the λ line) then the new intervention is not 
considered to be cost-effective. 
 
Figure 3.2. Cost-effectiveness plane (with λ indicating hypothetical ceiling ratio) 
 
However, there are problems with the ICER as a summary statistic. The first is that it 
is based on four sample means and is calculated whether or not the differences in 
costs or outcomes are statistically significant (Briggs, 2001). One option is to generate 
confidence intervals for the ICER, which can be calculated using bootstrapping 
(Barber and Thompson, 2000) and this will be discussed later in this chapter. The 
second problem is that a negative ICER can occur for two reasons. If the difference in 
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mean cost is negative and the difference in mean effects is positive, the new 
intervention is cost-effective. However, a negative ICER could also be produced when 
there is a positive difference in mean costs and a negative difference in mean effects. 
Then, the new intervention falls in the north-west quadrant and is not cost-effective 
 
Cost effectiveness acceptability curves 
 
Another commonly-used method for comparing cost and effectiveness simultaneously 
is to use cost-effectiveness acceptability curves (CEACs) that will be applied to the 
cost-utility analysis in Chapter 7. CEACs can be constructed using the net benefit 




where λ = threshold value, △E = difference in effects between study arms, and △C = 
difference in costs between study arms. 
 
A net benefit approach was used in the analyses of this thesis. Net benefits for the 
sample using values for λ (i.e. willingness to pay for an additional quality-adjusted 
life-year (QALY)) ranging from NTD 0 - NTD 3,000,000 (approximately £60,000) 
were calculated. Regression models were constructed to estimate the difference in net 
benefit between study groups and bootstrapping used to produce 1000 differences for 
each value of λ. (Bootstrapping is a non-parametric approach to analysis that is based 
on resampling from sample data with replacement (Efron and Tibsirani, 1993).) The 
proportion of these replications that were greater than zero indicated the probability 
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that the treatment of interest was more cost-effective than the alternatives (coded as 
zero) for that value of λ. Plotting these probabilities on a graph created a CEAC, 
which depicted graphically the probability that the treatment of interest was most 
likely to be cost-effective (Fenwick et al., 2001; Fenwick et al., 2004). These curves 
incorporate both the uncertainty that exist around the estimates of mean costs and 
effects as a result of sampling variation and the uncertainty regarding the maximum 
cost-effectiveness ratio that a decision-maker would consider acceptable (Fenwick 
and Byford, 2005).  
 
CEACs assess the likelihood of the treatments of interest being more cost-effective 
than the alternative for a range of willingness-to-pay values for an additional unit of 
outcome (e.g. a QALY). This approach assumes that there is a theoretical but 
unknown value that society would place on an improvement in outcomes. In this 
thesis, the threshold was assumed to be between NTD 1,500,000 (£30,000) and NTD 




Because every evaluation contains some degree of uncertainty, imprecision or 
methodological controversy, sensitivity analyses were applied in this thesis, i.e. 
critical methodological assumptions or areas of uncertainty were identified and then 
different assumptions or estimates employed in order to test the sensitivity of the 
results and conclusions to such changes. If large variations in the assumptions or 
estimates underlying the analysis do not produce substantial alterations in the results 
then one would tend to have more confidence in the original results. If the converse 
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occurs, more effort is then required to reduce the uncertainty and/or improve the 
accuracy in estimating the values of the critical variables.  
 
There are a number of sources of uncertainty in economic evaluation. First, no data 
may be available and expert-informed estimates are required. This may be the case for 
estimates of the effectiveness of new technologies. Second, estimates may be 
available but they may be known to be imprecise. For example, only the average cost 
per day may be known for estimates of hospital costs. Third, there may be 
methodological controversy about some parameter values. This may be the case for 
analytic decisions such as the choice of the source of values for health state 
preferences as in this thesis. Finally, the analyst may use sensitivity analysis to 
explore the generalisability of study results to other settings. Sensitivity analysis 
typically involves three steps:  
 
(1) identify the uncertain parameters for which sensitivity analysis is required; (2) 
specify the plausible range over which uncertain factors are thought to vary; and (3) 
calculate study results based on combinations of the best estimate and most 
conservative and least conservative estimates.  
 
All variables in the analysis are potential candidates for sensitivity analysis. Possible 
reasons for exclusion could be that parameter estimates are known with absolute 
certainty, or that a preliminary analysis shows that, even if the variable is allowed to 






In this chapter, strengths and limitations of study designs using the proposed database 
analyses were discussed. For example, it is ‘expenditures’ that were analysed in this 
thesis under the assumption that these represent ‘costs’. However, ‘expenditures’ may 
not reflect ‘true costs’ which should be borne in mind while interpreting the related 
findings. The NHIRD and methods for data extraction were described as well as the 
proposed approaches of evaluations, e.g. CEACs and sensitivity analysis. 
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Chapter 4. Costs of care received by patients with depression and analysis of cost 
variations 
 
The purpose of this chapter is to identify which demographic and clinical 
characteristics and comorbidities are associated with healthcare costs with a particular 
focus on comorbid pain and cardiovascular diseases. Cost comparisons between 
patients using different categories of antidepressants are also examined. Analyses are 
conducted on different cost categories, i.e. psychiatric, non-psychiatric, and total costs. 





The total direct healthcare costs of depression in Taiwan rose by 50% over the period 
of 2000-2002 (Chan et al., 2006). Furthermore, the prevalence of antidepressant use 
doubled from 1997 to 2004 (Chien et al., 2007a). These results based on analysis of 
NHIRD data could imply an increase in the need for depression treatment, a reduction 
in the treatment gap, or over-provision of care. Future research is needed to determine 
the true cause of the phenomena. 
 
As mentioned in previous chapters, the National Health Insurance (NHI) in Taiwan is 
a single-payer compulsory social insurance plan that guarantees equal access to health 
care for all citizens. Patients can freely choose between providers and have direct 
access to specialist care without going through a gatekeeper or referral system. There 
is also no limit to the number of visits a patient can make to services (Chen et al., 
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2007). Given the all-inclusive nature of this system and relatively affordable 
co-payments, it seems reasonable to anticipate a further rise in healthcare costs for 
patients with depressive disorders. It is thus particularly important to assess the 
impact of depression treatments on both expenditures and related outcomes in the 
context of the insurance system in Taiwan.  
 
As seen in Chapter 1, depressive disorders are known to be associated with a variety 
of physical conditions (Katon, 2003), certain of which warrant further research. 
Depression and cardiovascular diseases (CVD) are projected to be the first and second 
leading causes of health-related burden in 2015 (WHO, 2008). Currently, depression 
is found to be among the top-ranking causes of global disability H(Vos et al., 2012), 
while CVD constitutes the leading cause of premature death H(Lozano et al., 2012). 
These two conditions frequently co-occur H(Joynt et al., 2003) and there is 
accumulating evidence suggesting close interrelationships between them (Sorensenf et 
al., 2005; Thombs et al., 2006). For example, depressive symptoms have been found 
to be a risk factor for cardiac events in patients with coronary heart disease (Barth et 
al., 2004; van Melle et al., 2004). Given that the two conditions co-occur it is useful to 
evaluate the impact of comorbid CVD when performing economic analyses of 
treatment for depression. 
 
Another disease entity, painful physical symptoms (PPS), may also be of importance 
when assessing the economic impact of treatment for depression. Previous studies 
have revealed a high prevalence of pain complaints in depressed patients (Bair et al., 
2004; Bair et al., 2003; Husain et al., 2007; Ohayon and Schatzberg, 2003) and 
outcomes of treatment for depression may be poorer in the presence of PPS (Fava et 
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al., 2004; Gameroff and Olfson, 2006; Leuchter et al., 2010). The severity of pain 
seems to be a strong predictor of poor treatment response to antidepressants as well as 
impaired quality of life outcomes after initial treatment (Bair et al., 2004) which may 
lead to a more severe and chronic relapsing course (Judd et al., 2000). Evidence also 
suggests a relationship between increased healthcare costs and the presence of 
comorbid moderate to extreme pain interference among patients with major 
depressive disorder (MDD) (Gameroff and Olfson, 2006). It is thus reasonable to 
assume that there are impacts of PPS on patients' help-seeking behaviours and 
treatment costs.  
 
CVD and PPS may also have greater effects than other physical comorbidities on the 
choice of antidepressants or on treatment outcomes. Individual antidepressants are 
shown to have a wide range of cardiovascular effects (Taylor, 2008),
 
which would be 
a great concern for treating depressed patients with comorbid CVD. Conversely, 
treating PPS in patients with depression has been an emphasis of pharmaceutical 
research during the past decade. Individual antidepressants may differ in their 
effectiveness for the relief of PPS (Sullivan and Robinson, 2006) and classes such as 
serotonin norepinephrine reuptake inhibitors (SNRIs) have been reported as 
particularly effective in reducing pain. Given the above characteristics, the presence 
of co-occurring CVD and PPS may influence the choice of antidepressants, with a 
potential impact on healthcare costs. Besides physical comorbidities and choice of 
antidepressants, treatment history, as well as comorbidities of mental illnesses, should 
also be taken into consideration when analysing costs of depression treatment.  
 
This chapter seeks to measure healthcare costs from the healthcare perspective for 
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people with depression using claims data from the NHIRD in Taiwan. The specific 
objectives are to identify which demographic and clinical characteristics and 
comorbidities are associated with total healthcare costs, as well as costs for specific 
groups of services, with a particular focus on comorbid pain and CVD. 
 




Data on all NHI information for each subject of the identified cohort (see inclusion 
criteria below) were extracted for the two-year period spanning the index date (one 
year preceding, and one year following). As stated in Chapter 3, the available data 
included the preceding year before and the following three years after the index date. 
In this chapter, only analyses of the costs for the following one year are given because 
it would be difficult to interpret relationships between variables of interest at baseline 
and costs for the whole three years. The impact of initial outcomes on costs for the 





All subjects in NHIRD meeting the following criteria were included: 
 At least one prescription for an antidepressant for treatment of MDD (ICD-9-CM 
codes: 296.2x, 296.3x) or other depression (ICD-9-CM codes: 311.xx, 300.4x) in 
2003.  
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 Data available for a minimum of 12 months before and after the index date. 
 Age 18 years or over on the index date. 
 
As defined previously in Chapter 3, a subsample of patients with newly diagnosed 
depression was also identified within this overall sample (operationally defined as 
individuals who were free of antidepressant use or a depression diagnosis for a 
minimum of 12 months before the index date). 
 
Demographic and clinical information 
 
Demographic and clinical data were extracted, including age, gender, diagnosis of 
depressive disorders, and initial choice of antidepressants on the index date. 
Participants were further grouped according to past treatment history, i.e. newly 
diagnosed depression and non-newly diagnosed depression. 
 
Baseline characteristics were traced back for all included subjects for the 12 months 
prior to the index date, including comorbid mental disorders, physical illnesses (CVD, 
diabetes mellitus (DM), chronic obstructive pulmonary disease (COPD), renal 
diseases, and cancer), PPS (backache, headache, musculoskeletal and gastrointestinal 
pain), and healthcare utilisation/expenditure. Because many physical comorbidities 
co-occur (CVD and DM), inclusion of all these physical comorbidities (other than 





Service use and costs 
 
Service use data extracted from the NHIRD included outpatient visits, emergency 
department attendances, and inpatient stays. Service use over the 12-month study 
period was described by the percentage of patients with at least one unit of service use 
and the mean number of service contacts. Medication use regarding prescriptions of 
antidepressants was identified. Annual costs (including all medication costs) were 
calculated from the actual claims data, were converted by purchasing power parity 
(PPP) conversion rates and expressed in international dollars (World Economic 




Sociodemographic data, clinical characteristics, baseline healthcare 
utilisation/expenditure, and initial antidepressant treatment were described for the 
overall sample and compared between newly diagnosed depression and non-newly 
diagnosed depression groups. To identify characteristics predictive of healthcare costs 
over the 12-month period, univariate analyses were first performed. Then a 
multivariable generalised linear regression model with a log link and gamma variance 
function was employed (McCullagh and Nelder, 1989). Separate models were run for 
total healthcare costs, psychiatric costs, and non-psychiatric costs. To measure the 
model fit, the root mean square error (RMSE) (Zheng and Agresti, 2000) for each 
model was computed after excluding 0.1% of subjects with extremely large predicted 
values in costs. The independent variables considered were age, sex, index depression 
diagnosis, past treatment history, initial choice of antidepressants, baseline comorbid 
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mental/physical disorders, baseline PPS, and baseline total healthcare expenditure. 
These variables were first selected based on the univariate analyses and those 
significant at the 5% level were subsequently included. A backward selection process 
was then applied to obtain the final multivariable model, again using a 5% level of 
significance. Such analyses were subsequently performed in a subsample of subjects 
with newly diagnosed depression to determine whether having a past treatment 
history influenced costs. 
 
As use of psychiatric emergency and/or inpatient services may be indicators for 
patients who require more intensive care, thus generating higher costs, variations in 
use of these two key services were further examined. Use of these services was 
represented by binary variables in a multivariable logistic regression model and 
independent variables were entered using a forward LR (likelihood ratio) method to 
identify predictors of use over the 12-month study period. A p-value of 0.05 was 
considered significant for all statistical analyses, which were performed using SPSS 




A total of 216,557 adults met the inclusion criteria for the current analysis, including 
84,577 with newly diagnosed depression. Table 4.1 shows that for the overall sample, 
61.9% were females and 18.7% were aged 65 years or over on the index date. 
Regarding baseline comorbidities, 26.9% of the sample had CVD. Comorbid PPS 
rates were particularly high for both the overall sample and the subsample of 
individuals with newly diagnosed depression. At the index visit, 45.6% of the overall 
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sample was prescribed selective serotonin reuptake inhibitors (SSRIs) and 8.6% 
prescribed SNRIs. Only 3.1% of patients received other newer antidepressants 
(bupropion and mirtazapine) at the index visit. 
 
Patients with newly diagnosed depression tended to be younger and a greater 
proportion were females compared to those with non-newly diagnosed depression. 
They also had lower rates of comorbid physical/mental illnesses and lower prevalence 
of PPS. Health service utilisation at baseline was lower for those with newly 
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Service use and costs 
 
Service use data are summarised in Table 4.4. Of the overall sample, 85.1% had used 
psychiatric outpatient services over the 12-month study period. Over the same period, 
5.0% of them had been admitted to psychiatric wards for inpatient treatment and 1.6% 
had psychiatric emergency attendances. Costs of outpatient contacts (psychiatric and 
non-psychiatric outpatient services) accounted for 63.6% of total healthcare costs. 
Psychiatric services accounted for 29.2% of the total and the mean cost for psychiatric 
services was 840 international dollars. 
 
Total healthcare costs 
 
Table 4.7 reveals that higher total healthcare costs were associated with older age, 
male gender, an index diagnosis of MDD, non-newly diagnosed depression, and 
having CVD, DM, COPD, renal disease, cancer or PPS at baseline. Male gender was 
associated with 14.3% higher healthcare costs compared to female gender. Patients 
who had a MDD diagnosis had 13.4% higher total healthcare costs than those who 
had a diagnosis of other depression. For those with comorbid CVD, total costs were 
18% higher. 
 
Use of SNRIs, other newer generation antidepressants and use of multiple 
antidepressants were related to higher costs compared to use of SSRIs at the index 
date. Lower costs were observed for those using tricyclic antidepressants, 
flupentixol/melitracen and other older antidepressants (maprotiline, moclobemide, 
and trazodone). The analysis on the subsample of newly diagnosed depression 
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revealed similar results to those from the full sample. Regarding the model fit, RMSE 
of the model for total costs was 1316. The predicted mean total costs were 3197 
international dollars, slightly higher than the actual mean cost of 2875 international 
dollars. 
 
Non-psychiatric healthcare costs 
 
Older age, and male gender were related to higher non-psychiatric costs in the 
following year (Table 4.8). Compared to patients with history of antidepressant 
treatment or a diagnosis of depression, those with newly diagnosed depression had 
higher non-psychiatric costs. An index diagnosis of MDD or a baseline comorbid 
mental disorder were associated with lower non-psychiatric costs, with the only 
exceptions being alcohol, substance misuse, multiple drugs-related mental disorders 
and dementia. The presence of a comorbid physical illness or PPS at baseline was 
related to higher non-psychiatric costs. The potential implications for above findings 
will be discussed later in this chapter.  
 
Patients prescribed older antidepressants had higher non-psychiatric costs in the 
following year compared to those prescribed SSRIs while patients prescribed newer 
antidepressants such as SNRIs or bupropion/mirtazapine had non-psychiatric costs 
that did not differ significantly from those prescribed SSRIs. The RMSE of the model 
was 4380. And the predicted mean of non-psychiatric costs was 2410 international 




Psychiatric healthcare costs 
 
As shown in Table 4.8, male gender was associated with higher psychiatric costs in 
the following year. Not surprisingly, patients having an index diagnosis of MDD had 
increased costs as did those with baseline comorbid mental disorders. Patients with 
newly diagnosed depression had lower psychiatric costs compared to those who had 
been diagnosed prior to the index date, which may be related to lower levels of 
engagement with psychiatric treatments for these patients. Younger age was shown to 
be related to higher psychiatric costs. 
 
Use of newer generation antidepressants or multiple antidepressants prescribed on the 
index date were related to higher psychiatric costs (including all drugs costs) 
compared to those prescribed SSRIs, while use of older antidepressants was related to 
lower costs. Among comorbid physical illnesses, CVD was the only one found to be 
associated with higher psychiatric costs. Among PPS, only pain relating to the central 
nervous system (CNS), i.e. headache/dizziness/or migraine, were related to higher 
psychiatric costs. The RMSE of the model was 1074. The predicted mean of 
psychiatric costs was 958 international dollars and the actual mean was 840 
international dollars. 
 
Use of psychiatric emergency and inpatient services 
 
Younger age, male gender, a diagnosis of MDD or certain comorbid mental disorders 
(e.g. psychotic disorders, alcohol or drug-related mental disorders) were more likely 
to lead to psychiatric emergency attendances and hospitalisations (Table 4.9). CVD or 
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COPD was also related to higher odds of using these services as were headache, 




This section has provided new evidence on the associations between antidepressant 
type, comorbidities, service use, and healthcare costs for patients with depression. 
Although the nature of the associations differed across cost categories, the 
multivariable models revealed that age, gender, depression severity, past treatment 
history, comorbid mental/physical illnesses, PPS, and choice of initial antidepressants 
were all associated with healthcare costs in the following year. Factors including 
comorbid CVD and PPS were further explored to understand patterns of variation in 
psychiatric emergency and inpatient service use over the 12-month study period.  
 
Demographic and clinical characteristics 
 
Although previous studies have suggested that medical costs are higher for women 
than men (Owens, 2008; Woolhandler and Himmelstein, 2007), this study found a 
different result; for patients with depressive disorders, and taking into account other 
influences on costs, male gender was shown to be associated with higher costs for 
both non-psychiatric and psychiatric healthcare services. A study of elderly patients 
with psychiatric diagnoses suggested that men had more emergency attendances and 
had greater inpatient costs than women, which led some investigators to propose that 
when men eschew regular visits to physicians, it is likely that emergency or inpatient 
treatment may be required as illness progresses (Husaini et al., 2002). Consistently, 
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male gender was shown to be associated with increased use of psychiatric emergency 
and inpatient services in the current analysis. One interpretation of the results is 
therefore that male patients with depression may enter the healthcare system later in 
the disease course, by which time their illness is more severe, thus generating higher 
costs.  
 
As shown in Table 4.8, an index diagnosis of MDD or a baseline comorbidity of some 
mental disorders were associated with lower non-psychiatric costs. This lower cost (or 
fewer use) in non-psychiatric services may be due to the fact that mental health 
problems were clinically more important for these subjects compared to the 





The current cost analysis showed that initial choice of antidepressants appears to be 
associated with total healthcare costs in the following year. Compared to patients 
prescribed SSRIs, those prescribed older antidepressants had lower total and 
psychiatric costs, whilst patients prescribed SNRIs, and other newer antidepressants 
had higher total and psychiatric costs. However, to a large extent these differences 
may be attributed to physician selection; patients prescribed older antidepressants 
were more likely to suffer other types of depression, to be older, and to have more 
PPS and physical comorbidities at baseline. Conversely, patients prescribed newer 
antidepressants were more likely to have MDD, to be younger, and to have fewer 
baseline physical comorbidities (Table 4.2). These distinctive characteristics may 
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suggest the existence of physician selection based on patients' clinical characteristics 
that unfortunately could not be fully adjusted for in the current analyses. 
 
Patients prescribed SNRIs and other newer antidepressants were similar to those 
prescribed SSRIs in non-psychiatric costs, whilst patients prescribed TCAs and other 
older antidepressants generally had higher non-psychiatric costs. These results could 
be interpreted as showing that there were differences in physical comorbidities 
between these two groups of depressed patients. A systematic review on previous 
database analyses has suggested that SSRI users may have higher depression-related 
service expenditures but lower non-depression-related service expenditures than TCA 
users (Pan et al., 2012). Along with these findings, the current results suggest that 
depressed patients prescribed older antidepressants may be different from those 
prescribed SSRIs, SNRIs, and other newer antidepressants in terms of clinical features 
of depression and comorbidities. 
 
Comorbid cardiovascular disease 
 
Among the frequently co-occurring physical illnesses considered in this chapter, CVD 
was the only one shown to be positively associated with both non-psychiatric and 
psychiatric costs. Depression has been revealed to be an independent risk factor for 
the future onset, progression, and recurrence of CVD (Carney et al., 1988; Ferketich 
et al., 2000; Nicholson et al., 2006; Rugulies, 2002; Sesso et al., 1998; 
Wassertheil-Smoller et al., 2004), which can be mediated both by poor health 
behaviour and by the pathophysiological correlates of depressive symptoms, e.g. 
neuroendocrine and inflammatory activation (Frasure-Smith and Lesperance, 2010; 
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Rozanski et al., 2005). Additionally, individual antidepressants have a wide range of 
cardiovascular effects which may affect cardiovascular-related morbidity and 
mortality (Coupland et al., 1997; Taylor, 2008; Vieweg and Wood, 2004). It seems 
likely that the co-existence of CVD and depression may have an impact on the 
physical conditions of patients and their non-psychiatric costs.  
 
The presence of comorbid CVD was related to higher odds of using both psychiatric 
emergency and hospitalisation services (Table 4.9) which was consistent with the 
finding of increased psychiatric costs in these patients. CVD has been shown to be 
correlated with certain lifestyles, alcohol consumption, and personality traits (e.g. 
Type D personality), some of which seem to be highly correlated with use of 
psychiatric services. For instance, Type D has been conceptualised as a personality 
trait comprising negative affectivity and social inhibition that often co-occurs with 
depression in patients with coronary artery disease, and that may inhibit remission of 
depressive symptoms (Albus et al., 2011; Denollet et al., 2010). Although speculative, 
the association between the presence of CVD and increased psychiatric service 
utilisation/expenditure in this study may be understood as being indirectly influenced 
by these unmeasured and potentially associated factors.   
 
Painful physical symptoms 
 
The relationships between depression and pain are complex with similar brain areas 
regulating both mood and the affective components of pain (Giesecke et al., 2005). 
High prevalence of pain complaints has been reported in patients with depression 
(Bair et al., 2003; Husain et al., 2007; Ohayon and Schatzberg, 2003). The current 
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results added to this evidence in finding a high percentage of comorbid PPS in 
patients with newly diagnosed depression, which supports findings from previous 
studies that pain usually appears before the development of MDD (Ohayon and 
Schatzberg, 2010). On the other hand, pain complaints have been reported to be 
associated not only with higher odds of having depressive disorders (Barry et al., 
2012), but also with an adverse impact on poor treatment response (Bair et al., 2004). 
Pain complaints seem to be characteristic of depression that is more severe, as 
evidenced by higher healthcare utilisation, and higher costs (Gameroff and Olfson, 
2006).  
 
As most previous studies were based on highly selective samples and did not consider 
many comorbidities, it is unclear whether these results can be generalised to larger 
samples of patients in real-world settings, and to what extent other factors such as 
comorbid mental/physical illnesses would contribute to the possible association 
between PPS, healthcare utilisation, and treatment outcome. The current results 
concurred with previous studies in suggesting that the presence of PPS was associated 
with higher total healthcare costs in the following year. This remained true for those 
with newly diagnosed depression. In addition, analyses based on origins of pain 
complaints found that the co-existence of PPS was generally associated with higher 
non-psychiatric costs but lower psychiatric costs, with headache being the only 
exception. Unlike other pain complaints, having headache was associated with higher 
psychiatric costs and greater odds of using psychiatric emergency and inpatient 
services. A recent study suggested the existence of differences in separate pain 
modalities in relation to depression, and that a closer relationship may exist between 
MDD and neuropathic pain than non-neuropathic pain (Ohayon and Stingl, 2012). It 
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seems possible that a more direct relationship might exist between depression and 
pain complaints over the central nervous system than PPS from other somatic systems 
as the current analyses might suggest. 
 
4.5. Limitations and implications 
 
There are limitations with these analyses and two in particular stand out. Firstly, as 
service use data contained in the NHIRD relate only to health services financed by the 
NHI system in Taiwan, the perspective of the current analysis was relatively limited, 
and it was not possible to assess wider economic impacts. Secondly, although the 
real-world context and whole-country coverage are strengths, the confounding or 
selection bias due to the non-randomised study design should always be borne in 
mind while interpreting the results. RCTs may still be regarded as the gold standard 
approach for estimating the ‘true’ effects of treatments on outcomes because the 
random treatment allocation ensures that treatment status will not be confounded with 
either measured or unmeasured baseline characteristics. In the current cost analysis, 
the baseline characteristics differed systematically across antidepressant groups. As 
stated in Section 4.4, physician selection (perhaps based on the differences in patients’ 
baseline characteristics) was suggested to account for a substantial proportion of the 
cost differences across antidepressant groups. Therefore, the interpretations of the 
cost-analysis results regarding antidepressant treatments should be made when taking 
into considerations the potential confounding effects (Austin, 2011). 
 
In conclusion, the analyses suggest a set of significant correlates of healthcare costs 
for depressed patients. Male gender and a diagnosis of MDD were significantly 
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associated with higher total healthcare costs. The baseline comorbidities of CVD and 
headache were associated not only with higher non-psychiatric but also with higher 
psychiatric costs; in particular, these comorbidities were related to increased use of 
psychiatric emergency and inpatient services in the following year. 
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Chapter 5. Effectiveness and utility measurement 
 
The purpose of this chapter is to identify types of outcome measure (both 
effectiveness and utility measures) that may be appropriate for an economic 
evaluation of antidepressant treatments for depression in general and specifically in 
studies using a database approach. Suitability of effectiveness measures for remission 
and treatment-free status are discussed and compared and methods available for 
measuring utility are presented. Finally, the strengths, limitations and potential 
applications to research based on database analyses of these outcome measures are 
discussed. 
 
5.1. Outcomes in health care evaluations 
 
In evaluating healthcare interventions, a decision regarding the manner in which 
change is to be measured is required. Given that an intervention may impact on an 
individual in different ways, there are frequently a number of potentially relevant 
outcomes and it is useful to separate them into intermediate outcomes and final 
outcomes. 
 
While intermediate outcome measures generally tend towards biomedical markers, 
final outcome measures usually focus on morbidity and mortality. Intermediate 
outcome measures are particularly useful in evaluations when the final outcome 
measure cannot be observed within the period of the study. When an intermediate 
outcome measure is used, decisions regarding the effectiveness of the intervention are 
made on the basis of theoretical or proven relationships (for example, epidemiological 
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or biological evidence) between the intermediate and the final outcome. For instance, 
changes in blood pressure may be used as an intermediate outcome while deaths from 
cerebrovascular accidents are the final outcome. The choice of an intermediate or final 
outcome measure is thus a function of the disease characteristics. 
 
Brazier et al. (2007b) have argued that health consequences are frequently 
multi-dimensional, uncertain and disparate and therefore attempting to capture these 
complexities in a single effectiveness measure is very difficult. Considering the 
potential need for multiple outcome measures, Craig et al. (2008) suggest that 
researchers need to choose a primary outcome measure whilst acknowledging the 
usefulness of secondary outcome measures. It is also necessary to plan exactly how 
multiple outcome measures will be dealt with in analyses, particularly when the 
intervention is expected to have an impact on a range of domains. For example, 
researchers may argue that scores on the Hamilton Depression Rating Scale (HDRS) 
be used as a primary outcome measure in a study with patients with depressive 
disorders and that remission be used as a secondary outcome measure. 
 
Economists argue that economic evaluation should have another purpose: to aid 
decision-makers in maximising the healthcare benefits from available budgets 
(although it may be equally important to also focus on the distribution of outcomes 
across populations). As a result, the measure of outcome should better allow the 
comparison of interventions across a range of diseases and conditions, which is not 
possible when every disease area uses a different outcome measure. If a new 
intervention costs more than the comparator but leads to improvements in outcomes, 
it is necessary for decision-makers to have a view of how much they are willing to 
 161 
pay for the improvements in outcomes. It is very difficult for decision-makers to take 
a view on their willingness to pay for improvements in different outcomes across 
disease areas. These related arguments have led to a growth in generic outcome 
measures, and specifically utility measures, such as the quality-adjusted life-year 
(QALY).  
 
The concept of QALYs has been first introduced in a paper on kidney transplants in 
the 1960s (Klarman et al., 1968). In that paper, the authors noted that the quality of 
life with a kidney transplant was better than that with dialysis, and this information 
was used to adjust measures of life expectancy. Sometimes there can be more 
complicated cases: for example, cancer treatments may cause a QALY loss in the 
short term in order to achieve a QALY gain in the longer term (Drummond et al., 
1997). Although not without controversy, in technology appraisals by agencies 
including NICE in England/Wales, Pharmaceutical Benefits Advisory Committee 
(PBAC) in Australia, and Canadian Agency for Drugs and Technologies in Health 
(CADTH) in Canada, the QALY is often used. In such appraisals, clinical outcome 
measures are expected to have an impact on both survival or health-related quality of 
life and should be able to be translated into QALYs for evaluations of 
cost-effectiveness (NICE, 2008; CADTH, 2013; PBAC, 2013). The concept of 
QALYs will be discussed in more detail in section 5.7. 
 
5.2. Effectiveness measure for depression treatment  
 
Historically, clinicians or researchers have often assessed the short-term effectiveness 
of depression treatment according to response rates using different clinical scales. For 
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instance, antidepressants are typically evaluated in clinical trials using efficacy 
measures (e.g. the HDRS or the Montgomery-Asberg Depression Rating Scale 
(MADRS)), and efficacy is usually determined by defined reductions on the scale 
used, say of 50% (Zajecka, 2003). However, as a chronic and relapsing illness, the 
long-term outcome for depression remains rather disappointing despite many 
short-term studies with antidepressants having demonstrated efficacy.  
 
While response often denotes a 50% reduction in depression symptom scores, the 
term remission refers to the virtual elimination of active depressive symptoms (for 
example, 17-item Hamilton Depression Rating Scale (HDRS17) scores <=7) (Frank et 
al., 1991; McIntyre et al., 2002). Over the past decades, it has become increasingly 
recognised that responding to depression treatment but failing to achieve full 
remission constitutes an adverse outcome (Anderson et al., 2000; Ballenger, 1999). 
The consequences of not achieving remission can be serious, leading to greater risk of 
relapse/recurrence (Judd et al., 2000; Ramana et al., 1995), more frequent depressive 
episodes and shorter periods between episodes (Judd et al., 2000); it may even result 
in increased mortality and morbidity (de Groot et al., 2001; Empana et al., 2005; 
Ickovics et al., 2001). In contrast, treating to remission is shown to be beneficial to 
long-term outcomes, leading to a reduced risk of relapse and improved psychosocial 
functioning (Judd et al., 2000; Miller et al., 1998; Thase et al., 1992). Therefore, 
where possible, the key goal of an intervention for depression treatment should be 
remission (Kennedy and Foy, 2005).  
 
Although desirable, obstacles remain in the way of achieving remission. Drop-outs 
from treatments are high. In clinical practice, a large proportion of patients 
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discontinue antidepressant therapy during the first 30 days (42.4%) and only 27.6% 
continue antidepressant therapy for more than 90 days (Olfson et al., 2006). Besides, 
inadequate treatment response is a concern. The typical rates of response across 
antidepressant trials are 60% to 70% over the study periods, usually lasting several 
months, while remission rates are much lower, ranging from 30% to 50% (Ferrier, 
1999; Rush and Trivedi, 1995). For example, antidepressant response rates in a 
tertiary, university-affiliated hospital database of 259 patients (with symptoms 
assessed at 8, 14, 20, and 26 weeks) revealed that only 36% of patients achieved full 
remission with antidepressant treatment, implying that 64% of patients had 
unsatisfactory treatment response (Kennedy et al., 2001). 
 
Evidence suggests that there is a window of opportunity for achieving full remission 
of depression and an increasing duration of depression has a negative impact on the 
probability of recovery (Keller et al., 1992; Lin et al., 1998). In an observational study 
of 431 patients treated with MDD, 50% of patients recovered within the first six 
months (Keller et al., 1992). The likelihood of recovery in subsequent months 
declined from 15% during the first three months of follow-up to 1% to 2% per month 
three to five years after the start of the study. Therefore, history of previous episodes 
or disease duration seems to be an important factor in determining the clinical 
outcomes of depression. 
 
Failing to achieve full remission of MDD increases the risk of relapse (Judd et al., 
1998; Judd et al., 2000; Lin et al., 1998; Paykel et al., 1995). The presence of ongoing 
subthreshold symptoms suggests that the depressive illness is still active (Judd et al., 
1998). Patients with residual subthreshold depressive symptoms have significantly 
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more severe and chronic courses, with shorter well intervals than asymptomatic 
patients (Judd et al., 2000). Several studies have reported that the risk of recurrence is 
three times that of patients without residual symptoms (Judd et al., 1998; Lin et al., 
1998; Paykel et al., 1995). Patients with residual symptoms relapsed to their next 
major depressive episode more than three times faster than asymptomatic patients and 
to any depressive episode more than five times faster in a naturalistic study that 
followed up patients (n=237) for at least ten years after treatment (Judd et al., 1998). 
As a strong predictor of subsequent relapses, researchers have reported that after 15 
months of follow up, relapses occurred in 76% of the patients with residual symptoms 
versus 25% of those without (Paykel, 1998; Paykel et al., 1995).  
 
Furthermore, evidence from a randomised trial in primary care clinics showed there 
may be potential savings in costs by treating depression to remission (Simon et al., 
2000). In a naturalistic study, remitting patients have been reported to have three 
fewer outpatient visits and 22 fewer sick leave days than non-remitting patients. 
Health-related quality-of-life scores measured by the EuroQol five dimension (EQ-5D) 
improved by 40% for remitting patients when compared with non-remitting ones 
(Sobocki et al., 2006). Although the above findings are all context-specific, remission 
is likely to have substantial economic benefits, which further strengthens the case of 
aiming for full remission in the treatment of depression. 
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5.3. Use of remission as an outcome measure in database studies 
 
Prospective naturalistic studies have been carried out to explore health problems using 
computerised databases. Compared to clinical trials, use of databases can improve 
generalisability of findings due to the use of less restrictive inclusion criteria. 
Database studies are also useful when assessing economic impacts of depression 
treatment to complement results from randomised trials. The relative completeness of 
information (albeit from a narrower perspective) in databases can be the best available 
direct source of cost information particularly when treatment costs are the main 
concern. Moreover, given the chronic and relapsing nature of depression, the 
longer-term economic impact of the illness and treatment would be of greater 
importance than its short-term effects. In this sense, database studies can provide 
longitudinal information on service use, and hence costs, after the acute and/or even 
continuation phase of treatment which clinical trials seldom afford.  
 
However, clinical rating scales are usually not available in databases because key data 
in these databases are prescriptions, pharmacy claims and service use. It is not 
possible to ascertain the remission defined by clinical rating scales, like the HDRS, in 
database analyses. As a result, the measurement of longer-term clinical impacts 
following the outcome of acute phase treatment, e.g. remission/non-remission, cannot 
be readily generated. 
 
In response to this, the use of ‘approximate definitions’ has been proposed. 
Sicras-Mainar and colleagues described the concordance between remission 
determined by clinical assessment and a database definition of remission, i.e. 
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cessation of antidepressant use based on information obtained from computerised 
prescription databases of patients with major depression (Sicras-Mainar et al., 2010a). 
In that study, a specialist in psychiatry assessed a random sample of patient histories 
and determined whether patients were in remission according to clinical criteria, i.e. 
International Classification of Primary Care (ICPC-2) (Lamberts et al., 1993). 
Regarding the database definition, patients were considered in remission when they 
did not receive further prescriptions of antidepressants for at least six months after 
completing treatment for a new episode. The 4,572 subjects were selected according 
to the following criteria: 1) over 17 years old, 2) had a major depression episode with 
a treatment prescribed between January 2003 and March 2007, 3) demonstrated a 
period of at least six months without depression prior to the major depression episode, 
4) prescription followed minimum required treatment criteria, i.e. > 60 days of 
antidepressant treatment after the first prescription (NICE, 2004), and 5) a follow-up 
occurred of at least 18 months (12-month study period and another six-month 
observational period to assign study sub-group). Two sub-groups were considered: 
patients in remission and patients not in remission. The underlying assumption seems 
to be that a new episode for depression is defined as having an antidepressant 
prescription with no prescription in the previous six months (Wade et al., 2007) and 
from this, it can be derived that if a patient stops treatment and has no new 
prescription during the following six months, he/she has completed a depression 
episode. If he/she starts an antidepressant after that, it will be a new episode. While 
this proxy definition of remission may have its merits for database analyses, there are 
obviously other reasons for a patient to stop medication, e.g. lack of effectiveness, 
side effects, or patient-physician communication failures (Demyttenaere, 1997; 
Johnson, 1981). Therefore, modifications may be needed in applying this proxy 
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definition to analyses which will be discussed later in this chapter. The concordance 
between remission by approximation and remission according to clinical criteria in 
Sicras-Mainar et al (2010) is detailed in Table 5.1. 
 
Table 5.1. Validity of remission by approximation from Sicras-Mainar et al. 
(2010) 
Validation Method 
Remission by Approximation 




Positive 74 5 
Negative 6 48 
Statistics Value (%) 95% CI 
Validity of the measurement   
   Sensitivity 92.5 88.0 - 96.9 
   Specificity  90.6 85.6 - 95.6 
   Positive predictive value  93.7 89.6 - 97.8 
   Negative predictive value  88.9 83.6 - 94.2 
   False positives  7.5 3.0 - 11.9 
   False negatives  9.4 4.4 - 14.4 
Reliability   
   Cronbach’s alpha 90.6 85.6 - 95.6 
   Area under the curve  91.2 86.5 - 96.1 
Concordance   
   McNemar test   58.1 49.7 - 66.5 
   Pearson correlation  82.8 73.1 - 92.5 
   Weighted kappa (Cohen) 82.8 73.1 - 92.6 
Clinical utility   
   Positive Probability Ratio  9.8 — 
   Negative Probability Ratio 0.1 — 
Reference criteria: Review of patients’ histories. Significance: p < .001 in all 
cases. CI: confidence intervals (adapted from Sicras-Mainar et al. 2010) 
(Sicras-Mainar et al., 2010a)
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This database definition of remission has been employed in another economic 
evaluation study (Byford et al., 2011) in which 12-month costs were compared 
between remitters and non-remitters. Costs were significantly lower for patients who 
experienced remission after the acute treatment phase than for those with less favourable 
outcomes, and total costs fell over time at a faster rate for remitters compared to 
non-remitters. Nevertheless, this approximate definition can cause several problems. 
There may be other motives for discontinuing the prescription other than the patient 
being in remission (lack of effectiveness or adverse side effects etc.). On the other 
hand, persistence of treatment with antidepressants should not always be interpreted 
as absence of remission, as it is recommended that patients be maintained on 
medications after achieving remission, and for a longer period in selected patients at 
risk of relapse (Kupfer, 1991). Limitations of this database definition of remission and 
its potential application will be discussed in the next section. 
 
5.4. Limitations and modifications of the database definition of remission and 
consideration of ‘treatment-free status’ 
 
The justification for the above-mentioned database definition of remission is based on 
its comparison with the clinical criteria by a chart review of patients from six primary 
care centres in Spain. In their discussion, the authors suggested ‘caution in 
generalising the results’ (Sicras-Mainar et al., 2010a). Indeed, the generalisability is 
questionable when applied to other populations, e.g. in Taiwan. Moreover, in the 
above study, the authors provide data on the internal consistency of treatment 
cessation in relation to clinical remission. The validity of this approach to determining 
remission could be still invalid as other measures should have been used for assessing 
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its reliability and predictive ability. Taking into consideration both the strengths and 
limitations, it may be better to interpret this definition of remission in other ways to 
avoid confusion with actual remission defined by clinical rating scales. 
 
In the analyses presented in this thesis, a more descriptive term ‘treatment-free status’ 
is thus used instead of ‘remission’ (Pan et al., 2013c). Meanwhile, ‘late re-contact’ is 
used instead of ‘relapse/recurrence’. In recent research using the same database 
definition, ‘sustained treatment-free status’ was further defined which required no 
re-start of antidepressant treatments (late re-contacts) through the 18-months 
follow-up period (Pan et al., 2013c). The ‘sustained treatment-free status’ was shown 
to be associated with early attrition and also to impact long-term treatment costs as 
shown in Chapter 6 of this thesis (Pan et al., 2013a). While acknowledging the 
limitations of this database definition, the term ‘sustained treatment-free status’ seems 
likely to indicate initial treatment effectiveness without later clinical fluctuations 
sufficient to trigger a medical contact while simultaneously specifying another 
subgroup of subjects who have later re-contacts which may reflect changes in clinical 
conditions such that help-seeking is considered beneficial. 
 
Since the National Health Insurance Research Database (NHIRD) in Taiwan did not 
provide direct clinical information, diagnostic accuracy, severity of depression and 
treatment response could not be definitively ascertained in this thesis. The use of 
‘sustained treatment-free status’ instead of remission in this thesis may therefore make 
any conclusion about remission, relapse or clinical outcome more challenging to make. 
Clinical visits might be triggered and/or maintained by clinical contingencies, as well 
as other factors pertinent to help-seeking behaviours, and so ‘sustained treatment-free 
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status’ and ‘late re-contact’ are not equivalent to clinical outcomes although they may 
be considered as proxies for such effects. Furthermore, regular service attendance 
does not ensure compliance to prescribed medication. These methodological issues 
can be difficult to resolve, given the case numbers in a study such as this and the 
inherent clinical heterogeneity. Through proper sampling and linkage to clinical 
records, further studies may focus on proper validation of the clinical diagnosis, 
ascertainment of symptoms and severity, to explore the correspondence and disparity 
between help-seeking behaviours and clinical outcomes. 
 
5.5. Utility/quality weights for health states 
 
In economic evaluations ‘utilities’ are often used to measure outcomes and are 
anchored by 0 and 1, where 0 indicates death and 1 indicates full health (Drummond et 
al., 1997). States worse than death can also be included, with these taking a negative 
value. Measurement of utility requires health states to be defined and described and 
then valued. Such valuation can be direct or indirect.  
 
Direct elicitation methods 
 
In direct measurements, the relevant dimensions of health and levels of each 
dimension are assessed. Examples of these dimensions include physical, social and 
cognitive function; psychological well-being; and pain. These are incorporated into a 
health state description for the disease or condition of interest and should be based on 
direct patient experience, although health professional views and values from the 
literature can also be used (Whitehead and Ali, 2010). The most well-known 
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approaches to value health states are the visual analogue scale (VAS), the time trade-off 
(TTO) and the standard gamble (SG). 
 
The simplest approach to measuring utilities is to ask the individual to rank health states 
from most preferred to least preferred and to place the states on a scale such that the 
intervals between placements relate to their preferences (Drummond et al., 1997). The 
VAS is an example of this approach which involves the use of a scale shown on a single 
line.  
 
The SG approach is considered the classical method of measuring utilities when 
uncertainty exists. It was formulated by von Neumann and Morgenstern (1944) who 
developed a model where they described how a rational individual would make 
decisions in the face of uncertain outcomes. The SG approach involves presenting the 
individual with a choice between two alternatives: a health state that is certain and a 
gamble with one better (full health) and one worse (usually death) outcome possible. 
The probability of experiencing the worse outcome is varied until the individual is 
indifferent between the gamble and the health state currently being experienced (or 
assumed). The probability at that point represents the value of the health state. 
 
The TTO approach requires the individual to consider how much time in full health 
they would be willing to sacrifice to avoid a certain poorer health state (Burstrom et 
al., 2006). The individual may be indifferent between a particular health state say of 
ten years and a shorter lifetime of seven years, resulting in an estimated utility for this 
health state of 0.7 (seven years divided by ten years).  
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Indirect elicitation methods 
 
Direct elicitation methods are time consuming and thus rarely used in evaluations. 
Indirect elicitation methods are seen as a practical alternative in many studies because 
they involve the use of pre-scored generic preference-based measures. In these 
standardised measurements, health states are described, which cover a range of general 
aspects (or dimensions) of health. The EuroQol five dimensions (EQ-5D), the Short 
Form 6D (SF-6D) (Brazier et al., 2002) and the Health Utilities Index (HUI) (Horsman 
et al., 2003) are examples. The above measures differ in the dimensions of health that 
are assessed and the number of levels defined for each dimension. The values derived 
for each state were obtained from a TTO exercise for the EQ-5D and HUI (Drummond 
et al., 1997), while the SF-6D was based upon the SG approach (Brazier et al., 2002).  
 
The EQ-5D was found to be the most commonly used generic instrument in cost utility 
analyses by a previous review (Richardson and Manca, 2004). It has five domains: 
mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 
three levels: no problems, some problems or severe problems. The 243 possible health 
states from the EQ-5D have a utility value attached to them. The EQ-5D is short and 
can be self-completed or used in face-to-face interviews (EuroQol Group, 2013). 
 
Generic instruments may allow comparisons across disease groups, but may be 
insensitive to particular aspects of certain conditions. This has led to the development 
of some condition-specific measures such as the Asthma Quality of Life Questionnaire 
(Haldar et al., 2009) and the Inflammatory Bowel Disease Questionnaire 
(Dudley-Brown et al., 2009).  
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Limitations and controversy in valuing utilities 
 
It is noteworthy that various approaches can generate different utility values, even 
where the same individual is valuing the health states. This can partly be due to 
differences in the health domains that are assessed as well as the use of different 
valuation methods. Therefore, the method used to generate utility values should be 
cautiously considered when applying such values. 
 
5.6. Utility weights (quality weights) and related studies in patients with 
depressive disorders 
 
Since depression is associated with marked decreases in functioning and health-related 
quality of life (Hays et al., 1995; Saarijarvi et al., 2002), as well as an increase in 
disability days (Lecrubier, 2001), it is essential to evaluate economic impacts of 
depressive disorders while incorporating quality of life data. Additionally, because 
antidepressant treatments have been shown to be effective in reducing depression 
severity (Brown et al., 2000; Nierenberg, 2001) and in increasing patient functioning 
and health-related quality of life (Revicki et al., 1998; Reynolds, 1997), conducting a 
cost-utility analysis comparing impacts of antidepressant treatments on cost and quality 
of life seems sensible. Analysis of data from randomised trials found that patients in 
remission were more likely to maintain paid employment and report fewer days missed 
from work (Simon et al., 2000). Possibly, depressed patients with different levels of 
clinical responses may differ in levels of functioning and quality of life as well.  
 
In depressive disorders, a number of studies have evaluated the suitability of the use of 
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the EQ-5D, which has been applied in various areas as a measure of outcome in studies 
comparing different treatments (EuroQol Group, 2013). The EQ-5D shows good 
correlation to clinician rated measures of depressive symptoms severity, e.g. CGI 
(clinical global impression scale) and BRAMES (Bech-Rafaelsen melancholia scale) 
(-0.539, -0.576) in patients with depression (Gunther et al., 2008). For patient-rated 
severity measures such as the Patient Health Questionnaire (PHQ), the correlation is 
also moderately good (-0.451 to -0.638) (Mann et al., 2009). In terms of responsiveness, 
the EQ-5D is very responsive to improvement in depressed patients (Caruso et al., 2010; 
Fernandez et al., 2005; Reed et al., 2009; Sapin et al., 2004; Sobocki et al., 2007; Swan 
et al., 2004). But the findings from Serfaty et al (2009) suggest that the EQ-5D is less 
responsive than the BDI-II (Beck depression inventory-II). The patient group in that 
study had a mean age over 70 years old, suggesting that the EQ-5D might perform 
worse for older persons with depression. 
 
Using clinical rating scales, depressed patients are usually categorised as responders 
and remitters (Committee for Proprietary Medicinal Products, 2002). Previous utility 
studies have also found substantial differences in EQ-5D mean utility between patients 
identified as in remission versus those who are not (Mann et al., 2009; Sapin et al., 
2004). Moreover, as responders sometimes present residual depressive symptoms, 
‘responder remitters’ ‘responders non-remitter’ and ‘non-responders’ were further 
categorised in a study with MDD patients in primary care (Sapin et al., 2004). In that 
study, the different clinical response profiles, assessed by the MADRS, were also 
revealed by EQ-5D at endpoint: 0.85 for ‘responder remitters’, 0.72 for ‘responders 
non-remitter’, and 0.58 for ‘non-responders’. Considering that the study was 
conducted in France, it may have been better to use social preference values based on 
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the French general population. But these values were not available and weights were 
therefore adopted from a UK study that provided the technical estimates widely used in 
countries that lack their own reference data (Dolan et al., 1995). 
 
For different countries including the UK, Germany, Japan, and the USA (Dolan, 1997; 
Greiner et al., 2005; Tsuchiya et al., 2002; Shaw et al., 2005), an index score is 
available and assigned to all health states described by the EQ-5D according to a set of 
preference values derived from surveys of the general populations. In depressive 
disorders, a number of studies have evaluated the suitability of applying the EQ-5D 
index-UK, derived from preference values of the UK general population (Hayhurst et 
al., 2006; Lamers et al., 2006; Sapin et al., 2004). For instance, more severe patients 
with MDD have been demonstrated to have lower scores of EQ-5D index-UK (Sapin et 
al., 2004). Several other studies showed that the EQ-5D index-UK discriminates 
between groups with varying levels of depression (Hayhurst et al., 2006; Lamers et al., 
2006). Overall, the results demonstrated that the EQ-5D index-UK had medium to large 
correlations with clinical measurements of depression severity.  
 
Utility values are needed for calculating QALYs in economic evaluations (Gold et al., 
1996b; Pyne et al., 1997; Torrance and Feeny, 1989). However, despite of the 
availability of the Taiwanese valuation set for the EQ-5D health states (Lee et al., 
2013), there have been no utility data on the different health states of depression based 
on the EQ-5D index-Taiwan. Therefore, the utility values from research using the 




Limitations in the use of quality weights elicited from a different country 
 
The use of the EQ-5D index-UK to assign utility values to Taiwanese patients could 
have potential problems. People from different countries could differ in the preference 
values they place on health states (Badia et al., 2001; Johnson et al., 2005). Indeed, 
these preference values have also been shown to differ between ethnic groups even 
within a country (Shaw et al., 2007). Despite these limitations, it is not uncommon to 
apply social preference values elicited from other countries in cost-utility studies due 
to the lack of well-established data from the country where the study is set. Among 
the country-specific scores, the EQ-5D index-UK has been widely applied in 
cost-utility studies in countries other than the UK. For instance, despite the 
availability of the EQ-5D social tariff from neighbouring Denmark, one Swedish 
study chose to use the EQ-5D index-UK because it was more established and widely 
used (Burstrom et al., 2006). 
 
There are other reasons to choose the EQ-5D index-UK rather than index scores from 
other countries to assign utility values in this thesis. Firstly, compared to other 
country-specific scores, the EQ-5D index-UK has been widely tested for its suitability 
in the field of depression research and data on the utility values of different depressive 
health states using the EQ-5D index-UK are relatively complete. Secondly, despite 
the availability of the Taiwanese valuation set for EQ-5D health states, there have 
been no utility data on health states of depression based on this index (Lee et al., 
2013). The index in Taiwan was estimated using TTO method (Lee et al., 2013). The 
rank correlation coefficients and mean absolute differences between estimated quality 
weights of 243 health states in the Taiwanese sample and those estimated in the UK 
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(Dolan, 1997), Japan (Tsuchiya et al., 2002) and South Korea (Jo et al., 2008) have 
been calculated. The magnitude of the mean absolute differences between the Taiwan 
and the UK weights (0.146) was much smaller than the differences between the 
Taiwan weights and those from Japan and South Korea (0.422 and 0.592, 
respectively). Additionally, the rank correlation coefficient of estimated values 
between the Taiwanese and the UK weights was 0.924, indicating a strong positive 
correlation, whereas the correlations between the Taiwan weights and those of Japan 
and South Korea were 0.879 and 0.811, respectively. Therefore, if weights from 
another country are to be used in this study, then the weights from the UK seem more 
appropriate compared to those from apparently more similar countries in the same 
region as Taiwan.  
 
An international comparison of country-specific EQ-5D values for health states has 
showed the same approximate relative importance of health states across countries 
(Norman et al., 2009). It seems likely that despite the presence of different preference 
values for certain health states across countries, the main trend for the rank of health 
states is similar. Specifically in depressive disorders, a previous study demonstrated 
that despite the differences in the absolute utility values based on the EQ-5D 
index-UK and EQ-5D index-Germany, changes in utility values between different 
health states of depression are very similar for the two country-specific index scores 
(Günther et al., 2008). In this sense, the adoption of the EQ-5D weights from another 
country seems to be a viable choice in the proposed cost-utility analyses in this thesis 
given the focus on the changes in utility values (but not in the absolute values) 
between health states of patients with depressive disorders. 
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5.7. Quality-adjusted life-years (QALYs) 
 
In cost utility analysis, QALYs are used as outcome measures and these are derived 
from the utility values using area-under-the-curve methods (Drummond et al., 1997). 
Given that the QALY combines information on mortality and morbidity, it is 
potentially of use for comparing interventions (Kind et al., 2009). However, it has 
been criticised as being too reductionist (Knapp, 2007). It may account for some 
aspects of a healthcare intervention but may neglect many others. Other concerns are 
associated with the fundamental underpinnings of the QALY (Lipscomb et al., 2009). 
It is for example assumed that the value of being in a health state for two years is twice 
that of being in the health state for one year (Hauber, 2009). Related to this is the 
assumption that any combination of time in a health state and utility of that state that 
gives rise to X QALYs is equivalent. This independence between quantity and quality 
may not hold. Therefore, although QALYs are potentially powerful measures, we 
should also be cautious in how they are applied.  
 
5.8. Summary and implications 
 
In this chapter, effectiveness measures for depression treatment were considered 
within the specific context of the proposed database analyses based on 
routinely-collected healthcare information in Taiwan. Clinically judged remission is 
an ideal treatment goal for depression treatment, but it may not be a viable choice in 
this thesis due to lack of the necessary clinical outcome data. Alternatively, the 
suitability of a database-derived remission definition was evaluated and then, the 
usefulness of a modified definition of sustained treatment-free status was considered. 
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Valuation methods for utilities were summarised with a focus on generic utility 
instruments. Specific data on utilities of health states for patients with depression 
were reviewed. Limitations and controversy regarding utilities and valuation methods 
were discussed as well. Data of utilities for health states of depression are relatively 
limited. Future research is needed to provide utility values through both direct and 
indirect elicitation methods, and to explore appropriate methods for linking these to 




Chapter 6. Relationship between depression outcomes and subsequent costs 
 
The purpose of this chapter is to assess the longer-term economic impacts of outcome 
status following initial treatment for depression. Service use and costs for patients 
with depression for a longer period of follow-up (i.e. three consecutive years) are 
described. Since the type of depression, past treatment history, comorbid 
mental/physical illnesses, painful physical symptoms (PPS), and choice of initial 
antidepressants were found in Chapter 4 to be associated with healthcare costs and 
service use for patients treated for depression in Taiwan (Pan et al., 2013b), the 
analyses in this chapter are conducted taking into account the above factors. Specific 
objectives are to explore factors associated with initial treatment outcome status 
(sustained treatment-free status, continuous treatment, and late re-contact) and to 




Although the relationship between depression and levels of health service use and 
costs has been consistently reported (Katon, 2003; Simon et al., 1995), much less is 
known about how this relationship is influenced by treatment outcomes. Data from 
longitudinal studies suggest that costs are significantly lower for patients who 
experience remission after the acute treatment phase than for those with less 
favourable outcomes (Sicras-Mainar et al., 2010b; Simon et al., 2006; Sobocki et al., 
2006). Furthermore, total costs have been shown to fall over time at a faster rate for 
remitters compared to non-remitters (Byford et al., 2011). However, the existing 
literature is limited in a number of ways. First, findings have been based on relatively 
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small samples (Simon et al., 2006; Sobocki et al., 2006). Second, the duration over 
which study subjects have been followed-up in each study has been limited to six to 
12 months; and so the impact of initial treatment outcome status on service use and 
costs beyond this point is unknown. Third, many of the studies assessed outcome, e.g. 
remission, at a point when a large proportion of participants were still receiving 
antidepressants, thus leaving the impact of cessation of antidepressant treatments, 






Data were extracted from the National Health Insurance Research Database (NHIRD). 
As stated previously, the index date for the analyses was defined as the date on which 
the subject was first prescribed with an antidepressant for a diagnosis of depressive 




All insured subjects of the NHI system in Taiwan meeting the following criteria were 
included: 
 
 Age 18 years or over on the index date. 
 At least one prescription for an antidepressant for treatment of major depressive  
disorder (MDD: ICD-9-CM codes: 296.2x, 296.3x) or other depressive disorders 
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(ICD-9-CM codes: 300.4x, 311.xx) in 2003.   
 At least three antidepressant prescriptions within the first three months of the 
index date (Byford et al., 2011). 
 Data available for a minimum of 12 months before the index date and a  
minimum of 36 months after the index date. 
 
Definition of initial outcome status 
 
In this chapter, proxy criteria for treatment outcomes were operationally defined, 
which focused on the cessation of antidepressant treatment. This proxy measure has 
been validated by evaluating the concordance between ‘remission’ as defined by 
antidepressant cessation for at least six months and remission determined by clinical 
criteria; the level of concordance between the two approaches was considered 
acceptable (Cronbach's alpha 90.6%, 95% CI 85.6, 95.6) (Sicras-Mainar et al., 2010a). 
The proxy measure of remission was also used in a recent economic evaluation for 
patients with depression (Byford et al., 2011), a naturalistic, longitudinal study carried 
out using data from a large primary care UK general practice research database 
between 2001 and 2006. That study included patients receiving at least three 
antidepressant prescriptions in the first three months and remission was defined as 
patients not using antidepressants for at least six months after antidepressant treatment 
had ended. The results showed that over 12 months from the index prescription, 
patients classified as non-remitters had more contact with primary care services (17 vs. 
13 GP visits) and secondary care psychiatrists and other specialists (47% vs. 40%). 
Total 12-month costs per participant were significantly lower for remitters. 
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Despite the usefulness of this proxy definition of remission in previous studies, to 
prevent confusion from actual remission defined by clinical rating scales, a more 
descriptive term (treatment-free status) instead of remission was used in this thesis 
(also see Chapter 5). Additionally, ‘sustained treatment-free status’ was defined as no 
re-start of antidepressant treatments (late re-contacts) through the 18-month follow-up 
period (Pan et al., 2013c). As with Byford et al. (2011), only participants who had at 
least three antidepressant prescriptions in the first three months were included to 
ensure that a group of depressed patients with an initial presentation that justifies 
antidepressant treatment was identified (Byford et al., 2011). 
 
Study participants were therefore grouped according to three treatment outcomes: 
 (i) Sustained treatment-free status: patients who had antidepressant cessation for 
at least six months and had not restarted antidepressant use by the end of the 
18-month observation period (see below for definition of the 18-month observation 
period). 
(ii) Continuous treatment: patients who had not had cessation of antidepressant 
use for at least six months by the end of the 18-month observation period.   
 (iii) Late re-contacts: patients who had achieved antidepressant cessation for at 
least six months but later restarted antidepressant use during the 18-month period of 
observation. 
 
Observation period for treatment outcome status 
 
For each individual, the observation period started on the index date, and continued 
for 18 months after this point. The additional six months after the first 12 months was 
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included to ensure there was adequate time to assess whether treatment-free status had 
been achieved, given the definition described above. The treatment-free period, i.e. 
cessation of antidepressant treatment, could begin at any point during the 12 months 
after the index date (please refer to Figure. 6.1.), but a participant needed to remain 
off antidepressants for a minimum of six months to meet the definition. Hence, an 
observation period of 18 months was required. 
 
Figure. 6.1. Diagram for time periods used in the analyses 
 
 
Demographic and clinical information 
 
Demographic and clinical data, including age, gender, index diagnosis of depressive 
disorders (MDD vs. other depression), and initial choice of antidepressants were 
extracted. Provider information (the prescribing physician: psychiatrist vs. 
non-psychiatrist) and clinical setting at the initial visit (outpatient, emergency or 
inpatient services) were also extracted. Participants were grouped according to past 
treatment history: newly diagnosed depression (defined as people who had not 
received antidepressant treatment or a depression diagnosis in the 12 months before 
the index date) and non-newly diagnosed depression. 
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Baseline characteristics were collected regarding comorbid mental disorders, physical 
illnesses (cardiovascular disease, diabetes mellitus, chronic obstructive pulmonary 
disease, renal diseases, and cancer), painful physical symptoms (PPS) (headache, 
backache, musculoskeletal and gastrointestinal pain, and others) (also see Chapter 3, 
Section 3.2.), as well as healthcare utilisation/expenditure during the 12 months prior 
to the index visit.  
 
Service use and costs 
 
Service use data extracted from the NHIRD for the three years following the index 
date included contacts with outpatient services, emergency attendances, and inpatient 
stays (for all reasons). The percentage of patients with at least one unit of service use 
and the mean number of service contacts were reported. Annual costs (including all 
medication costs) were calculated from the actual claims data, were converted by 
purchasing power parity (PPP) conversion rates (World Economic Outlook (WEO) 
data, 2013) and expressed in international dollars. 
 
Statistical analyses  
 
Sociodemographic data, clinical characteristics, baseline comorbidities, as well as 
initial choice of antidepressants were described and compared between groups by 
initial outcome status. Service use and costs of groups based on these outcomes were 




To identify characteristics predictive of outcome statuses, a multinomial logistic 
regression analysis was performed, with treatment outcomes as the dependent 
variables; the independent variables included age, sex, index depression diagnosis, 
past treatment history, physician specialty, clinical settings at index visit, initial choice 
of antidepressants, baseline comorbid mental/physical disorders, and baseline PPS. 
 
A multivariable generalised linear model regression with a log link and gamma 
variance function was employed (McCullagh and Nelder, 1989) to examine the effects 
of initial treatment outcomes on total healthcare costs while adjusting for other 
independent factors. Besides the first year model, separate models were separately run 
for the second year, and third year total healthcare costs to explore the impacts of 
initial outcome status on total healthcare costs over the longer-term follow-up. 
Considering potential issues of multiple comparisons, a stringent significance criteria 
of p-value < 0.01 was adopted for all statistical analyses, which were performed using 




Besides the inclusion criteria used in Chapter 4, subjects were required to have at least 
three antidepressant prescriptions within the first three months of the index date to be 
included in the current analysis. This was to recruit a population of patients whose 
depressive disorders were initially severe enough to trigger clinical visits with 
antidepressant treatments and to follow up them for the consecutive three years (also 
see Section 6.2.). As a result, a total of 126,471 adults met the inclusion criteria. 
Among them, 43,065 (34.1%) were classified as having achieved sustained 
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treatment-free status, 71,543 (56.6%) were classified as being continuously on 
antidepressant treatment, and 11,863 (9.4%) had cessation of antidepressants for six 
months and late re-contacts during the observation period. 
 
Table 6.1 shows that there were noticeable differences in several demographic and 
clinical variables between groups by treatment outcomes. The largest difference was 
noted for past treatment history. Index depression diagnosis and comorbid mental 
disorders also differed substantially between the groups. 
 
Table 6.2 shows that there were significant differences in the use of various services 
and costs between the three outcome groups (except for psychiatric emergency 
services in the first year). These differences remained until the end of the three-year 
follow-up. Notably, while service use and costs in the first year were relatively 
comparable between the groups, service use and costs for those who achieved 
sustained treatment-free status sharply decreased in the second and third years (e.g. 
84.6% used psychiatric outpatient services in the first year while only 27.1% and 
28.2% used such services in the second and third year respectively) and were much 
lower than those for the other groups of patients: 87.5% of subjects in the group of 
late re-contact used psychiatric outpatient services in he first year, 78.4% in the 
second year and 59.6% in the third year). 
 
Factors associated with treatment outcome status  
 
In Table 6.3, the multinomial logistic regression shows that patients who achieved 
sustained treatment-free status tended to be younger than those who were on 
 188 
continuous treatment. Younger age was also predictive of having late re-contacts. 
Females were more likely to have late re-contacts than being on continuous treatment. 
Patients who had MDD were more likely to be continuously on antidepressant 
treatment. Newly diagnosed depression was associated with sustained treatment-free 
status and late re-contact, rather than being on continuous treatment. Patients with a 
history of both antidepressant treatment and a diagnosis of depression were the most 
likely to be on continuous treatment. Physician specialty at the index visit was 
associated with sustained treatment-free status and being diagnosed and prescribed 
antidepressant treatment by a psychiatrist (compared to other physicians) was 
associated with higher odds of being continuously on antidepressant treatment.  
 
Regarding baseline comorbidities, having cancer or renal disease was associated with 
sustained treatment-free status rather than being continuously on antidepressant 
treatment. Certain kinds of PPS (backache, musculoskeletal, or gastrointestinal pain) 
were associated with higher odds of having late re-contacts. The presence of comorbid 
mental illnesses was associated with higher odds of being on continuous treatment, 
with the only exception being dementia which was associated with higher odds of 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Factors associated with total costs in the years after initial treatment 
 
The analysis of total healthcare costs over the subsequent three years (Table 6.4) 
revealed that sustained treatment-free status was associated with the lowest total costs 
in the second and third years compared to either patients who were on continuous 
treatment or those who had late re-contacts.  
 
Beyond the first year, total costs appeared to increase consistently with age, and this 
trend became more prominent through the second year to third year. Male gender was 
associated with higher total costs for all three years, as was having a diagnosis of 
MDD. In these models, patients who were diagnosed by non-psychiatrists on the 
index date had higher total costs for the subsequent three years as did those diagnosed 
when they were inpatients. The presence of physical comorbidities and PPS were 
associated with higher costs for all three years. Having comorbid mental illnesses was 
generally associated with higher total costs, with exceptions being generalised anxiety 





This chapter has described the distributions of treatment outcomes after initial 
antidepressant treatment in a real-world setting using data from a large national cohort. 
Demographic and clinical factors associated with treatment outcomes were also 
explored. These analyses have added to the evidence base by showing that treatment 
outcomes following initial antidepressant treatments can impact total healthcare costs 
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over the longer-term. Specifically, patients who experienced sustained treatment-free 
status following initial treatment were found to have significantly lower costs in the 
second and third years after the index date, compared to those with less favourable 
outcomes. In addition, treatment outcomes and total costs differed according to initial 
choice of antidepressants as well as the presence of comorbid mental disorders and 
PPS. 
 
The impact of treatment outcome status on costs 
 
The focus in this chapter on sustained treatment-free status is relevant in assessing the 
impacts of treatment outcomes over a longer-term follow-up since a high 
relapse/recurrence rate has previously been reported within the first six to twelve 
months of follow-up (Lin et al., 1998; Paykel, 1998; Shapiro and Keller, 1981). 
Although elsewhere a high rate of recovery (67.5%) has been reported during the first 
six months following treatment (Bottomley et al., 2010), earlier studies showed that 
only 30% of recovered patients remain in recovery and symptom-free during a 
one-year follow-up (Keller and Shapiro, 1981). This is in accordance with the current 
results that around 34% of subjects were classified as having sustained treatment-free 
status over the 18-month period of observation. In addition, the time course following 
discontinuation of treatment has been shown to be an important factor in determining 
the probability of relapse or recurrence. The risk of relapse is greatest shortly after 
recovery, especially in the first three to six months, and decreases over time (Keller, 
2003; Solomon et al., 2000). Therefore, to assess the real impact of treatment 
outcomes, it is important to evaluate the effect of sustained treatment-free status while 
taking into account re-contacts soon after this. 
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In this chapter, patients who achieved sustained treatment-free status after initial 
treatment have lower total costs in the second and third years after the index date 
compared to those with less favourable outcomes. The evidence from similar previous 
studies has been limited to examining service use and costs in the first six or twelve 
months following initial treatment, and these may include the treatment that led to the 
treatment outcomes. In this chapter, it was found that first year costs were higher for 
those patients achieving sustained treatment-free status than those who experienced 
late re-contacts. Compared to service use and costs for those who achieved sustained 
treatment-free status in the first year, it is noteworthy that their use of psychiatric or 
non-psychiatric services clearly decreased in the second and third years. An 
interpretation of this result could be that the higher total first year costs for those who 
achieved sustained treatment-free status may be due to the treatment required to 
achieve the sustained treatment-free status which then reduces costs in subsequent 
years. However, patients with insufficient treatment in the first year may then have 
higher costs subsequently as a result of not experiencing sustained treatment-free 
status.  
 
Depression type, physician specialty, and other clinical characteristics 
 
Patients with a diagnosis of MDD were more likely to remain on treatment than to be 
in either sustained treatment-free status or to have late re-contacts. A diagnosis of 
MDD at the index visit also predicted higher costs in the subsequent three years. In 
contrast, newly diagnosed depression was associated with sustained treatment-free 
status rather than being on continuous treatment, compared to those patients who had 
been diagnosed or treated prior to the index date. Having newly diagnosed depression 
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was also associated with lower costs in the second and third years. Regarding 
treatment setting on the index date, patients who had been diagnosed by a psychiatrist 
were more likely to be on continuous treatment, and they were found to have lower 
total costs over the three-year follow-up period than those diagnosed by a 
non-psychiatrist. Patients who were initially diagnosed in inpatient settings were more 
likely to subsequently have sustained treatment-free status rather than being on 
continuous treatment despite the fact that this was associated with higher total costs 
for the following years. 
 
These results support those from a previous study (Sobocki et al., 2006) in finding 
that disease severity could be an important factor in determining treatment outcomes 
after initial treatment. Although speculative, being diagnosed in inpatient settings 
could imply that depression is diagnosed through a psychiatric consultation during 
hospitalisation with it not being the primary disease leading to the hospitalisation. 
Conversely, a diagnosis of MDD, being diagnosed from a psychiatrist, or the presence 
of a prior history of treatment/or a diagnosis, could be indicators of greater disease 
severity and thus poorer outcome. Patients with non-newly diagnosed depression were 
shown to be least likely to have sustained treatment-free status as well as to have the 
highest costs in each of the three follow-up years, which may be related to the more 
chronic disease course. Along with increased age and physical comorbidities 
(discussed below), patients initially diagnosed in inpatient settings or diagnosed by a 
non-psychiatrist, possibly implying the presence of medical conditions, had higher 




Choice of initial antidepressants 
 
People prescribed with selective serotonin reuptake inhibitors (SSRIs) were more 
likely to have sustained treatment-free status than being on continuous treatment 
compared to patients prescribed other antidepressants (except flupentixol/melitracen); 
they were also more likely to have late re-contacts (Table 6.3). Flupentixol/melitracen 
was shown to be different from other antidepressants in having higher odds of 
sustained treatment-free status than SSRIs. To put this into context, 84.1% of the 
patients initially prescribed with flupentixol/melitracen were cases with depression 
other than MDD. Patients prescribed with SSRIs, compared to the overall sample, 
were also younger and more likely to be newly diagnosed with depression (also see 
Table 4.2). As patients with these characteristics tended to have an outcome profile of 
either sustained treatment-free status or late re-contacts, it seems probable that 
treatment outcomes for patients prescribed SSRIs may be partly accounted for by such 
characteristics. 
 
Compared to patients prescribed SSRIs, those prescribed serotonin norepinephrine 
reuptake inhibitors (SNRIs) and multiple antidepressants at the index visit had higher 
total costs over the subsequent three years. One interpretation is that patients with 
initial presentations of greater disease severity were more likely to be prescribed with 
SNRIs or multiple antidepressants than SSRIs, thus generating higher costs. 
Meanwhile, those prescribed tricyclic antidepressants (TCAs) or other older 
antidepressants had costs that did not differ significantly in the second and third years 
despite their lower total costs in the first year. This is consistent with a previous 
systematic review showing that while higher non-depression-related costs and lower 
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depression-related costs were found in TCA users in some studies, patients using 
TCAs generally had comparable healthcare costs to those using SSRIs in database 
studies (Pan et al., 2012). As comparable efficacy has been often reported between 
SSRIs and TCAs, what the current findings may add to the evidence base is that by 
showing that after taking into account treatment outcomes, total healthcare costs do 
not differ between patients prescribed SSRIs and older generation antidepressants 
over a longer-term follow-up.  
 
Physical comorbidities and painful physical symptoms  
 
Contrary to the presence of physical comorbidities and PPS being associated with 
higher total costs in each of the three follow-up years, these baseline comorbidities 
were shown to have different impacts on treatment outcomes. The presence of cancer 
or renal disease was associated with higher odds of having sustained treatment-free 
status than being on continuous treatment, while the presence of certain types of PPS 
was related to higher odds of having late re-contacts. Previous studies have 
conceptualised a variety of reasons for the occurrence of depressive disorders in 
patients with physical illnesses, including depression being a secondary psychological 
reaction (Katon, 2003). Therefore, the current results might be interpreted as 
depression in patients with cancer or renal disease being a psychological reaction, and 
thus potentially transient. Patients with these physical illnesses may also tend to stop 
antidepressants quickly after depressive symptoms improve as the perceived 
side-effects can be particularly intolerable with a major physical illness. This 
phenomenon could furthermore indicate that depression may be under-recognised or 
under-treated in those with serious physical health problems. 
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Pain and depression are among the top causes of quality-adjusted life-year (QALY) 
losses in primary care (Fernandez et al., 2010) and co-occurring pain complaints are 
commonly prevalent in depressed patients (Bair et al., 2003; Husain et al., 2007; 
Ohayon and Schatzberg, 2003). Patients with PPS have been shown to be less likely 
to achieve remission following acute treatment for depression (Fava et al., 2004), and 
the current analysis concurs with these previous studies in finding that having certain 
PPS (backache, musculoskeletal, and GI pain) is associated with late re-contacts. 
Higher healthcare utilisation and costs have also been found in depression with PPS in 
other studies (Gameroff and Olfson, 2006). The current findings add to this evidence 
base by showing that the presence of each kind of PPS at baseline is associated with 
an increase in total healthcare costs, not only in the first year but also in the second 
and third years. 
 
Comorbid mental disorders 
 
In the current analysis, the presence of most comorbid mental disorders was 
associated with decreased odds of sustained treatment-free status and increased odds 
of staying on continuous treatment, with the only exception being dementia. Despite 
the existence of conflicting findings from studies with relatively short follow-up 
periods (Ryu et al., 2005), depressive symptoms in dementia have been shown rarely 
to persist over a longer-term follow-up, e.g. two years (Aalten et al., 2005; Savva et 
al., 2009; Wetzels et al., 2010). Over time, depression has tended to decrease while 
apathy has increased in these patients (Aalten et al., 2005; Wetzels et al., 2010). 
Another study also found a high resolution rate of depressive symptoms for patients 
with dementia (Bergh et al., 2011). In addition, there has been evidence supporting 
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depression as a prodrome of dementia (Amieva et al., 2008; Wilson et al., 2010). 
Therefore, one possible interpretation of the results could be that depression occurs 
over certain stages in the course of dementia and disappears later when the illness 
progresses.  
 
The presence of comorbid mental disorders was associated with increased costs in the 
following years with the exceptions of GAD, panic, and phobic disorder. Patients with 
anxiety disorders have been shown to be less likely to use services compared to those 
with mood disorders (Alonso et al., 2004b; Mojtabai et al., 2002); they have also been 
shown to have reduced perceived need for help (Mojtabai et al., 2002). It seems 
probable that the lower service use and costs of these patients may be largely 
influenced by the nature of their anxiety disorders, especially in their use of mental 
health services and this could be particularly the case when the anxiety problems 
dominate patients' clinical presentations. However, the extent to which these 
anxiety-related problems of patients can influence their health behaviours regarding 
physical conditions remains to be determined.  
 
6.5. Implications and limitations 
 
Implications and policy recommendations 
 
The choice of index antidepressants between SSRIs and older generation 
antidepressants did not reveal significant differences in healthcare costs in the second 
and third years following the start of the treatment episode while prescriptions of 
multiple antidepressants at the index visit, although possibly influenced by physician 
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preferences and the nature of the depressive disorders, was associated with higher 
total healthcare costs in the following years, implying that initial prescription of a 
single antidepressant may be preferable in order to constrain costs.  
 
Patients not achieving sustained treatment-free status were shown to have higher 
healthcare costs in the follow-up years. As shown elsewhere (Pan et al., 2013c), 
patients remaining engaged with antidepressant treatment within the first three months 
after the index visit have higher odds of achieving sustained treatment-free status and 
lower odds of having late re-contacts over the 18-month period. Endeavours to reduce 
early attrition - probably through shared decision-making and proper 
patient-physician communication - to improve initial treatment outcome of depression 
could be emphasised to reduce total healthcare costs in the subsequent years.  
 
Limitations and conclusions 
 
As service use data contained in the NHIRD includes only health services provided by 
the NHI system in Taiwan, the perspective of the current analysis was relatively 
limited, and it was not possible to analyse wider economic impacts outside the health 
system. The lack of information on clinical symptoms and use of a proxy definition is 
clearly a major limitation. Ending psychopharmacological therapy may be for 
complex reasons other than achieving good clinical response, e.g. experiences of 
side-effects of medications. However, with the 18-month observation period in this 
chapter, the sustained treatment-free status seems likely to indicate initial treatment 
effectiveness without later clinical fluctuations sufficient to trigger a medical contact 
when simultaneously specifying another subgroup of subjects who have later 
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re-contacts which may reflect changes in clinical conditions in which help-seeking is 
considered beneficial (Pan et al., 2013c).  
 
Moreover, as a secondary analysis of a large healthcare database, the analysis of the 
patterns of care and related costs over time may require combining further 
information from other sources such as bottom-up longitudinal studies of treated 
prevalence, and prior expert knowledge to give firmer conclusions. A replication 
study with a more recent cohort in Taiwan may be also warranted to reflect changes in 
the healthcare system over time as well as its associated impacts on subjects' service 
use and healthcare costs. 
 
Factors which may further limit generalisability of the current findings include 
differences in the insurance system and the role of private health insurance between 
countries. As seen in this chapter, most patients with depression received specialised 
treatment from psychiatrists which is quite different from countries in which a referral 
system has been emphasised. Within the NHI system in Taiwan, patients can easily 
have access to specialists without referrals from general practitioners and with 
affordable co-payments. Therefore, this unique medical environment of Taiwan 
should be borne in mind while interpreting these results.  
 
In conclusion, this analysis, based on a large national cohort, suggests that the 
outcome status following initial treatment could exert an impact on total healthcare 
costs in the second and third years after the index date. Furthermore, the presence of 
comorbid anxiety disorders and PPS seem to affect healthcare costs over the 
longer-term. It is important for both physicians and policy-makers to further improve 
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initial treatment outcomes of depression through effective strategies. Future 
endeavours to explore the impacts of comorbid anxiety disorders and PPS on health 
service use and treatment of depression are warranted.
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Chapter 7. Cost-effectiveness and cost-utility analyses of antidepressant 
treatment 
 
The purpose of this chapter is twofold: first to compare the cost-effectiveness and 
cost-utility of different categories of antidepressant treatments and second to test 




In Chapter 4, a cost analysis was presented which explored relationships between 
demographic and clinical characteristics and healthcare costs for patients with 
depression. Comorbid CVD and headache were found to be associated with both 
higher non-psychiatric and psychiatric costs. In Chapter 6, a group of patients out of 
the whole cohort was further defined (who initially received minimal treatment of 
three visits within the first three months) and costs for the consecutive three years 
after the index date were compared between patients in different treatment outcome 
groups. As seen in previous chapters, various categories of antidepressant treatments 
were associated with total and psychiatric costs. Whether the categories of 
antidepressants differ in terms of cost-effectiveness and cost-utility remains to be 
determined. This is addressed in the current chapter where such analyses are 
conducted. 
 
As stated in a previous chapter, depression frequently co-occurs with CVD (Joynt et 
al., 2003).H Globally, while depression is among the top-ranking causes of disability 
(Vos et al., 2012), CVD constitutes the leading cause of premature death (Lozano et 
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al., 2012). The health and economic burdens of depression and CVD are great 
individually, but they can be substantially more pronounced when the two conditions 
co-occur. Indeed, an additive effect of major depressive disorder (MDD) and CVD on 
health related quality of life has previously been reported (O'Neil et al., 2013). 
 
Although compelling evidence has suggested depression, over physiological factors 
like left ventricular ejection fraction and ischemia, as having the most important 
influence on health related quality of life of cardiac patients (Ruo et al., 2003), it is 
less clear how the relationship between depression and health related quality of life is 
attenuated by the presence of CVD. While treating one condition could subsequently 
impact the other pre-existing condition, resulting in lower quality of life than would 
be expected as a result of the pre-existing condition on its own, the extent to which 
comorbid CVD may impact patients' quality of life during the course of depression 
treatment remains unclear. Given the huge burdens of these conditions as well as 
CVD being the most prevalent comorbid physical condition (26.9%) considered in 
this study (see Table 4.1), it is important that the economic impact of depression 
treatment on quality of life be examined in the presence of comorbid CVD.  
 
There are certain issues regarding existing evidence. First, most previous studies 
comparing the cost per quality-adjusted life-year (QALY) between antidepressant 
treatments have been modelling exercises (Pirraglia et al., 2004). These are useful and 
an be adaptped to different situations, but they are based on a variety of assumptions 
(Haji Ali Afzali et al., 2012). Only a limited number of prospective studies addressing 
the cost-utility of antidepressant treatments have been conducted (Kendrick et al., 
2006; Serrano-Blanco et al., 2009) and sample sizes have been small and may not be 
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representative. Third, the findings from those prospective studies are conflicting 
(Kendrick et al., 2006; Serrano-Blanco et al., 2009). One study suggested that 
selective serotonin reuptake inhibitors (SSRIs) are more cost-effective than tricyclic 
antidepressants (TCAs) (Kendrick et al., 2006) but findings from the other study 
suggested treatment with a TCA dominated fluoxetine (a SSRI) (Serrano-Blanco et al., 
2009). Fourth, the impact of major comorbidities like CVD on costs and QALYs for 
individual antidepressant treatments remains unknown. Finally, most of the existing 
data are from Western countries. Whether individual antidepressant treatments are 
cost-effective in terms of improving quality of life in Asian countries like Taiwan 
needs to be determined. 
 
The aim of this chapter is to compare the cost-effectiveness and cost-utility between 
individual antidepressants from the healthcare perspective. To further address the 
effects of comorbid CVD, the analyses are conducted taking into account the presence 






As in earlier chapters, data were extracted from the National Health Insurance 
Research Database (NHIRD) in Taiwan. In this chapter, subjects were first identified 
from the NHIRD according to inclusion criteria (see below) and the index date was 
defined as the date on which the subject was first prescribed an antidepressant for 
treatment of depressive disorders in 2003. A two and half year dataset containing all 
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NHI healthcare information on each subject spanning the index date (one year 




In contrast to earlier chapters, a narrower inclusion criterion was used. Specifically, 
only patients who were initially prescribed SSRIs, SNRIs or TCAs, were included. 
Therefore, patients receiving other newer antidepressants (bupropion and mirtazapine), 
other older antidepressants (maprotiline, moclobemide, and trazodone), 
flupentixol/melitracen and multiple antidepressants at the index date were excluded. 
 
In summary, participants aged 18 or over meeting the following criteria were 
included: 
 At least one prescription for an antidepressant of interest (SSRIs, SNRIs and 
TCAs) for treatment of MDD or other depression in 2003.  
 Data available for a minimum of 12 months before the index date and 18 months 
after the index date. 
 At least three antidepressant prescriptions in the first three months after the index 
date or at least four prescriptions over the 18-month observation period despite 
having had less than three antidepressant prescriptions in the first three months 
after the index date. 
 
Definition of treatment outcome status 
 
As discussed in Chapter 5, a proxy criteria for remission – antidepressant cessation for 
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at least six months (Sicras-Mainar et al., 2010a) – was modified and then employed in 
this chapter. This database measure of remission has been previously examined for its 
validity with an acceptable level of concordance with clinical criteria reported 
(Cronbach's alpha 90.6%, 95% CI 85.6, 95.6) (Sicras-Mainar et al., 2010a). It was 
further required in this thesis that there were no late re-contacts (defined as a restart of 
antidepressants) noted during the 18-month observation period to be considered 
having a ‘sustained treatment-free status’. Study participants were therefore divided 
into three mutually exclusive groups: 
 
 Sustained treatment-free status: patients who had an antidepressant cessation for 
at least six months and had not restarted antidepressant use by the end of the 
observation period. 
 Continuous treatment: patients who had not had an antidepressant cessation for 
at least six months. 
 Late re-contact: patients who had an antidepressant cessation for at least six 
months and had restarted antidepressant use after the cessation of antidepressant 
treatment.  
 
Observation period for treatment outcome 
 
For each individual, the observation period started on the index date and continued for 
18 months. The additional six-months after the first 12 months were included to 
ensure adequate time had elapsed to assess whether treatment-free status had been 
achieved. The treatment-free period, i.e. cessation of antidepressant treatment, could 
begin at any point during the 12 months after the index date (see Figure 6.1), but a 
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participant needed to have remained off antidepressants for a minimum of six months 
to fulfill the definition. Hence, a maximum observation period of 18 months for 




The baseline utility scores were from a naturalistic longitudinal observational study 
with 447 patients recruited at 56 Swedish primary care centres (Sobocki et al., 2007). 
The inclusion criteria of that study were similar to the current analyses (patients older 
than 18 years who initiated an antidepressant therapy in clinical settings because of 
depression); the sample size was reasonably large and patient composition was 
representative (comprising a heterogeneous population of patients with depression 
ranging from mild to severe cases). The EuroQol five-dimensions (EQ-5D) 
questionnaire was completed at each visit by the patients and used to generate utility 
scores. The baseline utility score for patients with MDD in this chapter was set at 0.42 
assuming a heterogeneous group of MDD patients comprising those with moderate 
(79.6%, utility=0.46) and severe (20.4%, utility=0.27) depression as in that study; 
baseline utility scores for those with other depression was assumed to be 0.60 
(Sobocki et al., 2007). 
 
The utility score for the ‘sustained treatment-free status’ health state was set at 0.85 
(equivalent to ‘responders remitters’ in Sapin et al (2004). It was further assumed that 
people who remained off antidepressants for six months but resumed them later would 
have the same utility, 0.72, as those ‘responders non-remitters’ (Sapin et al., 2004) at 
the time when they were off antidepressants.  
 215 
As people who remained on continuous treatment would likely comprise a group of 
patients with heterogeneous disease severity, a utility score of 0.66 was adopted from 
those who remained on antidepressants and were followed-up for a mean of 165 days 
in the naturalistic observational study of Sobocki et al. (2007). The utility score for 
the ‘late re-contact’ health state in the current analyses was set at 0.47 – the baseline 
mean utility score of depressed patients from the same study. The uncertainty in the 
utility scores of the ‘late re-contact’ health state and ‘continuous treatment’ health 
state (95% confidence interval 0.53, 0.75) as well as other utility values were tested 
later in the section of sensitivity analyses. 
 
Estimation of quality-adjusted life years 
 
By applying the above utility scores, the QALY profiles over the 12 months after the 
index date were estimated using area-under-the-curve methods based on the following 
assumptions: 
 
●   Sustained treatment-free status: a linear increase from the baseline utility score 
(MDD=0.42 and other depression=0.60) to the ‘sustained treatment-free status’ health 
state (0.85) over the 12-month period. 
●   Late re-contact: a linear increase from the baseline utility score (0.42 or 0.60) to 
the ‘responders non-remitters’ health state (0.72) over the initial six-month period, 
followed by a linear deterioration back to the ‘late re-contact’ health state (0.47) over 
the remaining six months. 
●   Continuous treatment: a linear increase from the baseline utility score (0.42 or 




Demographic and clinical information 
 
Demographic and clinical data, including age, gender, diagnosis of depressive 
disorders (MDD vs. other depression), initial choice of antidepressants (SSRIs, SNRIs 
and TCAs), physician specialty, and clinical setting on the index date were extracted. 
Participants were grouped according to past treatment history, i.e. newly diagnosed 
depression (those who were free of antidepressant use or a depression diagnosis for a 
minimum of 12 months before the index date) and non-newly diagnosed depression.  
 
Baseline characteristics regarding comorbid mental disorders, physical illnesses 
(CVD, diabetes mellitus, chronic obstructive pulmonary disease, renal diseases, and 
cancer), several kinds of painful physical symptoms, as well as healthcare expenditure 




Service use components extracted from the NHIRD included outpatient contacts, 
emergency attendances, and inpatient stays for all reasons. All costs were calculated 
from the actual claims data, were described by categories of services, e.g. psychiatric 
costs, non-psychiatric costs, and total costs, and were expressed in international 
dollars (the implied PPP conversion rate between 2003-2004 New Taiwan Dollar 
(NTD) and international dollar is 20.43:1) (World Economic Outlook (WEO) data, 
2013). However, the figures in the local national currency, NTD, instead of 
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international dollars, were used to interpret results along with the willingness-to-pay 
data in Taiwan expressed in NTD. 
 
A cost-effectiveness and a cost-utility analysis were conducted from the perspective 
of healthcare providers. Comparative analyses were undertaken between 
antidepressant treatment groups on both psychiatric and total costs. Rates of sustained 
treatment-free status (i.e. treatment success) and QALYs accrued during the 12-month 
period were compared between treatment groups. Incremental cost-effectiveness 
ratios (ICERs) and incremental cost-utility ratios (ICURs), defined as the difference in 
costs divided by the difference in outcomes (rates of sustained treatment-free status, 
QALYs accrued) were calculated.  
 
As stated at the beginning of the chapter, one of the aims is to assess the 
cost-effectiveness and cost-utility of antidepressant treatments in the context of 
comorbid CVD. Therefore, these analyses were first performed using the full study 
sample, then all analyses were compared in subgroups defined by whether participants 
had comorbid CVD or not. To aid interpretability as well as to address potential 
selection bias with treatment groups in this real-world sample, the probability that an 
antidepressant therapy is cost-effective compared with the alternatives as a function of 
the decision makers’ maximum willingness-to-pay for an additional QALY was 
illustrated by cost-effectiveness acceptability curves (CEACs) (Briggs et al., 1997) 
while controlling for above mentioned demographic and clinical factors. The methods 





Unadjusted costs and QALYs gained were first compared using ANOVA while rates 
of sustained treatment-free status were compared via chi-squared tests between 
treatment groups. Then, adjusted means of costs and QALYs for antidepressant 
groups were obtained by linear regression analyses in which demographic and clinical 
covariates (as described in earlier section of demographic and clinical information) 
were controlled for. Adjusted rates of sustained treatment-free status for treatment 
groups were obtained by logistic regression while simultaneously taking other 
covariates into consideration. ICERs (incremental psychiatric cost per percentage 
point of treatment success) and ICURs (incremental psychiatric cost per QALY gained) 
were then calculated based on those adjusted estimates. 
 
The robustness of the results was confirmed using nonparametric bootstrapping 
techniques to account for any non-normality in their distribution. The original dataset 
was used to generate 1000 resamples and mean differences, P-values and confidence 
intervals were computed with demographic/clinical covariates being controlled for. 
CEACs were constructed using the net benefit approach (Briggs, 2001; Briggs et al., 
1997). That is, a range of willingness-to-pay values for an additional QALY gained 
was mapped alongside the proportion of the estimates of the net benefit values above 
zero for which an antidepressant of interest was more cost-effective over the 
alternatives. The range of willingness-to-pay values considered were from NTD 0 to 
3,000,000 (roughly equal to £0-60,000; international dollars 0-150,000). This 
approach assumes that there is a theoretical but not necessarily known value that 
society would place on a gain of one extra QALY. NTD 1,500,000 (equal to £30,000; 
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international dollars 75,000) and 2,000,000 (equal to £40,000; international dollars 




To examine the responsiveness of cost-utility results to changes in different utility 
weights, sensitivity analyses were also performed. The four scenarios included: (i) 
varying the utility weights for the ‘continuous treatment’ health state to the highest 
value (0.75); (ii) varying the utility weights for the ‘continuous treatment’ health state 
to the lowest value (0.53); (iii) varying the utility weights for the ‘late re-contact’ 
health state to the baseline value, i.e. 0.42 for those with baseline MDD and 0.60 for 
those with other depression (assuming the relapses of depression would revert back to 
baseline severity for each subject); and (iv) varying the utility weights for the ‘late 
re-contact’ health state to a lower value (0.27) (assuming the relapse of depression 






A total of 96,501 adult individuals in the NHIRD met the inclusion criteria for the 
study. The number with comorbid CVD was 27,484 (12.4% SNRI, 17.1% TCA, 
70.4% SSRI) and 69,017 were without CVD (14.5% SNRI, 13.6% TCA, 71.9% 
SSRI). Patients prescribed TCAs were older than those prescribed SSRIs and SNRIs 
(Table 7.1; also see Table 4.2). There were more cases of other depression among 
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TCAs users than those prescribed SSRIs or SNRIs. Patients with newly diagnosed 




Over the 18-month observation period, 31,466 of the subjects were categorised as 
having sustained treatment-free status (32.6%), 50,652 (52.5%) were having 
continuous treatment and 14,383 (14.9%) late re-contacts. Of TCA recipients, 57.6% 
(the highest proportion among the antidepressant groups) were having continuous 
treatment while only 28.3% (the lowest among antidepressant groups) of them 
achieved sustained treatment-free status (Table 7.2).  
 
Unadjusted rates of sustained treatment-free status were lower in subjects with CVD, 
compared to their counterparts without CVD, with the exception of those prescribed 
with TCAs. For the latter patients, those with CVD had higher unadjusted rates of 
sustained treatment-free status (see Table 7.2). After adjusting for other 
demographic/clinical covariates, people with CVD had lower treatment success rates 
regardless of antidepressant groups (Table 7.3). As shown in Table 7.3, SSRI 
recipients had the highest adjusted rates of treatment success and QALYs accrued 




Table 7.2 shows that in general, patients with comorbid CVD had lower psychiatric 
costs but higher total costs than those without CVD. Regarding treatment groups, 
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SNRIs users had both the highest psychiatric and total costs over the 12-month period 




From the perspective of psychiatric services, the ICERs showed that SSRIs dominated 
SNRIs for the full sample while the ICER was 51 international dollars (psychiatric 
cost; 1,042 NTD) per one percentage point increase in rates of sustained 
treatment-free status for SSRIs over TCAs; for SNRIs over TCAs, the ICER was 223 
international dollars (4,556 NTD). The ICUR for SSRIs over TCAs in the full sample 
was 67,333 international dollars (1,375,613 NTD) per one additional QALY (Table 
7.3). 
 
For those with CVD, there was an incremental cost of 53 international dollars 
(psychiatric costs) to gain one percentage point increase in rates of sustained 
treatment-free status for SSRIs over TCAs, while SNRIs were dominated by SSRIs 
(higher costs and worse outcomes). For the non-CVD population the ICER was 59 
international dollars (psychiatric costs; 1,205 NTD) per one percentage point increase 
in rates of sustained treatment-free status for SSRIs over TCAs. For the CVD and 
non-CVD populations, the ICURs for SSRIs over TCAs were 53,333 (1,089,593 NTD) 
and 78,333 (1,600,343 NTD) international dollars per one additional QALY gained 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































CEACs were used to interpret the cost-utility results, while demographic/clinical 
correlates were controlled for. For the full sample, TCAs would be 100% likely to be 
the most cost-effective option rather than SSRIs and SNRIs if society is willing to pay 
nothing for an additional gain in QALY (Figure 7.1a based on psychiatric costs, 
Figure7.1b based on total costs).  
 
Figure 7.1a: CEAC based on psychiatric costs (full sample) 
 
 
Figure 7.1b: CEAC based on total costs (full sample) 
 
 
Footnote: The horizontal axis: willingness-to-pay for an additional QALY in the local 
national currency, NTD. The vertical axis: probability for an antidepressant group of interest 
to be more cost-effective than the alternatives. 
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As seen in Figure 7.1, when society is willing to pay NTD 1,500,000 (£30,000) for an 
additional QALY, there is a 76.4% (psychiatric costs) to 64.5% (total costs) 
likelihood that SSRIs would be most cost-effective compared to TCAs and SNRIs in 
patients with depression (the full sample). This is also in accordance with the above 
results: the ICUR for SSRIs over TCAs in the full sample was 67,333 international 
dollars (around £30,000) per one additional QALY. Then, if the willingness-to-pay 
increases to NTD 2,000,000 (£40,000) for an additional QALY, there is a 99.1% 
(psychiatric costs) to 95.9% (total costs) likelihood that SSRIs are the most 
cost-effective option compared to TCAs and SNRIs (Figure 7.1). 
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In subgroup analyses shown in Figure 7.2a (CEAC based on psychiatric costs) and 
7.2b (CEAC based on total costs), the darker lines represented the CEACs of different 
antidepressant categories for the non-CVD patients and lighter lines represented those 
for patients with comorbid CVD (TCA_noncvd: TCA recipients from the non-CVD 
group; SNRI_cvd: SNRI recipients from the CVD group). 
 




Regardless of the presence of comorbid CVD, if society is willing to pay nothing for 
an additional QALY, TCAs would be 100% likely to be the most cost-effective option 
compared to SSRIs and SNRIs. However, if society is willing to pay NTD 1,500,000 
(£30,000) for an additional QALY, there is a 55% (psychiatric costs) to 74.5% (total 
costs) likelihood that SSRIs would be most cost-effective compared to TCAs and 
SNRIs for those without comorbid CVD whereas for those with CVD, the figures are 
68.9% (psychiatric costs) and 46.1% (total costs), respectively. 
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Figure 7.2b: CEACs based on total costs (subgroup analysis by comorbid CVD) 
 
 
Furthermore, if society is willing to pay NTD 2,000,000 (£40,000) - the reported 
willingness-to-pay threshold for an additional QALY in Taiwan (Shiroiwa et al., 2010) 
- the likelihood for SSRIs to be the most cost-effective is 94.4% (psychiatric costs) 
and 96.6% (total costs) in patients without comorbid CVD. The figures are 91.7% 
(psychiatric costs) and 68.8% (total costs), respectively, in patients with comorbid 
CVD (Figure 7.2a and Figure 7.2b). Therefore, the higher the value society places on 
an additional gain in QALY, the greater the net benefit to society from the use of 
SSRIs over TCAs and SNRIs for both patients with comorbid CVD and those without. 
At willingness-to-pay values up to NTD 3,000,000, the likelihood of SSRI being most 




(i) Varying the utility weight for the continuous treatment health state to the highest 
value of 0.75: As presented in Figure 7.3a to 7.3d, TCAs (the dotted line) had over 
90% likelihood of being the most cost-effective option than the other antidepressants 
up to a willingness-to-pay level of NTD 2,000,000 (Figures 7.3a to 7.3d). 
 
Figure 7.3a. Sensitivity analysis (i): CEAC based on psychiatric costs (for 
patients without comorbid CVD) 
 
Figure 7.3b. Sensitivity analysis (i): CEAC based on psychiatric costs (for 
patients with comorbid CVD) 
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Figure 7.3c. Sensitivity analysis (i): CEAC based on total costs (for patients 
without comorbid CVD) 
 
 





(ii) Varying the utility weight for ‘continuous treatment’ health state to the lowest 
value of 0.53: For patients without CVD, there is a 100% likelihood that SSRIs would 
be the most cost-effective option compared to the other antidepressants at the 
willingness-to-pay level at or over NTD 1,500,000; the probabilities are 99.5% 
(psychiatric costs) and 94.9% (total costs), respectively, at NTD 1,500,000 for those 
with CVD (Figures 7.4a to 7.4d). 
 
Figure 7.4a. Sensitivity analysis (ii): CEAC based on psychiatric costs (for 
patients without comorbid CVD) 
 
 
Figure 7.4b. Sensitivity analysis (ii): CEAC based on psychiatric costs (for 




Figure 7.4c. Sensitivity analysis (ii): CEAC based on total costs (for patients 
without comorbid CVD) 
 
 





(iii) Varying the utility weight for the late re-contact health state to the baseline value 
of 0.42 for those with MDD and 0.60 for those with other types of depression: At the 
willingness-to-pay level of NTD 1,500,000, SSRIs start to gain advantage over TCAs 
(Figures 7.5a to 7.5d).  
 
Figure 7.5a. Sensitivity analysis (iii): CEAC based on psychiatric costs (for 
patients without comorbid CVD) 
 
 
Figure 7.5b. Sensitivity analysis (iii): CEAC based on psychiatric costs (for 




Figure 7.5c. Sensitivity analysis (iii): CEAC based on total costs (for patients 
without comorbid CVD) 
 
 
Figure 7.5d. Sensitivity analysis (iii): CEAC based on total costs (for patients 





(iv) Varying the utility weight for the late re-contact health state to a lower value of 
0.27: In Figures 7.6a to 7.6d), SSRIs gained advantage of being more cost-effective 
when willingness-to-pay values were at or over NTD 2,000,000 with the exception of 
patients with CVD (total costs, see Figure 7.6d): At a willingness-to-pay level up to 
NTD 3,000,000, the likelihood is 66.5%. 
 
Figure 7.6a. Sensitivity analysis (iv): CEAC based on psychiatric costs (for 
patients without comorbid CVD) 
 
 
Figure 7.6b. Sensitivity analysis (iv): CEAC based on psychiatric costs (for 







Figure 7.6c. Sensitivity analysis (iv): CEAC based on total costs (for patients 




Figure 7.6d. Sensitivity analysis (iv): CEAC based on total costs (for patients 






The analyses presented in this chapter have provided information comparing the 
cost-effectiveness and cost-utility of individual antidepressant classes and have 
examined the impact of CVD. In the whole sample, the ICERs showed that SSRIs 
dominated SNRIs and the ICER was 51 international dollars (psychiatric cost; 1,042 
NTD) per one percentage point increase in rates of sustained treatment-free status for 
SSRIs over TCAs. The ICUR for SSRIs over TCAs in the full sample was 67,333 
international dollars (1,375,613 NTD) per one additional QALY. For the CVD and 
non-CVD populations, the ICURs for SSRIs over TCAs were 53,333 international 
dollars (1,089593 NTD) and 78,333 (1,600,343 NTD) per one additional QALY 
gained respectively (Table 7.3). 
 
In the CEACs, SSRIs were shown to be more cost-effective compared to TCAs and 
SNRIs at a willingness to pay of NTD 1,500,000 for an additional QALY. The CEACs 
showed differences in cost-utility between antidepressant treatments by comorbid 
CVD. For patients without CVD, SSRIs were clearly most cost-effective but for those 
with comorbid CVD, the advantage of SSRIs over TCAs seemed relatively modest. 
These results add to the literature by providing such information at the population 
level rather than for groups of patients meeting the specific criteria for trials.  
 
Some previous studies have shown that SSRIs may improve quality of life more than 
TCAs for patients with depression (Taylor et al., 2011). The analyses here suggest that 
such gains may be achieved in a cost-effective way by showing that when 
willingness-to-pay increases (but remains below the threshold), the probability for 
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SSRIs to be more cost-effective in improving patients' quality of life increases. From 
the perspectives of healthcare providers, the results are in accordance with a previous 
cost-utility study (Kendrick et al., 2006) in finding that SSRIs are more cost-effective 
in improving quality of life in routine clinical settings. To date, only a very limited 
number of prospective studies have been conducted to address the cost-utility of 
antidepressant treatments and the findings are inconclusive. The aforementioned study 
has suggested SSRIs may be more cost-effective than TCAs but only with a 
probability of up to 0.6 (Kendrick et al., 2006) while elsewhere it has been suggested 
that imipramine (a TCA) dominates fluoxetine (a SSRI) with 81.5% of the bootstrap 
replications in the quadrant of the cost-effectiveness plane indicating dominance 
(Serrano-Blanco et al., 2009). There are different explanations for the inconsistency 
between previous results. Two key issues are the differences in cost perspectives 
adopted and the fact that the sample sizes of these studies are small, thus leaving the 
cost-effectiveness results unstable with wide confidence intervals. In this thesis the 
perspective was still relatively limited but the sample size of this national cohort was 
substantial. Analyses were conducted controlling for potential demographic/clinical 
confounders which makes the results relatively robust. 
 
Moreover, these analyses have also addressed cost-utility differences of antidepressant 
treatments in patients with comorbid depression and CVD, something not been 
previously studied. Depression has been suggested as an independent risk factor for 
the future onset, progression, and recurrence of CVD (Carney et al., 1988; Ferketich 
et al., 2000; Nicholson et al., 2006; Rugulies, 2002; Sesso et al., 1998; 
Wassertheil-Smoller et al., 2004). There is also evidence suggesting that factors 
related to CVD might influence outcomes of depression (Albus et al., 2011; Denollet 
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et al., 2010). Given that both depression and CVD are very prevalent conditions and 
leading causes of disease burden (WHO, 2008), the importance of in-depth 
investigations into their effects cannot be over-emphasised. The findings that SSRIs 
can be more cost-effective than TCAs and SNRIs in both patients with and without 
comorbid CVD could serve as useful information for guiding depression management 
in the presence of CVD in clinical settings.  
 
However, the finding that SSRIs have a relatively modest advantage over TCAs in 
patients with CVD (compared to patients without CVD) appears counterintuitive at 
first sight. Because TCAs have been shown to be associated with a variety of 
cardiovascular effects (Coupland et al., 1997; Taylor, 2008; Vieweg and Wood, 2004), 
it would be expected that treatment with TCAs may be related to higher costs 
assuming the same efficacy and more adverse effects. Yet the reality appears to be the 
opposite. There are explanations for this phenomenon among which physician choice 
could play a critical role. In a previous cost-utility study, a higher proportion of 
patients randomised to TCAs were in fact prescribed a different class of 
antidepressants than those randomised to SSRIs (TCA: 42% vs. SSRI: 16%) and 
physician preference was the stated cause for over half of these cases who did not 
receive the allocated treatment (Kendrick et al., 2006). It is understandable that 
instead of TCAs, physicians may tend to prescribe SSRIs to patients with more 
complicated physical conditions, including CVD. As a result, the QALY gains used in 
the estimates of net benefits for those SSRIs users might be offset by increased costs 
due to more complicated physical conditions. This may be reflected in Figure 7.2 
where for individuals with CVD, SSRIs were shown to be more cost-effective 
(compared to TCAs) in the model estimated using psychiatric costs than in that using 
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total costs. The higher non-psychiatric costs of those SSRIs users, even after adjusting 
for age and severity of depression, may diminish the cost-effectiveness advantage 
over TCAs in the model using total costs. 
 
In this chapter, SSRIs were shown to be more likely to be cost-effective in most 
scenarios covered by the sensitivity analyses. An exception (sensitivity analysis (i)) is 
when the ‘continuous treatment’ utility score is changed to 0.75; TCAs then become 
the most cost-effective choice. This implies that the utility scores for the ‘continuous 
treatment’ health state is a major driver of the cost-utility results. Since TCA users 
had the highest proportion of being on continuous treatment (57.6%) between 
antidepressant groups (51.1% of SSRI users were having continuous treatment - the 
lowest proportion between groups, see Table 7.2), varying utility scores for the 
‘continuous treatment’ health state to the highest level would naturally favour TCAs. 
Nonetheless, it seems unlikely that a heterogeneous group of people on continuous 
treatment would have a mean utility higher than for the responders/non-remitters 
health state of 0.72. Depression severity has been shown to impact utility scores 
(Sapin et al., 2004; Sobocki et al., 2007) and patients with moderate or severe 
depression are the most likely to be on continuous treatment given their 
relapsing/chronic disease nature. From the available observational studies following 
depressed patients in clinical settings, Gunther et al (2008) reported a mean EQ-5D 
index UK score of 0.65 (n=104) at 18-months follow up and Reed et al (2009) also 
suggested a nearly identical EQ-5D value at six-months follow up based on a sample 
of 3468 adult patients with a clinically diagnosed episode of depression after 
commencing antidepressant treatment. Hence, the utility score 0.66 applied in the 
base model (Sobocki et al., 2007) may be the most appropriate estimate for the current 
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analysis and the finding that SSRIs are more cost-effective appears valid. 
 
The issue to be raised herein is the level of quality of life for patients on continuous 
treatment. In this chapter, a high (52.5%) percentage of patients had a treatment 
outcome status of being on continuous treatment. Despite efforts to improve treatment 
outcomes of depression, only 12-18% of patients with MDD who receive 
antidepressant treatment may achieve complete symptom remission and full 
functional recovery (Fava et al., 1994; Gasto et al., 2003; Israel, 2010; Nierenberg et 
al., 1999). As a result, the majority of patients can be on continuous treatment for a 
long period of time. However, most previous studies used hypothesised contexts and 
questions to generate utility scores and there has been no population-based study 
specifically examining utility scores for patients who are on continuous treatment 
over a longer term in real-world settings. Future in-depth investigations of patients' 
quality of life when receiving treatment in clinical settings are warranted to further 
improve depression management and patients' quality of life. 
 
7.5. Limitations and implications 
 
There are various limitations to be considered in these analyses. The adoption of 
utility scores from previous studies is a major one. Whether utility values from 
different settings (and countries) can be adequately applied to other study settings is a 
concern because preference values towards health states have been shown to differ 
between countries (Badia et al., 2001; Johnson et al., 2005). The current analysis 
adopted utility values of depressive health states from other countries under the 
assumption that changes in utility values between health states of depression (for 
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instance, remission or relapse) would be similar despite the presence of differences in 
the absolute utility values across countries (also see Section 5.6). Although sensitivity 
analyses based on different assumptions for these utility scores were conducted to 
confirm the validity of the results from the base model, the limitation due to the use of 
social preference values elicited from a different country should still be noted. Future 
research to obtain utility weights for patients with depression in Taiwan is warranted 
to validate the current results. Besides, since the perspective of healthcare providers 
for the economic analysis was adopted in this chapter, it was unable to examine wider 
effects. The strength of this analysis is the large sample size, good representativeness 
(whole country coverage), and the complete cost data. In addition, availability of 
willingness-to-pay data from Taiwan renders the results more interpretable.  
 
Implications for practice 
 
The finding that at the threshold willingness-to-pay value, SSRIs are more 
cost-effective than TCAs and SNRIs in patients with and without comorbid CVD 
suggests that SSRIs can be the first choice of treatment in routine clinical settings to 
improve both treatment effectiveness and patients' quality of life in Taiwan. Although 
the advantage seems relatively modest in patients with CVD, considering the apparent 
safety of SSRIs in patients with CVD (Taylor et al., 2011) and the demonstrated 
cost-effectiveness and cost-utility in this chapter, SSRIs can be considered a better 
choice of antidepressant treatment for patients with comorbid CVD. 
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Chapter 8. Discussion and conclusions 
 
The aims of this thesis were to examine the background to depression treatment and 
the impact of antidepressant treatment and comorbidities on economic costs (Chapter 
1), to undertake a systematic review of published economic evaluations of 
antidepressant treatments for depression and to identify appropriate evaluation 
approaches and gaps in the methodology (Chapter 2), to critically appraise the 
methods of economic evaluation as applied to evaluations of antidepressant treatments 
(Chapter 3), to report results of the analysis of costs of antidepressant treatment for 
patients with depression (Chapter 4), to identify appropriate effectiveness and utility 
measures for the cost-effectiveness and cost-utility analyses (Chapter 5), to assess the 
impacts of treatment outcomes on costs over the following three years (Chapter 6), 
and to compare the relationship between cost and effectiveness/utility measure 
between antidepressant treatments (Chapter 7). All of the analyses in this thesis were 
conducted using healthcare data from Taiwan. 
 
The purpose of this discussion chapter is to pull together the findings that relate to the 
above aims. It will begin by summarising findings from the previous chapters 
followed by a discussion of the implications and main limitations. Finally, directions 
for future research will be suggested. 
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In Chapter 3, the appropriateness of different study designs for an economic 
evaluation of antidepressant treatments was considered. Using Black's list (Black, 
1996) of circumstances when randomisation is not appropriate, it was concluded that 
there may be a number of characteristics of the issues being addressed here that would 
make a randomised design difficult to apply and a database approach potentially more 
appropriate. For instance, an important issue is the need for the compliance and 
co-operation of patients and physicians. Preferences and other factors may influence 
physicians' choice and patients' adherence to antidepressants. Besides, because the 
aim of this thesis is to assess cost-effectiveness in routine settings, it is difficult to 




The relationship between the choice of outcome measure and study design used in 
economic evaluations was considered. Subsequently, a database definition of 
treatment outcome (Pan et al., 2013c), including sustained treatment-free status, late 
re-contact, and continuous treatment, was introduced in this thesis, rather than 
specifically using remission (Sicras-Mainar et al., 2010a) as an effectiveness measure 
(Chapter 5). Utility weights were attached to these different outcomes to conduct the 
cost-utility analysis presented in Chapter 7. 
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From the very beginning, it was considered that over the past decades, it has become 
increasingly recognised that responding to depression treatment but failing to achieve 
full remission can be an adverse outcome (Anderson et al., 2000; Ballenger, 1999). 
The consequences of not achieving full remission can lead to greater risk of 
relapse/recurrence (Judd et al., 2000; Ramana et al., 1995), more frequent depressive 
episodes and shorter periods between episodes (Judd et al., 2000); it may even lead to 
increased mortality and morbidity (de Groot et al., 2001; Empana et al., 2005; 
Ickovics et al., 2001). Conversely, treating to remission is shown to be beneficial to 
long-term outcomes. For example, it is associated with a reduced risk of relapse and 
improved psychosocial functioning (Judd et al., 2000; Miller et al., 1998; Thase et al., 
1992). Therefore, where possible, the key goal of an intervention should be remission 
- complete relief of symptoms, which is linked to better functioning and a lower 
likelihood of relapse (Kennedy and Foy, 2005).  
 
Although remission is a desired treatment goal for depression treatment, the necessary 
clinical data were not collected for ascertaining a remission as defined by clinical 
rating scale criteria. Hence, it was necessary to consider the specific issue of 
identifying an appropriate effectiveness or utility outcome measure for use in 
economic evaluations based on a database approach. An alternative term, 
treatment-free status (Pan et al., 2013c), was deemed more suitable, rather than a 
database-defined ‘remission’, and was employed in this thesis for all analyses. While 
sustained treatment-free status was not technically ‘remission’, it may indicate initial 
treatment effectiveness without later clinical fluctuations sufficient to trigger a 
medical contact. In effect then, the measure used in the thesis and ‘actual’ remission 
may amount to the same thing. 
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Because depression is associated with marked decreases in functioning, well being 
and health-related quality of life (Hays et al., 1995; Saarijarvi et al., 2002), and 
increases in disability days (Lecrubier, 2001), it is important to evaluate economic 
impacts of interventions to depression using quality of life data. Recent research 
suggests that the importance of using utility measures is not only because it can be 
compared between treatments from different fields, which matters to decision makers, 
but also because depression can seriously impact individuals' quality of life in varied 
ways. In Chapter 5, methods for valuing health states and obtaining data for deriving 
utility values for health states of patients with depressive disorders were summarised. 
 
Results of cost analysis 
 
In Chapter 4, results of the cost analysis were presented with a particular focus on 
factors influencing the costs of depression treatment, e.g. past treatment history, 
comorbid physical illnesses, painful physical symptoms, and choice of initial 
antidepressants. The cohort of adult cases (n=216,557) who received treatment for 
depression was identified from the National Health Insurance Research Database. 
Factors associated with service use and healthcare costs over a 12-month period were 
explored using generalised linear modelling. The results showed that depression 
severity, past treatment history, comorbid mental/physical illnesses, painful physical 
symptoms, and choice of initial antidepressants were found to be associated with 
healthcare costs in the following year, but the nature of the associations differed 
across cost categories (e.g. newly diagnosed depression or an initial prescription of a 
TCA was shown to be associated with higher non-psychiatric costs but lower 
psychiatric costs). The presence of comorbid cardiovascular disease (CVD) or certain 
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painful physical symptoms (PPS) at baseline was associated not only with higher 
non-psychiatric but also with higher psychiatric costs. Further logistic analyses 
showed that patients with these comorbidities had increased use of psychiatric 
emergency and inpatient services. Therefore, healthcare costs for depression can be 
affected by a number of clinical characteristics and comorbidities of patients. 
 
Impact of initial treatment outcome on costs 
 
In Chapter 4, treatment costs for patients with depression over the one year period 
following initial treatment were compared between groups defined by treatment 
outcomes, i.e. sustained treatment-free status, late re-contact, or continuous treatment. 
In Chapter 6, the aim was to identify demographic and clinical characteristics 
associated with these outcomes after initial treatment and to test whether and how 
these outcomes influence total healthcare costs over the subsequent three years. In a 
cohort of adult patients (n=126,471) who received at least three antidepressant 
prescriptions within the first three months of the index date, factors associated with 
the above outcomes were examined. Among them, 34.1% were classified as having 
sustained treatment-free status, 56.6% were continuously on antidepressant treatment, 
and another 9.4% had cessation of antidepressants for six months and had late 
re-contacts during the observation period. Potential predictors of total healthcare costs 
in the subsequent years were assessed via generalised linear modelling, with a 
particular focus on outcome status after initial treatment. The results showed that 
depression severity, past treatment history, physician specialty, choice of 
antidepressants, and comorbid mental/physical illnesses or painful physical symptoms 
were associated with outcomes after initial treatment. Furthermore, initial outcome 
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status was shown to affect total healthcare costs over the following three years. 
Specifically, patients who experienced sustained treatment-free status after initial 
treatment were found to have significantly lower costs in the second and third years 
after the index date, compared to those with less favourable outcomes.  
 
Cost effectiveness and cost utility analyses 
 
Since the literature review in Chapter 1 as well as the analyses in earlier chapters 
indicated that there is an impact of physical comorbidities on economic outcomes for 
depression, the effect of comorbid CVD on patients' quality of life during the course 
of depression treatment, and the cost-effectiveness of that treatment, were explored in 
Chapter 7. Subgroups of adult patients prescribed with antidepressants of interest 
(SSRIs, SNRIs, and TCAs) for depression were identified. A cost-effectiveness 
analysis and a cost-utility analysis were conducted comparing antidepressant 
treatments with and without the presence of comorbid CVD. The results from ICERs 
and ICURs showed that SSRIs are more cost-effective than TCAs and SNRIs in 
improving rates of treatment success as well as accrued QALYs. Moreover, the 
cost-effectiveness acceptability curves (CEACs) showed differences between 
antidepressant treatments according to CVD status. For patients without CVD, SSRIs 
were clearly more cost-effective than TCAs and SNRIs but for those with comorbid 




While randomised designs are useful in minimising bias and often acknowledged as 
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the highest quality comparative design, they are not appropriate for evaluating every 
study question. It is also difficult to conduct a randomised controlled trial in clinical 
settings without minimally interfering with routine practices. Therefore, a database 
analysis is particularly useful in complementing the findings from randomised 
controlled trials. 
 
Despite the difficulties involved in choosing the outcome measures in the current 
database analyses, the results suggest they were able to sufficiently capture some 
elements of the impact of the antidepressant treatments in patients with depression. 
Furthermore, the initial outcomes (as exemplified by treatment patterns like sustained 
treatment-free status, late re-contact and continuous treatment) of antidepressant 
treatment are shown to be affected by demographic and clinical characteristics of 
patients with depression and these outcomes can have a sustained impact on 
individuals' total healthcare costs over subsequent three years. Patients who 
experienced sustained treatment-free status from initial treatment may have 
significantly lower costs in the second and third years after the index date, compared 
to those with other outcomes. 
 
The importance of comorbid pain and CVD in terms of influencing treatment costs of 
depression as shown in Chapter 4 warrants further research. In Chapter 7, SSRIs are 
shown to be more cost-effective (in ICERs and ICURs) in improving both rates of 
treatment success and accrued QALYs than TCAs and SNRIs regardless of the 
comorbid CVD. Although the CEACs showed that the advantage of SSRIs over TCAs 
is relatively modest in patients with CVD, considering the apparent safety of SSRIs in 
patients with CVD and the demonstrated cost-effectiveness in improving quality of 
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life in this thesis, SSRIs can be considered a better choice of antidepressant treatment 
for patients with comorbid CVD. Since comorbid painful physical symptoms are 
shown to affect treatment costs for patients with depressive disorders as well, it is 





In this thesis, the perspectives of healthcare providers were adopted for all economic 
analyses. As service use data contained in the National Health Insurance Research 
Database (NHIRD) includes only health services provided by the National Health 
Insurance (NHI) system in Taiwan, the perspective of the current analysis was 
relatively limited, and it was not feasible to analyse wider economic impacts. Future 
database research may be conducted including proxy measures of employment status 
to address the impact of treatment on employment as well. 
 
Confounding or selection bias due to the non-randomised study design should always 
be borne in mind while interpreting the results. Although multivariable analyses were 
used in this thesis, some bias may remain. Future studies may consider the propensity 
score methods to remove the effects of confounding when estimating the effects of 
treatment on outcomes. A proxy measure of outcome status is adopted in these 
analyses. Despite that this proxy measure has been tested for its concordance with 
remission determined by clinical criteria and the level of concordance between the 
two approaches considered acceptable (Cronbach's alpha 90.6%; 95% CI: 85.6, 95.6) 
(Sicras-Mainar et al., 2010a), the lack of information on clinical symptoms in the 
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current database is clearly an important limitation.  
 
Additionally, the adoption of EQ-5D tariffs elicited in a different country to assign 
utility values to Taiwanese patients is another limitation. It should be borne in mind 
that people in different countries may differ in preferences towards health states due 
to ethnic, cultural, and socio-economic variations across countries. Although 
sensitivity analyses based on different assumptions of utility scores were conducted to 
confirm the validity of results from the base model (in Chapter 7), future efforts to 
obtain utility values of depressive health states from the Taiwanese populations are 
needed.  
 
Generalisability is another concern given the unique healthcare system in Taiwan 
which allows patients to bypass referrals by general practitioners and freely access to 
specialists care in Taiwan. Caution should be exercised while generalising current 
results unto different settings or countries.  
 
8.4. Implications for future research 
 
The thesis has highlighted areas which should be the focus of future research (not 
restricted to database analyses): 
 
1. Care must be taken to ensure that the choice of study design is suitable for the 
setting and the research question addressed. 
 
2. Care must be taken to ensure that the choice of appropriate outcome measures is 
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relevant to the research question. 
 
3. Care must be taken to ensure the use of adequate methods to remove the effects 
of confounding when estimating the effects of interventions on outcomes using 
database analyses. 
 
4. The validity of database-based outcome measure (e.g. remission or sustained 
treatment-free status) should be further examined and other potential outcome 
measures should be searched. Identification of adequate outcome measures, 
including intermediate outcome measures, may help facilitate future 
understanding of the relationship between outcomes of depression and costs of 
treatment. 
 
5. Given that utility scores (or quality weights) of different health states of 
depression on individual level are still lacking, it is important that further efforts 
should be placed upon collecting utility data as well as outcomes and costs for 
patients with depression in different settings and across countries.  
 
6. Although including treatment costs only may be an opportunity to simplify what 
can be a complicated costing method, wider economic perspectives should be 
applied in future research to further the understanding of economic impacts of 
depression treatment. 
 
7. Combination of cost-effectiveness and cost-utility analyses in a study may help 
interpret the results in a relatively complete way. It is good practice to present the 
results based on a clinically-relevant effectiveness measure initially and then 
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undertake a cost-utility analysis as presented in this thesis. 
 
8. Future research should further address the economic impacts of major physical 
comorbidities and different pain conditions, e.g. headache (Chapter 4), on 
depression treatment.  
 
9. Economic evaluations addressing newer antidepressants or other modalities of 
treatments for depression should be emphasised. 
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Background: Knowledge regarding the relative cost-effectiveness of different antidepressants
is crucial for the planning of depression treatment. However, there have been only a small
number of reviews of such evidence and synthesizing economic evidence across studies is
methodologically challenging. In particular, there have been few reviews of the methods
employed in database analyses (studies that use data from real-world practice).
Methods: Published economic evaluations based on database analyses were systematically
reviewed to compare antidepressant treatments in depression. Prospective studies of cost-
effectiveness were also reviewed to highlight unanswered questions through comparisons
between these two different study designs.
Results: Forty papers met the criteria and were included. A relatively large number of industry-
sponsored evaluations of escitalopram were identified and these found escitalopram to be
potentially cost-effective in depression treatment. Evidence of cost-effectiveness differences
between other individual SSRIs was not unequivocally established. Inconsistent findings
further emerged concerning the cost-effectiveness of SSRIs versus TCAs between retrospective
database analyses and prospective studies.
Limitations: Different outcome measures and cost perspectives make it difficult to make
comparisons across studies.
Conclusions: Evidence regarding the cost-effectiveness of different antidepressants in
depression continues to accumulate. Beyond the efficacy or tolerability data found for newer
antidepressants in controlled trials, further research from real-world settings is needed to
examine the relative cost-effectiveness of different antidepressant agents.
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1. Introduction
Depression is a severe and pervasive disorder. With an
estimated lifetime prevalence of 10–25% among women and
5–12% among men (Moore and Bona, 2001), unipolar depres-
sive disorder was the fourth leading cause of burden among all
diseases in 2002 and its impact will continue to grow in future
decades (Mathers andLoncar, 2006). It is predicted that unipolar
depressive disorder will become the leading cause of disease
burden by 2015 (WHO, 2008). Given itsmarked personal, social
and economic impacts, depressive disorder creates signiﬁcant
demands on individuals, health service providers and society as
a whole (NICE, 2009; Thomas and Morris, 2003).
Although pharmacological, psychological and casemanage-
ment interventions are all recommended, antidepressant drugs
remain the mainstay of treatment for depression for most
people in contact with healthcare services (Ellis, 2004; NICE,
2009). The last 20 years have seen dramatic changes in
antidepressant prescription patterns. Initially, there was an
increase in theuse of the selective serotonin reuptake inhibitors
(SSRIs), which resulted in a progressive rise in total drug
expenditures for antidepressants (Barbui et al., 2001; Eccles
et al., 1999). Subsequently, other novel antidepressant agents
with different pharmacological mechanisms entered the
market. Given the range of choices, clinicians must decide
about which is the most appropriate intervention for their
patients (Simon et al., 1996).
To this end, knowledge regarding the relative cost-
effectiveness of individual antidepressants is important. In
contrast to the ample evidence on efﬁcacy and tolerability of
antidepressant treatments from randomized controlled tri-
als (RCTs), data speciﬁcally addressing cost-effectiveness in
real-world settings are surprisingly scarce (Brunoni et al.,
2009; Montgomery et al., 2005). At the same time, the
clinical meaning of the statistical differences in the efﬁcacy
or tolerability in RCTs remains uncertain (Cipriani et al.,
2005,2009) because study settings and populations of RCTs
are principally protocol-driven and operate strict inclusion
criteria. This lack of external validity makes it difﬁcult to
generalize results to the context of routine medical practice.
Given the gap in knowledge from real-world settings,
database analyses using information from actual clinical
practice might provide valuable insights into depression
treatments for more heterogeneous populations to comple-
ment evidence from controlled trials. These studies utilized
large administrative databases such as medical claims that
captured patients' resource utilization. However, the meth-
odological approaches employed in economic evaluations
using database analyses have been diverse and there have
been few reviews of their strengths and limitations. The aim
of this paper is to systematically assess methodological
approaches used in retrospective database analyses of the
cost-effectiveness of antidepressant agents in depression
treatment. For comparative purposes, economic evaluations
from prospective studies are also reviewed to illustrate
differences in methodological approaches.
2. Methods
2.1. Search strategy
Studies were identiﬁed through a Medline, PsycInfo, and
Embase electronic search performedwith no limits in language
but with limits to human studies ranging from the year 1999 to
the present; the ﬁnal search date was 3 September 2010. Three
sets of key words included: cost or cost effectiveness or cost
beneﬁt or cost utility or cost consequence or comparative
effectiveness; antidepressant; depression or depress$ or major
depressive disorder. Reference lists of included papers and
previous reviews were hand-searched for published reports
missed by the electronic search. Unpublished studies/gray
literature were not searched in this review.
2.2. Inclusion criteria
A structured form was designed to record the eligibility of
the selected papers from the electronic search. All located
papers were ﬁrst screened by reviewing the titles. The review
was initially performed by one author (YPan) with a review of
this by another author (PMcCrone) to identify potentially
relevant studies. When it was not clear whether a particular
study should be included, the full paperwas reviewed to ensure
eligibility. No limitation on the age of study subjects was
Role of f source
Conﬂict rest
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applied. Articles had to meet the following criteria to be
included in the review:
1. Comparative analysis of alternative antidepressant treat-
ments (or antidepressant versus placebo) for depressive
disorders.
2. Studies undertaken based on a database analysis, an RCT
(either conventional or pragmatic), or a naturalistic
observational study.
3. Economic evaluations, including cost analysis, cost-
effectiveness analysis, cost-beneﬁt analysis, cost-utility
analysis, and cost-consequence analysis.
4. Published studies in peer-reviewed journals.
2.3. Data extraction
A structured form was used for the extraction of
information on the year of publication, study design, study
perspective, length of follow-up, country and setting of
the study, antidepressants compared, sample size, study
inclusion/exclusion criteria (including patient age, diagnosis,
and certain comorbidities), measurements of baseline disease
severity (e.g., number of comorbid physical or mental
disorders, emergency room visits, or hospitalization before
the index date), methods of economic evaluation, and
funding sources. Additional information on study results
was extracted with respect to measures of costs and
outcomes as well as cost-effectiveness.
2.4. Analysis
The outcomes of interest included total healthcare costs,
healthcare costs plus indirect costs, compliance with treatment,
hospitalization rates, and change in clinical symptoms/or quality
of life measurements. Results were compared and classiﬁed
according to study designs, i.e., retrospective database analyses,
conventional RCTs, and pragmatic RCTs plus naturalistic
observational studies.
3. Results
The electronic search yielded 4417 studies but an initial
review of titles led to the exclusion of 4220 because they did
not focus on depression treatment, they were not compara-
tive analyses of alternative antidepressants, or they did not
include costs. For the remaining 197, the abstracts were
reviewed to identify potentially relevant papers and a further
143 excluded mainly because on closer examination they
were found not to be economic evaluations, or they were not
based on a designated study design of this review. For the
remaining 54, the full papers were reviewed and a further 17
excluded because they were not economic evaluations based
on a database analyses, an RCT, or a naturalistic observational
study. Reference lists of included papers and previous reviews
were hand-searched and another three studies were identi-
ﬁed, thus 40 papers were included in the ﬁnal review: 28
retrospective database analyses and 12 prospective studies
(six conventional RCTs, ﬁve pragmatic RCTs and one
naturalistic observational study). A breakdown of inclusion
and exclusion is given in the QUOROM diagram in Fig. 1.
In assessing the quality of economic evaluations of mental
health interventions in a previous review, Evers et al. (1997)
identiﬁed a number of common weaknesses in study design,
including lack of randomization, short follow-up periods and
unexplained sample sizes. In a more recent review of cost-
effectiveness of treatments for depression, Barrett et al. (2005)
highlighted speciﬁc difﬁculties in synthesizing evidence from
various economic evaluations because of the use of different
Potentially relevant papers 
identified and screened, n=4417 
Papers retrieved, n=197 
Papers retrieved, n=54 
Papers retrieved, n=37 
Papers excluded, n=4220 
Papers excluded, n=143 
Papers excluded, n=17 
Papers from reference lists, n=3 
Papers included in review, n=40 
Fig. 1. QUOROM ﬂow diagram of articles included in the systematic review.
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outcome scales and different study perspectives across studies.
The key characteristics of the included papers are summarized
in Tables 1 and 2. Follow-up periods of ﬁve included RCTs were
less than or equal to 24 weeks. Fifteen studies lasted for
6 months and the remaining 19 studies for at least 12 months.
The effectiveness of the treatments was recorded using nearly
20 different outcome measures. Only four studies used a
primary outcomemeasure of quality of life.While indirect costs
including productivity losses may occur as a result of impaired
working ability, only 16 papers considered a broad perspective
of costs and the remainder (n=24) solely considered costs to
healthcare systems. Two of the included studies were carried
out in multinational settings; another eight studies were from
European countries, one from India, and the remainder
(n=29) from North America (Tables 1 and 2).
3.1. Findings from retrospective database analyses
3.1.1. Characteristics and methodological approaches of the
included studies based on database analyses
All included database analyses were carried out in the
United States/Canada with one exception using primary care
data fromtheUnitedKingdom(Wadeet al., 2010) (Table1). The
study populations were mostly adults aged 18 years or above
(some of them recruited only working-age adults), with the
exception of three studies focusing on elderly populations
(Tournier et al., 2009;Wu et al., 2008a,b). Themajority of these
analyses adopted a similar methodology, based on the
identiﬁcation of patients who had a paid insurance claim that
indicated a diagnosis of a depressive disorder and treatment
with antidepressants. Diagnoses of a depressive disorder
included major depressive disorder and dysthymic disorder
(or neurotic depression) in most studies; several studies
recruited only subjects with major depressive disorder and
one study researched exclusively on subjects with severe
depression (Wade et al., 2010). Another three studies recruited
subjects with a diagnosis of either depression or anxiety
disorder (Sheehan et al., 2004, 2005, 2008) while the others
also included subjects with a diagnosis of bipolar depression
(Grifﬁths et al., 1999; Sullivan et al., 2000) or bipolar disorder
(Ackermanet al., 2002) (Table1). Inmost cases, an intention-to-
treat (ITT)principlewas applied andpatientswere assigned to a
drug cohort on the basis of their initial prescription, with
resource utilization data over a speciﬁed study period after the
ﬁrst prescriptionanalyzedandcomparedbetweendrug cohorts.
The most often used proxies for disease severity was baseline
healthcare utilization and number of concomitant disease
states; number of emergency room visits or hospitalizations
before index date, or severity subcodes of diagnoses were also
used.
A healthcare perspective on costs was adopted in all studies,
although some of them also took into consideration out-of-
pocket payments by patients including copayment, coinsurance,
and/or deductibles (Table 1). Among the 28 database studies,
seven were cost analyses, and the remaining 21 were cost-
consequence analyses where costs were reported alongside a
range of outcome measures. Treatment persistence, odds of
hospitalization, and guideline adherence were the most fre-
quently used outcomemeasures. Studyperiods ranged from6 to
24 months. In the 28 included studies, 23 were funded by
pharmaceutical companies. In one of the two studies funded by
government agencies (Ackerman et al., 2002; Tournier et al.,
2009), the authors provided consultancy services to the
pharmaceutical industry (Tournier et al., 2009). In the further
two studies in which funding sources were not stated, the
authors either provided consultancy services to the pharmaceu-
tical industry (Sheehan et al., 2005) or were employees of the
pharmaceutical companies (Poret et al., 2001). Only one study
declared no conﬂicts of interest (Chung, 2005) (Table 1).
3.1.2. Economic evaluations comparing antidepressants using
database designs
Four studies were primarily designed to compare escitalo-
pram with other antidepressants. Escitalopram was shown to
have better treatment persistence and lower total healthcare
costs compared to other SSRI/SNRIs both in a larger sample of
adult patients (Wu et al., 2009) and in a smaller sample of
geriatric patients (Wu et al., 2008a). In another study with
severely depressed adult patients, therewere signiﬁcantly fewer
hospitalizations per patient in the escitalopram versus venlafax-
ine or generic SSRI groups; the total annual healthcare
expenditure per patient was lower in the escitalopram group
compared to venlafaxine but similar with escitalopram and
generic SSRIs (Wade et al., 2010). Escitalopram was shown to
have better treatment persistence, a lower hospitalization rate,
and lower total healthcare costs than citalopram in a geriatric
population (Wu et al., 2008b). As above studies were funded by
the same pharmaceutical companies and escitalopram was the
antidepressant of interest in all of them, ﬁndings from a cost
analysis primarily designed to compare another antidepressant
(paroxetine controlled release (CR)) with other SSRIs (including
escitalopram) were provided: the average unadjusted 6-month
medical costs of escitalopram treatment (n=14,527) were
slightly lower than the average costs of SSRIs as a whole
(n=136,003) in the treatment of depressed patients, but the
costs of escitalopramuserswere higher than the average costs of
those prescribed SSRIs when treating patients with anxiety
disorder or depression comorbidwith anxietydisorder (Sheehan
et al., 2005).
While comparing venlafaxine with SSRIs (citalopram,
ﬂuoxetine, paroxetine, and sertraline), better treatment per-
sistence was found for venlafaxine XR but total direct medical
costs were comparable with venlafaxine and SSRIs (Monfared
et al., 2006). Patients prescribed with venlafaxine were
reported to have lower odds of hospitalization for non-
mental-health reasons than those with SSRIs, while total
healthcare costs were similar between the two groups; these
studies failed to demonstrate differences in treatment persis-
tence between venlafaxine XR and SSRIs (Wan et al., 2002a,b).
Two cost analyseswith similar studydesigns revealed that total
medical expenditures were generally similar among patients
receiving venlafaxine, SSRIs, or TCAs as a second-line therapy
for depression (Grifﬁths et al., 1999; Sullivan et al., 2000).
Another study comparing healthcare costs of patients who
switched antidepressants versus those who did not found that
switchers had higher total healthcare costs thannon-switchers.
For patients switching from an SSRI to venlafaxine, mean
medical cost reductions offset higher pharmacy costs of
venlafaxine after the switch, and for those switching from
venlafaxine to an SSRI, mean medical and pharmacy costs
declined after the switch (Khandker et al., 2008). As each of the
above studies was funded by the same pharmaceutical
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company,ﬁndings fromanother study funded by a government
agency are informative (Tournier et al., 2009). This showed
similar treatment persistence and costs for medical service
utilization and psychiatric hospitalization between venlafaxine
(n=1937) and SSRIs (n=8186).
There were 12 included database analyses that used TCAs
as a comparator treatment. One study showed that patients
treated with SSRIs were more likely to meet treatment
duration recommendations than those treated with TCAs;
and among compliant patients, mean total healthcare costs
were lower for SSRIs (Baker et al., 2001). SSRIs were shown in
a bivariate probit model to reduce patients discontinuing
pharmacotherapy compared to TCAs, but total healthcare
charges were similar between the two groups (Dobrez et al.,
2000). Despite comparable total healthcare expenditures
between treatment groups, SSRI users were shown to have
higher depression-related service expenditures but have
lower non-depression-related service expenditures than
TCA users (Sullivan et al., 2000). It was further revealed by
Baker et al. (Baker et al., 2001) that among patients compliant
with treatment duration recommendations, non-depression-
related costs were lower for those prescribed SSRIs than for
those prescribed TCAs (Baker et al., 2001). SSRIs probably
reduced overall outpatient visits and the use of other
prescription drugs, but increased utilization of services for
depression, which then canceled out the potential cost
advantage of SSRIs over TCAs (Chung, 2005).
Compared to patients prescribed TCAs, ﬂuoxetine patients
were shown to be half as likely to be hospitalized (Croghan
et al., 2000) and have lower total healthcare costs (McCombs
et al., 1999). Similarly, citalopramwas reported to have better
treatment persistence and lower total healthcare costs than
the TCA amitriptyline (Sclar et al., 1999). Lower nursing home
and other costs were found in a comparison of sertraline
versus TCAs (McCombs et al., 1999), but another study
revealed similar likelihood of hospitalization for patients
initially prescribed sertraline and TCAs (Croghan et al., 2000).
In a study comparing bupropion SR with other antidepres-
sants, total healthcare costs were shown to be lower for
patients treated with bupropion SR than for those treated
with TCAs and in comparison with bupropion SR, patients
initiating therapy with sertraline had signiﬁcantly higher
mental health payments (Poret et al., 2001).
Turning to comparisons between different SSRIs, the
comparative results were largely mixed. A head-to-head
comparison favored sertraline in having lower depression-
related costs than citalopram (McLaughlin et al., 2004), but a
contradictory ﬁnding emerged in another study favoring
citalopram in having lower total and depression-related
healthcare costs (Sclar et al., 1999). Likewise, sertraline was
shown to have lower total and depression-related costs than
ﬂuoxetine in one study (Berndt et al., 2000), but in another
study, ﬂuoxetine was shown to have better treatment
persistence than sertraline and paroxetine while total health-
care costs were similar between antidepressant groups (Polsky
et al., 2002). In another two studies, no signiﬁcant differences
werenotedamongpatients treatedwithﬂuoxetine, paroxetine,
and sertraline.in depression-related costs (Russell et al., 1999)
or total healthcare costs (Crown et al., 2001). In the only study
examining the cost-persistence ratio (with non-persistence
deﬁned as treatment duration of less than 180 days), paroxe-
tine was shown to have the most favorable cost-persistence
ratio, but ﬂuoxetine was considered the best choice in terms of
incremental cost-persistence ratio (the difference in costs
between the two treatments divided by the difference in
outcomes (frequency of persistent treatments) between the
two treatments) (Tournier et al., 2009).
Beyond comparisons between different antidepressants,
one studywith patients of major depressive disorder revealed
signiﬁcantly higher total healthcare costs for patients not
receiving any initial psychotropic medications compared to
either those treated with TCAs or SSRIs (Optenberg et al.,
2002). Further studies compared the same antidepressant
compounds with different release patterns. Paroxetine CR
was shown to have better treatment persistence and lower
medical costs relative to paroxetine immediate release (IR)
(Sheehan et al., 2004); compared to other SSRIs (including
paroxetine IR) as a group, paroxetine CR was also shown to
have lower medical costs (Sheehan et al., 2005). Several
included studies principally focused on hospital charges
(Ackerman et al., 2002; Croghan et al., 2000). In one of
them, initial use of heterocyclic agents was shown to be
associated with higher hospital charges than monoamine
oxidase inhibitors (MAOIs), SSRIs and venlafaxine, despite
the major cost drivers being other more expensive pro-
cedures, e.g., electro-convulsive therapy, rather than choices
of antidepressant treatments (Ackerman et al., 2002). The
remaining study deﬁned all antidepressants launched after
2002 as “third-generation antidepressants” (bupropion XL,
duloxetine, venlafaxine XR, escitalopram, paroxetine CR) and
reported that newer generation antidepressants were asso-
ciated with lower total medical costs (excluding pharmacy
costs), lower odds of all-cause hospitalization, and better
adherence (Sheehan et al., 2008).
3.2. Findings from economic evaluations comparing
antidepressants using prospective study designs
3.2.1. Conventional RCTs
For illustrative purposes, ﬁndings from conventional RCTs
were also reviewed. Four of the six included conventional RCTs
were head-to-head cost-effectiveness comparisons between
antidepressant treatments for patients with major depressive
disorder: three studies compared the cost-effectiveness of
escitalopram to duloxetine (aged 18–65) (Wade et al., 2008),
citalopram (aged 18–65) (Fantino et al., 2007), and venlafaxine
(aged 18–85) (Fernandez et al., 2005), respectively. The results
revealed that escitalopram appeared as a dominant strategy
compared to either duloxetine or citalopram; it had similar
effectiveness but lower costs compared with venlafaxine. The
other head-to-head comparison examined the cost-effectiveness
ofmirtazapineversusparoxetine and suggested thatmirtazapine
may be a more cost-effective treatment choice (Romeo et al.,
2004).
In the remaining conventional RCTs, ﬂuoxetine was com-
pared to placebo or psychological treatment for the manage-
ment of commonmental disorders in adults (Patel et al., 2003)
and major depressive disorder in adolescents (Domino et al.,
2008). Fluoxetine was shown to be more cost-effective than
placebo and psychological treatment over both the short term
(2 months) and long term (12 months) in the former study
(Patel et al., 2003) and in the latter one, ﬂuoxetine was more
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cost-effective than placebo treatment when the threshold of
$100,000 per QALY (the quality-adjusted life year) was applied
(Domino et al., 2008).
Except for one study adopting a healthcare payer perspective
with a societal perspective considered in a sensitivity analysis
(Fernandez et al., 2005), all the conventional RCTs estimated
costs from a broader societal perspective, either healthcare with
loss of productivity costs (Fantinoet al., 2007;Romeoet al., 2004;
Wade et al., 2008) or healthcarewith patient and/or family costs
(Domino et al., 2008; Patel et al., 2003). The outcome measures
used in these conventional RCTs included the Sheehan Disability
Scale score (SDS), Children's Depression Rating Scale-Revised,
Montgomery-Asberg Depression Rating Scales Self-reported
(MADRS-S), EQ-5D, 17-item Hamilton Depression Rating Scale
(HDRS-17), remission, and psychiatric morbidity rated by the
Clinical Interview Schedule, Revised (CISR total score). Study
periods ranged from8 to24 weeks,with the exceptionof Patel et
al. (Patel et al., 2003) who measured and compared cost-
effectiveness up to 12 months (Table 2).
3.2.2. Pragmatic RCTs and naturalistic observational studies
Compared to conventional RCTs, pragmatic RCTs aim to
inform decisions about clinical practice by testing effectiveness
with relatively unselected participants and under ﬂexible
conditions. Therewereﬁve pragmatic RCTs and onenaturalistic
observational study included in this review (Table 2). From a
societal perspective, imipramine (a TCA) was shown to be a
more cost-effective treatment than ﬂuoxetine in a 6-month
randomized prospective naturalistic study as the similar
effectiveness was counteracted by lower total costs for the
imipramine group (Serrano-Blanco et al., 2006a). Imipramine
was also found to dominate ﬂuoxetine in a cost-utility analysis
(Serrano-Blanco et al., 2009).
The remaining three pragmatic RCTs adopted a healthcare
payer perspective. One of them compared TCAs, SSRIs and the
modiﬁed TCA lofepramine as ﬁrst choice of treatment for
depressive disorder in primary care, and revealed no signiﬁcant
differences between the antidepressants in either outcomes or
costs during the 12 months of follow up; however, the cost-
effectiveness acceptability curves suggested that SSRIs were
likely to be the most cost-effective option despite the
probability of this not rising above 0.6 (Peveler et al., 2005).
In a sample of depressive patients in primary care, randomi-
zation to ﬂuoxetine or a TCA (desipramine or imipramine) led
to similar clinical outcomes and overall treatment costs for
24 months (Simon et al., 1999). Using the number of
hospitalization-free days as the effectiveness measure, one
pragmatic RCT compared groups of initial use of antidepres-
sants (amitriptyline, citalopram, and ﬂuoxetine) and revealed
no differences in either depression treatment costs or effec-
tiveness over the period of 6 months (Hosak et al., 2000).
From a societal perspective, the only non-randomized
prospective 6-month follow-up naturalistic study showed that
ﬂuoxetine dominated paroxetine and citalopram in cost-
effectiveness and had a high probability of being more cost-
effective than sertraline (Serrano-Blanco et al., 2006b). Overall,
half of the included pragmatic RCTs and the naturalistic
observational study adopted the healthcare payer perspective
while the others estimated costs from a broader societal
perspective. The outcome measures in these studies included
the EQ-5D, MADRS, depression-free weeks, hospitalization-free
days, HDRS score, the Medical Outcomes Study SF-36 Health
Survey (SF-36), the anxiety and depression subscales of the
Hopkins Symptom Checklist (SCL), and remission. The study
periods ranged from 6 to 24 months (Table 2).
4. Discussion
4.1. Summary of main results comparing database analyses and
prospective studies
Basedon the available evidence frombothdatabase analyses
and conventional RCTs, depressed patients prescribed escitalo-
pram had lower total healthcare costs than those prescribed
certain SSRIs, and escitalopram appeared more effective than
certainSSRIs in termsof treatmentpersistence andsomeclinical
symptom measures. Compared to venlafaxine, patients pre-
scribed escitalopram in some studies had lower total healthcare
costs. The validity of applying these results to depressed
patients with anxiety disorder has not yet been established.
In database analyses, patients using TCAs generally had
comparable healthcare costs to those using SSRIs,while in some
studies, higher non-depression related costs and lower depres-
sion related costswere found in TCAusers. Someother database
studies reported that SSRI users had greater treatment
persistence and lower total healthcare costs than TCA users.
Different results emerged from prospective studies. From a
healthcare payer perspective, patients prescribed TCAs were
shown to have comparable costs and clinical outcomes with
SSRI users in pragmatic RCTs (Hosak et al., 2000; Peveler et al.,
2005; Simon et al., 1999). However, froma societal perspective,
TCA users in pragmatic RCTs, had similar or even better
outcomes but lower total costs than SSRI users (Serrano-Blanco
et al., 2006a; Serrano-Blanco et al., 2009).
Without randomization, the above results comparing TCAs
with SSRIs in database analyses may reﬂect physician choice
based on heterogeneous presentations of depressed patients
that could not be captured by the demographic factors or proxy
variables for disease severity used in the included studies. The
ﬁndings that TCA users had higher non-depression-related costs
and lower depression-related costs than SSRI users also implied
that in real-world settings, patients prescribed TCAs are
probably different from SSRI users in terms of clinical features
of depression or comorbid physical illnesses. Once randomiza-
tion was applied in a pragmatic RCT, TCA users were shown to
have equal or better effectiveness than SSRI users; total related
costs were found to be equal or even lower for patients
prescribed TCAs. It is also worth noting that the cost-
effectiveness advantage of TCAs over SSRIs revealed in the
pragmatic RCTs (but not in the database analyses) may not be
driven by the lower drug acquisition costs of TCAs considering
that the wider cost perspective, i.e., societal perspective, in the
pragmaticRCTswouldmean the contributionof drugacquisition
costs to total costs is very low. Therefore, the cost-effectiveness
differentials between TCAs and SSRIs among these studies could
be driven by other factors that warrant further research.
4.2. Strengths and limitations of economic evaluations using
database analyses
Database analyses can supplement RCTs to inform decision-
making in actual clinical practice, as conventional RCTs may not
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accurately reﬂect the real-world cost-effectiveness of competing
antidepressant treatments (Crown, 2000). Appropriate alloca-
tion of scarce resources among competing choices is a
fundamental policy concern. Economic evaluations conducted
within the context of conventional RCTsmay not be sufﬁcient to
inform decision-making, considering that individual behavior in
conventional RCTs is controlled through a strict, protocol-driven
environment. In light of these considerations, more ﬂexible
study designs are employed in pragmatic RCTs tomeasure cost-
effectiveness in a situation closer to the real-world settings.
However, the randomization proceduremakes physician choice
and other important factors inﬂuencing initial choice of
antidepressant treatment in real-world settings unobservable.
Economic evaluations based on RCTs may be underpow-
ered. The sample size of an RCT is usually calculated according
to clinical rather than economic criteria, and a much larger
sample may be needed to determine the signiﬁcance of
economic outcomes (Briggs, 2000). Although modeling and
other methods have been widely used in recent economic
evaluations, these approaches rely heavily on assumptions
that may not be easily testable. By contrast, retrospective
database analyses using routine administrative data can offer
quick access to large samples of patients in naturalistic
settings. Besides the advantages of lower research costs and
larger sample size than RCTs, database analyses potentially
assess economic outcomes over longer periods of follow-up
and from more heterogeneous populations, and hence are
capable of supplementing RCTs to inform decision-making.
Despite these strengths, several limitations shouldbeborne in
mind when interpreting results from database analyses. Lack of
clinical data on effectiveness is clearly a major limitation. Many
database analyses in this review focus on comparisons of costs.
Among studies comparing costs and outcomes simultaneously,
persistence of treatment and rate of hospitalization are frequent-
ly used as proxies for clinical effectiveness. There are concerns
regarding the use of these proxies; for example, poor outcome
tends to be assumed for individuals who discontinue their index
antidepressants without taking into consideration fast re-
sponders or patients with milder disease severity. The use of
hospitalization rate as an effectiveness indexmaybeproblematic
as it is also a resourcemeasure (andhencepotentially included in
the measurement of cost). Efforts to improve the effectiveness
measurements have been noted in the literature, such as the
application of a new approach to estimate health values (as an
effectiveness index) of alternative treatment patterns based on
expert panels (Watkins et al., 2009). Further efforts should be
made to incorporate newer approaches to effectiveness mea-
surement with administrative database analyses.
Compared to the more recent RCTs, database analyses
usually adopt a narrowerdeﬁnition of costs, andwhichmaynot
therefore pick up the impact of treatment on loss of
productivity and employment that may actually contribute
substantially to the overall costs of depression (Thomas and
Morris, 2003; Wang et al., 2003).
There are biases to be considered in database analyses.
Confounding or selection bias due to nonrandomized study
design is clearly important. For example, a patient'smedical and
social history, disease severity, and a physician's characteristics
may inﬂuence both the initial choice of antidepressant and the
subsequent outcome. To address this heterogeneity issue,
strategies including matching (Sheehan et al., 2004) and the
use of propensity score techniques (Wade et al., 2010) were
noted. Furthermore, the reverse causality of medical care
utilization to drug choice can be minimized through deﬁning
thedrug choice at baseline and estimatingutilization during the
following period. While this limits potential inquiries to
compare treatment effects in a counterfactual scenario using
database analyses, it also is cognizant of the real-world
situations in which physician preferences and heterogeneity
of clinical presentations inﬂuence both antidepressant choice
and cost-effectiveness outcomes for a patient with depression.
Publication/sponsorship bias would be another major
concern as complex statistical analyses could leave the results
open to a degree of subjectivity. Since 23 out of the total 28
database analyses included in this review were sponsored by
the pharmaceutical industry and another three studies had
authors afﬁliatedwithpharmaceutical companies, thepotential
for overestimation of effect due to sponsorship should be kept
inmind, especiallywhennocompanyhas apparently published
data that indicate their compound to be less cost-effective than
a rival. Of course, this consideration applies to many random-
ized trials too.
In this review, the antidepressant of interest was usually
new or just available in the months leading up to the study,
while the comparator drugs weremostly well established and
continuously available. Many physicians might not be able to
prescribe newer antidepressants in the beginning of the study
period and might have had inadequate time to gain sufﬁcient
experience with them. Some of them might preferentially
prescribe newer antidepressants to those patients refractory
to previous treatment, a tendency that has been called
channeling or allocation bias (Egberts et al., 1997). However,
the reverse might also be true, if not more common, i.e., to
prescribe newer antidepressants to patients with milder
disease to gain more clinical experience while the perceived
mild side effects would not harm patients. For example,
patients who are able to work may be prescribed newer
agents because these drugs are perceived as less disruptive
and more tolerable. The timing of studies therefore might
affect the economic outcomes presented due to the different
intervals from the launch dates of competing antidepressants.
Furthermore, diagnostic heterogeneity in the studied
populations was noted (please see Table 1). These population
characteristics may act as confounds when looking at the
relative cost-effectiveness of the various antidepressants.
Although most of the included database analyses adopt an
intention-to-treat (ITT)design, this approachmaynot bedirectly
transferrable from the analysis of RCTs where it was originally
used. The most important aim of ITT is to maintain treatment
groups that are similar apart from random variation. In database
analyses, patients are of course not randomized to treatments
and the possibility for selection bias must be addressed by
statistical methods other than ITT analysis. Furthermore, the
second fundamental idea behind ITT is to reduce bias that might
be introduced by excluding patients who did not complete the
originally assigned course of therapy from the analyses (Gillings
andKoch, 1991). Yet,most database analyses excluded those not
continuously enrolled in the insurance programduring the study
period, hence bringing in bias.
Except for one study from the United Kingdom (Wade et al.,
2010), all the database analyses are from the United States/
Canada and so all studies are from developed countries.
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Generalizability of effectiveness and cost data across different
countries might not be straightforward. Not only do prescribing
costs differ dramatically between settings, but also healthcare
systems are organized in very different ways, particularly when
looking at low- andmiddle-income countries (Dixon et al., 2006;
Knapp et al., 2006). Moreover, many of the included studies are
based on private insurance databases in which the subjects
might be healthier, with different socioeconomic characteristics,
or provided with different antidepressant choices compared to
people with public or no insurance (Chung, 2005; McCombs
et al., 1999). Future research isneeded fromdevelopingcountries
and covering different insurance systems, as well as a wider
range of populations.
Cost-effectiveness data for populations with different
characteristics/comorbidity are not available. Despite studies
comparing the characteristics across subjects initially treated
with individual antidepressants, there have been no cost-
effectiveness comparisons of individual antidepressant treat-
ments across speciﬁc populations with different needs.
5. Clinical implications
This review suggests database analyses are an important
source of evidence on the potential cost-effectiveness of
alternative antidepressant treatments. Even though database
analyses are susceptible to bias and confounding, they have the
advantage of being based on observations from real-world
practice. Given the limited external validity of RCTs, database
analyses using data from actual clinical practice can usefully
contribute to our understanding of the economic outcomes of
alternative antidepressant treatments. Prospective and retro-
spective studies have their own strengths and limitations. It is
essential to assess economic outcomes across a broad range of
contexts using a range of study designs, and only ﬁndings that
are consistent across a number of study designs and healthcare
settings should be accepted with conﬁdence.
Role of funding source
This review was conducted as a part of PhD research of author YP who
was funded by Department of Education, Taiwan. This funding body played
no roles in study design, analysis or interpretation of data in this review.
Conﬂict of interest
MK has acted as consultant and speaker for Lundbeck and Bristol Myers
Squibb. PM has received speaker and consultancy fees from Lundbeck, Bristol
Myers Squib, Lilly and Janssen-Cilag. YP declares no conﬂicts of interest.
References
Ackerman, D.L., Unutzer, J., Greenland, S., Gitlin, M., 2002. Inpatient
treatment of depression and associated hospital charges. Pharmacoepi-
demiol. Drug Saf. 11, 219–227.
Baker, A.M., Russell, J.M., Campbell, J.K., 2001. Variance in treatment
compliance and costs by antidepressant class: analysis in an HMO
setting. Formulary 36, 204–210.
Barbui, C., Campomori, A., Mezzalira, L., Lopatriello, S., Cas, R.D., Garattini, S.,
2001. Psychotropic drug use in Italy, 1984–99: the impact of a change in
reimbursement status. Int. Clin. Psychopharmacol. 16, 227–233.
Barrett, B., Byford, S., Knapp, M., 2005. Evidence of cost-effective treatments
for depression: a systematic review. J. Affect. Disord. 84, 1–13.
Berndt, E.R., Russell, J.M., Miceli, R., Colucci, S.V., Xu, Y., Grudzinski, A.N.,
2000. Comparing SSRI treatment costs for depression using retrospective
claims data: the role of nonrandom selection and skewed data. Value
Health 3, 208–221.
Briggs, A., 2000. Economic evaluation and clinical trials: size matters. BMJ
321, 1362–1363.
Brunoni, A.R., Fraguas, R., Fregni, F., Brunoni, A.R., Fraguas, R., Fregni, F., 2009.
Pharmacological and combined interventions for the acute depressive
episode: focus on efﬁcacy and tolerability. Ther. Clin. Risk Manage. 5,
897–910.
Chung, S., 2005. Does the use of SSRIs reduce medical care utilization and
expenditures? J. Ment. Health Policy Econ. 8, 119–129.
Cipriani, A., Brambilla, P., Furukawa, T.A., Geddes, J., Gregis, M., Hotopf, M.,
Malvini, L., Barbui, C., 2005. Fluoxetine versus other types of pharma-
cotherapy for depression. Cochrane Database Syst. Rev. Issue 4:
CD004185.
Cipriani, A., Santilli, C., Furukawa, T.A., Signoretti, A., Nakagawa, A., McGuire,
H., Churchill, R., Barbui, C., 2009b. Escitalopram versus other anti-
depressive agents for depression. Cochrane Database Syst. Rev. Issue 2:
CD006532.
Croghan, T.W., Kniesner, T.J., Melﬁ, C.A., Robinson, R.L., 2000. Effect of
antidepressant choice on the incidence and economic intensity of
hospitalization among depressed individuals. Adm. Policy Ment. Health
27, 183–195.
Crown, W.H., 2000. Economic outcomes associated with tricyclic antide-
pressant and selective serotonin reuptake inhibitor treatments for
depression. Acta Psychiatr. Scand. 101 (Suppl. 403), 62–66.
Crown, W.H., Treglia, M., Meneades, L., White, A., 2001. Long-term costs of
treatment for depression: impact of drug selection and guideline
adherence. Value Health 4, 295–307.
Dixon, A., McDaid, D., Knapp, M., Curran, C., 2006. Financing mental health
services in low- and middle-income countries. Health Policy Plan. 21,
171–182.
Dobrez, D.G., Melﬁ, C.A., Croghan, T.W., Kniesner, T.J., Obenchain, R.L., 2000.
Antidepressant treatment for depression: total charges and therapy
duration. J. Ment. Health Policy Econ. 3, 187–197.
Domino, M.E., Burns, B.J., Silva, S.G., Kratochvil, C.J., Vitiello, B., Reineche,
M.A., Mario, J., March, J.S., 2008. Cost-effectiveness of treatments for
adolescent depression: results from TADS. Am. J. Psychiatry 165,
588–596.
Eccles, M., Freemantle, N., Mason, J., 1999. North of England evidence-based
guideline development project: summary version of guidelines for the
choice of antidepressants for depression in primary care. North of
England Anti-depressant Guideline Development Group. Fam. Pract. 16,
103–111.
Egberts, A.C., Lenderink, A.W., de Koning, F.H., Leufkens, H.G., 1997.
Channeling of three newly introduced antidepressants to patients not
responding satisfactorily to previous treatment. J. Clin. Psychopharma-
col. 17, 149–155.
Ellis, P., 2004. Australian and New Zealand clinical practice guidelines for the
treatment of depression. Aust. N. Z. J. Psychiatry 38, 389–407.
Evers, S.M., Van Wijk, A.S., Ament, A.J., 1997. Economic evaluation of mental
health care interventions. A review. Heal. Econ. 6, 161–177.
Fantino, B., Moore, N., Verdoux, H., Auray, J.P., 2007. Cost-effectiveness of
escitalopram vs. citalopram in major depressive disorder. Int. Clin.
Psychopharmacol. 22, 107–115.
Fernandez, J.L., Montgomery, S., Francois, C., 2005. Evaluation of the cost
effectiveness of escitalopram versus venlafaxine XR in major depressive
disorder. PharmacoEconomics 23, 155–167.
Gillings, D., Koch, G., 1991. The application of the principle of intention-to-
treat to the analysis of clinical trials. Drug Inf. J. 25, 411–425.
Grifﬁths, R.I., Sullivan, E.M., Frank, R.G., Strauss, M.J., Herbert, R.J., Clouse, J.,
Goldman, H.H., 1999. Medical resource use and cost of venlafaxine or
tricyclic antidepressant therapy: following selective serotonin reuptake
inhibitor therapy for depression. PharmacoEconomics 15, 495–505.
Hosak, L., Tuma, I., Hanus, H., Straka, L., 2000. Costs and outcomes of use of
amitriptyline, citalopram and ﬂuoxetine in major depression: explor-
atory study. Acta Medica (Hradec Kralove) 43, 133–137.
Khandker, R.K., Kruzikas, D.T., McLaughlin, T.P., 2008. Pharmacy and medical
costs associated with switching between venlafaxine and SSRI antide-
pressant therapy for the treatment of major depressive disorder. J.
Manag. Care Pharm. 14, 426–441.
Knapp, M., Funk, M., Curran, C., Prince, M., Grigg, M., McDaid, D., 2006.
Economic barriers to better mental health practice and policy. Health
Policy Plan. 21, 157–170.
Mathers, C.D., Loncar, D., 2006. Projections of global mortality and burden of
disease from 2002 to 2030. PLoS Med. 3, e442.
McCombs, J.S., Nichol, M.B., Stimmel, G.L., 1999. The role of SSRI antidepres-
sants for treating depressed patients in the California Medicaid (Medi-
Cal) program. Value Health 2, 269–280.
McLaughlin, T.P., Eaddy, M.T., Grudzinski, A.N., 2004. A claims analysis
comparing citalopram with sertraline as initial pharmacotherapy for a
new episode of depression: impact on depression-related treatment
charges. Clin. Ther. 26, 115–124.
Monfared, A.A., Han, D., Sheehy, O., Bexton, B., Lelorier, J., 2006. Assessment
of Canadian provincial expenditures in depressed patients treated with
124 Y.-J. Pan et al. / Journal of Affective Disorders 139 (2012) 113–125
venlafaxine XR versus SSRIs: the APEX Study. Curr. Med. Res. Opin. 22,
83–94.
Montgomery, S., Doyle, J.J., Stern, L., McBurney, C.R., Montgomery, S., Doyle,
J.J., Stern, L., McBurney, C.R., 2005. Economic considerations in the
prescribing of third-generation antidepressants. PharmacoEconomics
23, 477–491.
Moore, J.D., Bona, J.R., 2001. Depression and dysthymia. Med. Clin. North Am.
85, 631–644.
NICE, 2009. Depression: Treatment management of depression in adults,
including adults with a chronic physical health problem. Clinical
Guideline 09 and 91. National Institute for Clinical Excellence,
London.
Optenberg, S.A., Lanctot, K.L., Herrmann, N., Oh, P.I., 2002. Antidepressant
selection, healthcare resource consumption and costs in a large
workplace environment: US and Canadian perspectives. Clin. Drug
Investig. 22, 685–694.
Patel, V., Chisholm, D., Rabe-Hesketh, S., Dias-Saxena, F., Andrew, G., Mann,
A., 2003. Efﬁcacy and cost-effectiveness of drug and psychological
treatments for common mental disorders in general health care in Goa,
India: a randomised, controlled trial. Lancet 361, 33–39.
Peveler, R., Kendrick, T., Buxton, M., Longworth, L., Baldwin, D., Moore, M.,
Chatwin, J., Goddard, J., Thornett, A., Smith, H., Campbell, M., Thompson,
C., 2005. A randomised controlled trial to compare the cost-effectiveness
of tricyclic antidepressants, selective serotonin reuptake inhibitors and
lofepramine. Health Technol. Assess. 9, 1–134 iii.
Polsky, D., Onesirosan, P., Bauer, M.S., Glick, H.A., 2002. Duration of therapy
and health care costs of ﬂuoxetine, paroxetine, and sertraline in 6 health
plans. J. Clin. Psychiatry 63, 156–164.
Poret, A.W., Neslusan, C., Ricci, J.F., Wang, S., Khan, Z.M., Kwong, J.W., 2001.
Retrospective analysis of the health-care costs of bupropion sustained
release in comparison with other antidepressants. Value Health 4,
362–369.
Romeo, R., Patel, A., Knapp, M., Thomas, C., 2004. The cost-effectiveness of
mirtazapine versus paroxetine in treating people with depression in
primary care. Int. Clin. Psychopharmacol. 19, 125–134.
Russell, J.M., Berndt, E.R., Miceli, R., Colucci, S., Grudzinski, A.N., 1999. Course
and cost of treatment for depression with ﬂuoxetine, paroxetine, and
sertraline. Am. J. Manag. Care 5, 597–606.
Sclar, D.A., Skaer, T.L., Robison, L.M., Galin, R.S., 1999. Economic appraisal of
citalopram in the management of single-episode depression. J. Clin.
Psychopharmacol. 19, 47S–54S.
Serrano-Blanco, A., Gabarron, E., Garcia-Bayo, I., Soler-Vila, M., Carames, E.,
Penarrubia-Maria, M.T., Pinto-Meza, A., Haro, J.M., 2006a. Effectiveness
and cost-effectiveness of antidepressant treatment in primary health
care: a six-month randomised study comparing ﬂuoxetine to imipra-
mine. J. Affect. Disord. 91, 153–163.
Serrano-Blanco, A., Pinto-Meza, A., Suarez, D., Penarrubia, M.T., Haro, J.M.,
2006b. Cost-utility of selective serotonin reuptake inhibitors for
depression in primary care in Catalonia. Acta Psychiatr. Scand. Suppl.
39–47.
Serrano-Blanco, A., Suarez, D., Pinto-Meza, A., Penarrubia, M.T., Haro, J.M.,
2009. Fluoxetine and imipramine: are there differences in cost-utility for
depression in primary care? J. Eval. Clin. Pract. 15, 195–203.
Sheehan, D.V., Eaddy, M., Sarnes, M., Vishalpura, T., Regan, T., 2004.
Evaluating the economic consequences of early antidepressant treat-
ment discontinuation: a comparison between controlled-release and
immediate-release paroxetine. J. Clin. Psychopharmacol. 24, 544–548.
Sheehan, D.V., Eaddy, M.T., Shah, M.B., Mauch, R.P., 2005. Differences in total
medical costs across the SSRIs for the treatment of depression and
anxiety. Am. J. Manag. Care 11, S354–S361.
Sheehan, D.V., Keene, M.S., Eaddy, M., Krulewicz, S., Kraus, J.E., Carpenter, D.J.,
2008. Differences in medication adherence and healthcare resource
utilization patterns: older versus newer antidepressant agents in patients
with depression and/or anxiety disorders. CNS Drugs 22, 963–973.
Simon, G.E., VonKorff, M., Heiligenstein, J.H., Revicki, D.A., Grothaus, L., Katon,
W., Wagner, E.H., 1996. Initial antidepressant choice in primary care.
Effectiveness and cost of ﬂuoxetine vs tricyclic antidepressants. JAMA
275, 1897–1902.
Simon, G.E., Heiligenstein, J., Revicki, D., VonKorff, M., Katon, W.J., Ludman, E.,
Grothaus, L.,Wagner, E., 1999. Long-termoutcomesof initial antidepressant
drug choice in a “real world” randomized trial. Arch. Fam.Med. 8, 319–325.
Sullivan, E.M., Grifﬁths, R.I., Frank, R.G., Strauss, M.J., Herbert, R.J., Clouse, J.,
Goldman, H.H., 2000. One-year costs of second-line therapies for
depression. J. Clin. Psychiatry 61, 290–298.
Thomas, C.M., Morris, S., 2003. Cost of depression among adults in England in
2000. Br. J. Psychiatry 183, 514–519.
Tournier, M., Moride, Y., Crott, R., du Fort, G.G., Ducruet, T., 2009. Economic
impact of non-persistence to antidepressant therapy in the Quebec
community-dwelling elderly population. J. Affect. Disord. 115, 160–166.
Wade, A.G., Fernandez, J.L., Francois, C., Hansen, K., Danchenko, N., Despiegel,
N., 2008. Escitalopram and duloxetine in major depressive disorder: a
pharmacoeconomic comparison using UK cost data. PharmacoEco-
nomics 26, 969–981.
Wade, A.G., Saragoussi, D., Despiegel, N., Francois, C., Guelfucci, F., Toumi, M.,
2010. Healthcare expenditure in severely depressed patients treated
with escitalopram, generic SSRIs or venlafaxine in the UK. Curr. Med. Res.
Opin. 26, 1161–1170.
Wan, G.J., Crown, W.H., Berndt, E.R., Finkelstein, S.N., Ling, D., 2002a.
Healthcare expenditure in patients treated with venlafaxine or selective
serotonin reuptake inhibitors for depression and anxiety. Int. J. Clin.
Pract. 56, 434–439.
Wan, G.J., Crown, W.H., Berndt, E.R., Finkelstein, S.N., Ling, D., 2002b.
Treatment costs of venlafaxine and selective serotonin-reuptake in-
hibitors for depression and anxiety. Manag. Care Interface 15, 24–30.
Wang, P.S., Simon,G., Kessler, R.C., 2003. Theeconomic burdenof depression and
the cost-effectiveness of treatment. Int. J. Methods Psychiatr. Res. 12, 22–33.
Watkins, K.E., Burnam, M.A., Orlando, M., Escarce, J.J., Huskamp, H.A.,
Goldman, H.H., 2009. The health value and cost of care for major
depression. Value Health 12, 65–72.
WHO, 2008. Projections of mortality and burden of disease, 2004–2030.
http://www.who.int/healthinfo/global_burden_disease/projections/en/
index.html. retrieved on 4 December, 2010.
Wu, E., Greenberg, P., Yang, E., Yu, A., Ben-Hamadi, R., Erder, M.H., 2008a.
Comparison of treatment persistence, hospital utilization and costs
among major depressive disorder geriatric patients treated with
escitalopram versus other SSRI/SNRI antidepressants. Curr. Med. Res.
Opin. 24, 2805–2813.
Wu, E., Greenberg, P.E., Yang, E., Yu, A., Erder, M.H., 2008b. Comparison of
escitalopram versus citalopram for the treatment of major depressive
disorder in a geriatric population. Curr. Med. Res. Opin. 24, 2587–2595.
Wu, E.Q., Greenberg, P.E., Yang, E., Yu, A.P., Ben-Hamadi, R., Erder, M.H., 2009.
Treatment persistence, healthcare utilisation and costs in adult patients
with major depressive disorder: a comparison between escitalopram
and other SSRI/SNRIs. J. Med. Econ. 12, 124–135.
125Y.-J. Pan et al. / Journal of Affective Disorders 139 (2012) 113–125
Treatment costs for depression with pain and cardiovascular comorbidities
Yi-Ju Pan a,b, Martin Knapp a,c, Ling-Ling Yeh d,*, Yu-Pei Chen d, Paul McCrone a
aCentre for the Economics of Mental and Physical Health, Health Service and Population Research Department, Institute of Psychiatry, King’s College London, United Kingdom
bDepartment of Psychiatry, Far Eastern Memorial Hospital, Taiwan
c Personal Social Services Research Unit, LSE Health and Social Care, London School of Economics and Political Science, United Kingdom
dDepartment of Healthcare Administration, Asia University, 500, Lioufeng Rd., Wufeng, Taichung 41354, Taiwan
a r t i c l e i n f o
Article history:
Received 22 June 2012
Received in revised form
30 October 2012







a b s t r a c t
Objective: As depressive disorders are highly heterogeneous, and as patients exhibit wide differences in
clinical characteristics and comorbidities, we aim to examine whether and how demographic and clinical
correlates affect healthcare costs for patients with depression in a real-world setting.
Method: A national cohort of adult patients (n ¼ 216,557) who received treatment for depression was
identiﬁed from the National Health Insurance Research Database in Taiwan. Factors associated with
service use and healthcare costs over a 12-month period were explored, with a particular focus on past
treatment history, comorbid physical illnesses, painful physical symptoms, and choice of initial
antidepressants.
Results: Depression severity, past treatment history, comorbid mental/physical illnesses, painful physical
symptoms, and choice of initial antidepressants were found to be associated with healthcare costs in the
following year, although the nature of the associations differed across cost categories. The presence of
comorbid cardiovascular disease or certain painful physical symptoms at baseline was associated not
only with higher non-psychiatric but also with higher psychiatric costs; moreover, patients with these
comorbidities were shown to have increased use of psychiatric emergency and inpatient services.
Conclusion: Healthcare costs for depression are affected by a number of clinical characteristics and
comorbidities of patients. The importance of comorbid pain and cardiovascular conditions warrants
further research.
 2012 Elsevier Ltd. All rights reserved.
1. Introduction
Unipolar depressive disorder was the fourth leading cause of
disease burden among all diseases in 2002 (Mathers and Loncar,
2006) and is predicted to become the leading cause in 2015
(WHO, 2008). The total direct healthcare costs of depression in
Taiwan, as in many other countries, rose by 50% over the period of
2000e2002 (Chan et al., 2006); the prevalence of antidepressant
use also doubled from 1997 to 2004 (Chien et al., 2007). This could
imply an increase in the need for depression treatment, a reduction
in the treatment gap, or over-provision of care. Given the antici-
pated rise in the future healthcare costs for patients with depres-
sion, it would help inform decision-making to assess the impact of
depression treatment from an economic perspective.
Depressive disorders comprise a group of heterogeneous
conditions. The extent to which treatment history, comorbidities of
physical/mental illnesses, and choice of antidepressants can inﬂu-
ence healthcare costs remains to be determined. Depression is
known to be associatedwith a variety of physical conditions (Katon,
2003) of whom cardiovascular diseases (CVD) and painful physical
symptoms (PPS) warrant further investigation. Depression and CVD
are projected to be the ﬁrst and second leading causes of health-
related burden in 2015 (WHO, 2008), and there is accumulating
evidence suggesting close interrelationships between these highly-
prevalent conditions (Sorensenf et al., 2005; Thombs et al., 2006):
for instance, depressive symptoms have been found to be a risk
factor for cardiac events in patients with coronary heart disease
(Barth et al., 2004; van Melle et al., 2004). To assess the economic
impact of treatment for depression, PPS should also be carefully
considered. Previous studies have revealed high prevalence of pain
complaints in depressed patients (Bair et al., 2003; Husain et al.,
2007; Ohayon and Schatzberg, 2003) and outcomes of treatment
for depression may be poorer in the presence of PPS (Fava et al.,
2004; Gameroff and Olfson, 2006; Leuchter et al., 2010).
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Furthermore, individual antidepressants have been shown to have
a wide range of cardiovascular effects (Taylor, 2008), and antide-
pressants may differ in the effectiveness for the relief of PPS.
Therefore, the presence of these co-occurring CVD and PPS may
inﬂuence the choice of antidepressants and healthcare utilization,
with potential impact on healthcare costs.
The current study, conducted in a real-world setting, seeks to
measure healthcare costs for people with depression using claims
data from the National Health Insurance Research Database
(NHIRD) in Taiwan. The objective of this study is to identify which
demographic and clinical characteristics and comorbidities are
associated with total healthcare costs, as well as costs for speciﬁc
groups of services, with a particular focus on comorbid pain and
cardiovascular diseases.
2. Materials and methods
2.1. Data
Taiwan is a country with a population of around 23,000,000. The
GDP per capita in 2003/2004 was 13,773/15,012 US dollars.
National Health Insurance (NHI) in Taiwan is a single-payer
compulsory social insurance plan that centralizes the disburse-
ment of healthcare funds and guarantees equal access to healthcare
for all citizens. In 2003, there were 21,869,478 individuals enrolled
in the NHI with a coverage rate of 96%. The NHI contracted 17,022
medical institutions, which constituted 93.8% of medical institu-
tions nationwide. By the end of 2005, approximately 22.7 million
individuals had been enrolled in Taiwan’s NHI program with
a coverage rate of 98%. The NHI system in Taiwan contains the
NHIRD which consists of data characterizing healthcare utilization
of insured residents, including expenditures, medical procedures/
treatments, and basic characteristics of patients, providers and
physicians. The NHIRD uses the International Classiﬁcation of
Diseases, 9th revision, clinical modiﬁcation diagnoses (ICD-9-CM).
In this study, the included subjects were identiﬁed from the
NHIRD. The index datewas deﬁned as the date onwhich the subject
was ﬁrst prescribed an antidepressant for a diagnosis of depressive
disorder in 2003. Data on all NHI information for each subject were
extracted for the two-year period spanning the index date (one
year preceding, and one year following).
2.2. Participants
All subjects in NHIRD meeting the following criteria were
included:
 At least one prescription for an antidepressant for treatment of
major depressive disorder (MDD) (ICD-9-CM codes: 296.2x,
296.3x) or minor depression (ICD-9-CM codes: 311.xx, 300.4x)
in 2003.
 Data available for a minimum of 12months before and after the
index date.
 Age 18 years or over on the index date.
A subsample of patients with newly-diagnosed depression was
also identiﬁed within this overall sample, which was operationally
deﬁned as individuals who were free of antidepressant use or
a depression diagnosis for a minimum of 12 months before the
index date.
2.3. Demographic and clinical information
Demographic and clinical data were extracted, including age,
gender, diagnosis of depressive disorders, and initial choice of
antidepressants on the index date. Participants were further
grouped according to past treatment history, i.e., newly-diagnosed
depression and non-newly-diagnosed depression.
Baseline characteristics were traced back for all subjects for the
12 months prior to the index date, including comorbid mental
disorders, physical illnesses (CVD, diabetes mellitus (DM), chronic
obstructive pulmonary disease (COPD), renal diseases, and cancer),
PPS (backache, headache, musculoskeletal and gastrointestinal
pain), and healthcare utilization/expenditure.
2.4. Service use and costs
Service use components extracted from the NHIRD included
outpatient services, emergency attendances, and inpatient stays.
Service use over the 12-month study period was described by the
percentage of patients with at least one unit of service use and the
mean number of service contacts for the whole sample. Medication
use regarding prescriptions of antidepressants was identiﬁed. All
costs over the 12-month study period were calculated from the
actual claims data, were described by service categories, and
expressed in 2003e4 US dollars.
2.5. Data analysis
Sociodemographic data, clinical characteristics, baseline
healthcare utilization/expenditure, and initial antidepressant
treatment were described for the overall sample and compared
between newly-diagnosed depression and non-newly-diagnosed
depression groups.
To identify characteristics predictive of healthcare costs over
the 12-month period, a multivariate generalized linear regression
model with a log link and gamma variance function was employed
(McCullagh and Nelder, 1989). Separate models were run for total
healthcare costs, psychiatric costs, and non-psychiatric costs. And
to measure the model ﬁt, the root mean square error (RMSE)
(Zheng and Agresti, 2000) for each model was computed after
excluding 0.1% of subjects with extremely large predicted values in
costs. The independent variables considered in these models were
age, sex, index depression diagnosis, past treatment history, initial
choice of antidepressants, baseline comorbid mental/physical
disorders, baseline PPS, and baseline total healthcare expenditure.
These variables were ﬁrst selected using a univariate model and
those signiﬁcant at the 5% level were included subsequently.
A backward selection process was then applied to obtain the
ﬁnal multivariate model, using a 5% level of signiﬁcance. Subse-
quently, such analyses were performed in a subsample of subjects
with newly-diagnosed depression as they were a group which
warrants further investigation. This was also to determine the
inﬂuence of past treatment history on the ﬁndings from the overall
sample.
As use of psychiatric emergency and/or inpatient services may
be indicators for patients who require more intensive care, thus
generating higher costs, we examined variations in use of these two
key services in further analyses. With use of psychiatric emergency
services and use of psychiatric inpatient services as dependent
variables, independent variables were entered in a multivariate
logistic regression with a forward LR (likelihood ratios) method to
explore predictors of use over the 12-month study period. A p-value
of 0.05 was considered signiﬁcant for all statistical analyses, which
were performed using SPSS version 17.0 (Chicago, IL, USA).
3. Results
A total of 216,557 adult individuals met the inclusion criteria,
including a subsample of 84,577 persons with newly-diagnosed
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depression. Table 1 shows that for the overall sample, 61.9% were
females and 18.7% were aged 65 years or over on the index date.
Regarding baseline comorbidities, 26.9% had CVD, 10.9% had DM,
and 15.2% had COPD. Comorbid PPS rates were particularly high for
both the overall sample and the subsample of individuals with
newly-diagnosed depression. At the index visit, 45.6% of the overall
sample were prescribed selective serotonin reuptake inhibitors
(SSRIs) and 8.6% prescribed serotonin norepinephrine reuptake
inhibitors (SNRIs). Only 3.1% of patients received other newer
antidepressants (bupropion and mirtazapine).
Patients with newly-diagnosed depression were younger and
had a greater proportion of females compared to those with non-
newly-diagnosed depression. They had lower rates of comorbid
physical/mental illnesses and lower prevalence of PPS. Health
Table 1






depression (n ¼ 131,980)
Age [mean (SD)] 47.4 (17.0) 43.9 (17.0) 49.7 (16.6)
Age categories [n (%)]
>¼85 1756 (0.8) 637 (0.8) 1119 (0.8)
75e84 13,626 (6.3) 4058 (4.8) 9568 (7.2)
65e74 25,019 (11.6) 7267 (8.6) 17,752 (13.5)
55e64 27,438 (12.7) 8787 (10.4) 18,651 (14.1)
45e54 44,252 (20.4) 15,520 (18.4) 28,732 (21.8)
35e44 46,692 (21.6) 18,115 (21.4) 28,577 (21.7)
25e34 36,338 (16.8) 17,740 (21.0) 18,598 (14.1)
18e24 21,436 (9.9) 12,453 (14.7) 8983 (6.8)
Sex [n (%)]
Male 82,414 (38.1) 30,683 (36.3) 51,731 (39.2)
Female 134,143 (61.9) 53,894 (63.7) 80,249 (60.8)
Depression diagnosis at index visit [n (%)]
Major depression 78,296 (36.2) 27,029 (32.0) 51,267 (38.8)
Minor depression 138,261 (63.8) 57,548 (68.0) 80,713 (61.2)
Baseline physical illnesses [n (%)]
Cardiovascular disease 58,350 (26.9) 18,132 (21.4) 40,218 (30.5)
Diabetes mellitus 23,563 (10.9) 7198 (8.5) 16,365 (12.4)
Chronic obstructive pulmonary disease 32,898 (15.2) 10,886 (12.9) 22,012 (16.7)
Hyperlipidemia 23,249 (10.7) 7351 (8.7) 15,898 (12.0)
Hypertension 51,271 (23.7) 15596 (18.4) 35,675 (27.0)
Renal disease 11,854 (5.5) 3766 (4.5) 8088 (6.1)
Cancer 8864 (4.1) 2850 (3.4) 6014 (4.6)
Baseline painful physical symptoms [n (%)]
Musculoskeletal 99,455 (45.9) 36,168 (42.8) 63,287 (48.0)
Back 69,981 (32.3) 25,036 (29.6) 44,945 (34.1)
Gastrointestinal 111,271 (51.4) 40,018 (47.3) 71,253 (54.0)
Headache/migraine/dizziness 88,164 (40.7) 29,996 (35.5) 58,168 (44.1)
Baseline mental illnesses [n (%)]
Schizophrenia 8207 (3.8) 1538 (1.8) 6669 (5.1)
Other psychotic disorder 4650 (2.1) 775 (0.9) 3875 (2.9)
Substance related 6127 (2.8) 1081 (1.3) 5046 (3.8)
Alcohol related 1748 (0.8) 254 (0.3) 1494 (1.1)
Drugs related 1084 (0.5) 196 (0.2) 888 (0.7)
Bipolar spectrum disorder 3882 (1.8) 457 (0.5) 3425 (2.6)
Dementia 7356 (3.4) 1426 (1.7) 5930 (4.5)
Generalized anxiety disorder 11,718 (5.4) 2313 (2.7) 9405 (7.1)
Obsessive-compulsive disorder 3797 (1.8) 180 (0.2) 3617 (2.7)
Panic disorder 7388 (3.4) 588 (0.7) 6800 (5.2)
Phobic disorder 1742 (0.8) 131 (0.2) 1611 (1.2)
Post-traumatic stress disorder 404 (0.2) 20 (0.0) 384 (0.3)
Sleep disorder 52,001 (24.0) 15,196 (18.0) 36,805 (27.9)
Hyperkinetic syndrome 133 (0.1) 22 (0.0) 111 (0.1)
Baseline healthcare service use
Number of outpatient visits [mean (SD)] 31.6 (24.8) 23.9 (20.9) 36.5 (25.8)
ER visit [n (%)] 74,970 (34.6) 26,178 (31.0) 48,792 (37.0)
Hospitalization [n (%)] 45,397 (21.0) 13,576 (16.1) 31,821 (24.1)
Total 12-month costs prior to index date [mean (SD)] 1365.6 (2397.2) 894.6 (2089.0) 16,67.5 (2529.6)
Index AD [n (%)]
SSRI 98,791 (45.6) 42,476 (50.2) 56,315 (42.7)
SNRI 18,520 (8.6) 7549 (8.9) 10,971 (8.3)
Other newer AD 6759 (3.1) 3104 (3.7) 3655 (2.8)
TCA 18,787 (8.7) 5873 (6.9) 12,914 (9.8)
Flupentixol/melitracen 11,449 (5.3) 4341 (5.1) 7108 (5.4)
Other older AD 40,897 (18.9) 14,016 (16.6) 26,881 (20.4)
Multiple AD 21,354 (9.9) 7218 (8.5) 14,136 (10.7)
Baseline characteristics were measured over the 12-month pre-index period.
Costs were expressed in 2003e4 US dollars.
SD ¼ standard deviation; AD ¼ antidepressant; SSRI ¼ selective serotonin reuptake inhibitor; SNRI ¼ serotonin norepinephrine reuptake inhibitor; TCA ¼ tricyclic antide-
pressant; other newer AD: bupropion and mirtazapine; other older AD: maprotiline, moclobemide, and trazodone.
a All comparisons between newly-diagnosed and non-newly-diagnosed depression were statistically signiﬁcant with a p < 0.001 (chi-squared test was used for categorical
variables and independent t-test for continuous variables).
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service utilization at baseline was lower as well. A higher propor-
tion of them were prescribed newer generation antidepressants.
3.1. Service use and costs
Service use data are summarized in Table 2. Of the overall
sample, 85.1% had used psychiatric outpatient services over the 12-
month study period. Over the same period, 5.0% of them had been
admitted to psychiatric wards for inpatient treatment and 1.6% had
psychiatric emergency attendances.
Costs of outpatient contacts in total accounted for 63.6% of total
healthcare costs for these patients. And overall expenditures on
psychiatric services were around 29.2% of the total healthcare costs.
3.2. Total healthcare costs
Table 3 reveals that higher total healthcare costs were associ-
ated with older age, male gender, an index diagnosis of MDD, non-
newly-diagnosed depression, and having CVD, DM, COPD, renal
disease, cancer or PPS at baseline.
Use of SNRIs, other newer generation antidepressants and use of
multiple antidepressants were related to higher costs compared to
use of SSRIs at the index date. Lower costs were observed for those
using tricyclic antidepressants (TCAs), ﬂupentixol/melitracen, and
other older antidepressants (maprotiline, moclobemide, and tra-
zodone). The analysis on the subsample of newly-diagnosed
depression revealed similar results with those from the full
sample. Regarding the model ﬁt, RMSE of the model for total costs
was 1316. The predicted mean of total costs was 1925 US dollars
versus the actual mean costs 1731 US dollars.
Table 3








Age 1.011 (1.011, 1.011) 1.013 (1.013, 1.014)
Sex




Major depression 1.134 (1.125, 1.143) 1.160 (1.144, 1.176)




0.959 (0.952, 0.967) e
Non-newly-diagnosed
depression with history
of both AD treatment
and depression diagnosis
1.136 (1.121, 1.151) e
Non-newly-diagnosed





SNRI 1.160 (1.144, 1.176) 1.144 (1.118, 1.170)







Other newer AD 1.142 (1.118, 1.166) 1.152 (1.114, 1.192)
TCA 0.905 (0.893, 0.918) 0.895 (0.872, 0.918)
Other older AD 0.956 (0.946, 0.965) 0.978 (0.960, 0.996)
Flupentixol/melitracen 0.876 (0.862, 0.891) 0.902 (0.876, 0.929)




Yes vs. No 1.180 (1.169, 1.191) 1.270 (1.248, 1.293)
Diabetes mellitus
Yes vs. No 1.256 (1.240, 1.271) 1.315 (1.284, 1.347)
Chronic obstructive pulmonary disease
Yes vs. No 1.122 (1.111, 1.134) 1.126 (1.104, 1.148)
Renal disease
Yes vs. No 1.161 (1.142, 1.181) 1.230 (1.190, 1.270)
Cancer
Yes vs. No 1.326 (1.302, 1.351) 1.478 (1.426, 1.532)
Baseline painful physical symptoms
Musculoskeletal
Yes vs. No 1.068 (1.060, 1.077) 1.069 (1.054, 1.084)
Back
Yes vs. No 1.062 (1.053, 1.071) 1.069 (1.053, 1.085)
Gastrointestinal
Yes vs. No 1.067 (1.059, 1.075) 1.059 (1.045, 1.073)
Headache/migraine/dizziness
Yes vs. No 1.049 (1.040, 1.057) 1.046 (1.032, 1.061)
Baseline mental illnesses
Schizophrenia
Yes vs. No 1.890 (1.854, 1.927) 2.456 (2.342, 2.575)
Other psychotic disorder
Yes vs. No 1.185 (1.156, 1.215) 1.368 (1.281, 1.461)
Substance related
Yes vs. No 1.301 (1.271, 1.331) 1.323 (1.249, 1.401)
Alcohol related
Yes vs. No 1.484 (1.423, 1.548) 1.662 (1.480, 1.867)
Drugs related
Yes vs. No 1.188 (1.128, 1.251) 1.483 (1.301, 1.690)
Bipolar spectrum disorder
Yes vs. No 1.233 (1.199, 1.267) 1.301 (1.194, 1.417)
Dementia
Yes vs. No 1.281 (1.255, 1.308) 1.355 (1.289, 1.424)
Generalized anxiety disorder
Yes vs. No 0.998 (0.982, 1.014) 0.996 (0.958, 1.035)
Obsessive-compulsive disorder
Yes vs. No 1.069 (1.039, 1.099) 0.978 (0.854, 1.120)
Panic disorder
Yes vs. No 0.961 (0.941, 0.980) 1.040 (0.964, 1.121)
Post-traumatic stress disorder
Yes vs. No 1.190 (1.094, 1.293) 0.983 (0.655, 1.476)
Total 12-month costs prior to
index date (1000 USD)
1.182 (1.179, 1.185) 1.175 (1.170, 1.181)
RR ¼ relative risk; CI ¼ conﬁdence interval; AD ¼ antidepressant; SNRI ¼ serotonin
norepinephrine reuptake inhibitor; TCA ¼ tricyclic antidepressant; SSRI ¼ selective
serotonin reuptake inhibitor; other newer AD: bupropion and mirtazapine; other
older AD: maprotiline, moclobemide, and trazodone.
Table 2
Service use and healthcare costs over the 12-month study period, overall sample.
Service use
n (% using) Mean (SD)
Psychiatric outpatient 184,271 (85.1) 7.30 (7.72)
Psychiatric inpatient 10,916 (5.0) 0.08 (0.46)
Psychiatric emergency 3515 (1.6) 0.03 (0.42)
Non-psychiatric outpatient 212,327 (98.0) 27.48 (25.51)
Non-psychiatric inpatient 39,077 (18.0) 0.33 (0.98)
Non-psychiatric emergency 70,812 (32.7) 0.76 (3.13)
Healthcare costs ($, year 2003e4 values)
Mean (SD)
Psychiatric outpatient 356.64 (465.87)
Psychiatric inpatient 148.22 (992.87)
Psychiatric emergency 0.86 (9.84)
Non-psychiatric outpatient 744.02 (1927.52)
Non-psychiatric inpatient 437.02 (2423.54)
Non-psychiatric emergency 44.46 (171.97)
Total 1731.21 (3508.72)
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3.3. Non-psychiatric healthcare costs
Older age, and male gender were related to higher non-
psychiatric costs in the following year (Table 4). Compared to
patients with history of either an antidepressant treatment or
a depression diagnosis, those with newly-diagnosed depression
had higher non-psychiatric costs. Patients with an index diagnosis
of MDD or a baseline comorbid mental disorder were associated
with lower costs, with the only exceptions being alcohol, substance
misuse, multiple drugs-relatedmental disorders and dementia. The
presence of a comorbid physical illness or PPS at baseline was
related to higher non-psychiatric costs.
Patients prescribed older antidepressants had higher non-
psychiatric costs in the following year compared to those
prescribed SSRIs while patients prescribed newer antidepressants
such as SNRIs or bupropion/mirtazapine had non-psychiatric costs
that did not differ signiﬁcantly. The RMSE of the model was 4380.
And the predicted mean of non-psychiatric costs was 1452 US
dollars while the actual mean cost was 1226 US dollars.
3.4. Psychiatric healthcare costs
As shown in Table 4, male gender was associated with higher
psychiatric costs in the following year. Not surprisingly, patients
having an index diagnosis of MDD had increased costs as did those
with baseline comorbid mental disorders. Patients with newly-
diagnosed depression had lower psychiatric costs compared to
those who had been diagnosed prior to the index date. Younger age
was shown to be related to higher psychiatric costs.
Use of newer generation antidepressants or multiple antide-
pressants prescribed on the index date were related to higher
psychiatric costs compared to those prescribed SSRIs, while use of
older antidepressants was related to lower costs. Among comorbid
physical illnesses, CVD was the only one found to increase psychi-
atric costs. And among PPS, only pain complaints relating to the
central nervous system (CNS), i.e., headache/dizziness/or migraine,
were related to higher psychiatric costs. The RMSE of the model
was 1074. The predicted mean of psychiatric costs was 577 US
dollars and the actual mean was 506 US dollars.
3.5. Use of psychiatric emergency and inpatient services
Younger age, male gender, a diagnosis of MDD or certain
comorbid mental disorders were more likely to lead to psychiatric
emergency attendances and hospitalizations (Table 5). CVD or
COPD was related to higher odds of using psychiatric emergency
and hospitalization services. Headache/dizziness/or migraine
complaints at baseline were associated with an increase in the odds
of using psychiatric emergency and hospitalization services as well.
4. Discussion
This study provided new evidence on the associations between
comorbidities, service use, and healthcare costs for patients with
depression. Although the nature of the associations differed across
cost categories, the multivariate models revealed that age, gender,
Table 4
Multivariate analysis (GLM) of non-psychiatric costs and psychiatric costs over the






Age 1.019 (1.019, 1.020) 0.998 (0.997, 0.998)
Sex




Major depression 0.978 (0.969, 0.987) 1.363 (1.349, 1.377)




1.110 (1.100, 1.121) 0.696 (0.689, 0.704)
Non-newly-diagnosed
depression with history
of both AD treatment
and depression diagnosis
1.076 (1.060, 1.093) 1.359 (1.334, 1.385)
Non-newly-diagnosed
depression with history




SNRI 0.995 (0.979, 1.011) 1.396 (1.372, 1.421)
Other newer AD 1.014 (0.988, 1.040) 1.323 (1.288, 1.360)
TCA 1.046 (1.029, 1.063) 0.709 (0.695, 0.723)
Other older AD 1.063 (1.051, 1.076) 0.841 (0.829, 0.853)
Flupentixol/melitracen 1.031 (1.011, 1.052) 0.681 (0.664, 0.699)




Yes vs. No 1.252 (1.238, 1.266) 1.015 (1.002, 1.029)
Diabetes mellitus
Yes vs. No 1.362 (1.343, 1.382) 0.991 (0.974, 1.009)
Chronic obstructive pulmonary disease
Yes vs. No 1.168 (1.153, 1.182) 1.004 (0.990, 1.019)
Renal disease
Yes vs. No 1.245 (1.220, 1.270) 0.855 (0.835, 0.876)
Cancer
Yes vs. No 1.562 (1.528, 1.597) 0.857 (0.835, 0.880)
Baseline painful physical symptoms
Musculoskeletal
Yes vs. No 1.132 (1.121, 1.143) 0.974 (0.963, 0.984)
Back
Yes vs. No 1.120 (1.109, 1.131) 0.971 (0.960, 0.982)
Gastrointestinal
Yes vs. No 1.163 (1.153, 1.174) 0.955 (0.945, 0.965)
Headache/migraine/dizziness
Yes vs. No 1.088 (1.078, 1.098) 1.033 (1.022, 1.044)
Baseline mental illnesses
Schizophrenia
Yes vs. No 0.892 (0.871, 0.931) 3.443 (3.358, 3.531)
Other psychotic disorder
Yes vs. No 0.966 (0.937, 0.996) 1.514 (1.465, 1.565)
Substance related
Yes vs. No 1.335 (1.298, 1.372) 1.323 (1.282, 1.364)
Alcohol related
Yes vs. No 1.467 (1.395, 1.544) 1.707 (1.614, 1.805)
Drugs related
Yes vs. No 1.196 (1.124, 1.273) 1.208 (1.129, 1.292)
Bipolar spectrum disorder
Yes vs. No 0.991 (0.958, 1.024) 1.649 (1.590, 1.709)
Dementia
Yes vs. No 1.291 (1.260, 1.323) 1.451 (1.407, 1.496)
Generalized anxiety disorder
Yes vs. No 1.007 (0.988, 1.026) 1.016 (0.994, 1.038)
Obsessive-compulsive disorder
Yes vs. No 0.837 (0.809, 0.865) 1.241 (1.197, 1.286)
Panic disorder
Yes vs. No 0.902 (0.881, 0.924) 1.062 (1.034, 1.090)
Post-traumatic stress disorder
Yes vs. No 1.045 (0.946, 1.154) 1.229 (1.104, 1.368)
Total 12-month costs prior to
index date (1000 USD)
1.200 (1.197, 1.203) 1.078 (1.074, 1.082)
RR ¼ relative risk; CI ¼ conﬁdence interval; AD ¼ antidepressant; SNRI ¼ serotonin
norepinephrine reuptake inhibitor; TCA ¼ tricyclic antidepressant; SSRI ¼ selective
serotonin reuptake inhibitor; other newer AD: bupropion and mirtazapine; other
older AD: maprotiline, moclobemide, and trazodone.
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depression severity, past treatment history, comorbid mental/
physical illnesses, PPS, and choice of initial antidepressants were all
associated with healthcare costs in the following year. Factors
including comorbid CVD and PPS were further explored to
understand patterns of variation in psychiatric emergency and
inpatient service use over the 12-month study period.
4.1. Demographic characteristics
Although previous studies have suggested that medical costs are
higher for women than men (Owens, 2008; Woolhandler and
Himmelstein, 2007), this study found a different result: for patients
with depressive disorders, and taking into account other inﬂuences
on costs, male gender was shown to be associated with higher costs
for both non-psychiatric and psychiatric healthcare services.
There have been few recent studies that speciﬁcally examined
the association between gender and healthcare utilization/expen-
diture for patients with depressive disorders. A study of elderly
patients with psychiatric diagnoses suggested that men had more
emergency attendances and had greater inpatient costs than
women, which led some investigators to propose that when men
eschew regular visits to physicians, it is likely that emergency or
inpatient treatment may be required as illness progresses (Husaini
et al., 2002). Consistently, male patients were shown to be associ-
ated with increased use of psychiatric emergency and inpatient
services in the current study. One interpretation of our results is
therefore that male patients with depression may enter the
healthcare system later in the disease course, by which time their
illness is more severe, thus generating higher costs.
4.2. Comorbid cardiovascular disease
Among the frequently co-occurring physical illnesses consid-
ered in this study, CVDwas the only one shown to increase not only
non-psychiatric but also psychiatric costs. Depression has been
revealed to be an independent risk factor for the future onset,
progression, and recurrence of CVD (Carney et al., 1988; Ferketich
et al., 2000; Nicholson et al., 2006; Rugulies, 2002; Sesso et al.,
1998; Wassertheil-Smoller et al., 2004), which can be mediated
both by poor health behavior and by the pathophysiological
correlates of depressive symptoms, e.g., neuroendocrine and
inﬂammatory activation (Frasure-Smith and Lesperance, 2010;
Rozanski et al., 2005). Additionally, individual antidepressants have
a wide range of cardiovascular effects which may affect
cardiovascular-related morbidity and mortality (Coupland et al.,
1997; Taylor, 2008; Vieweg and Wood, 2004); it seems likely that
the co-existence of CVD and depression may impact patients’
physical conditions and their non-psychiatric costs.
As well, we found that the presence of comorbid CVD was
related to higher odds of using both psychiatric emergency and
hospitalization services which was consistent with the ﬁnding of
increased psychiatric costs in these patients. CVD has been shown
to be correlated with certain lifestyles, alcohol consumption, and
personality traits (e.g., Type D personality), some of which seem to
be highly correlated with use of psychiatric services. For instance,
Type D has been conceptualized as a personality trait comprising
negative affectivity and social inhibition that often co-occurs with
depression in patients with coronary artery disease, and that may
inhibit remission of depressive symptoms (Albus et al., 2011;
Denollet et al., 2010). Although it can only be speculative, the
identiﬁed association between the presence of CVD and increased
psychiatric service utilization/expenditure in this study may be
understood as being indirectly inﬂuenced by these unmeasured
and potentially associated factors.
4.3. Painful physical symptoms
The relationships between depression and pain are complex
with similar brain areas regulating both mood and the affective
Table 5
Multivariate logistic analysis for use of psychiatric inpatient and emergency services






Age 0.974 (0.972, 0.975) 0.949 (0.947, 0.952)
Sex
Male 1.689 (1.620, 1.762) 1.731 (1.613, 1.858)
Female 1 1
Depression diagnosis at index visit
Major depression 1.909 (1.830, 1.991) 1.771 (1.650, 1.901)




1.093 (1.042, 1.147) 1.022 (0.943, 1.108)
Non-newly-diagnosed
depression with history
of both AD treatment and
depression diagnosis
2.445 (2.310, 2.588) 1.593 (1.441, 1.762)
Non-newly-diagnosed
depression with history




SNRI 1.385 (1.295, 1.481) 0.736 (0.642, 0.843)
Other newer AD 1.712 (1.558, 1.880) 1.007 (0.838, 1.209)
TCA 0.747 (0.680, 0.820) 0.831 (0.708, 0.974)
Other older AD 0.926 (0.872, 0.984) 1.169 (1.062, 1.287)
Flupentixol/melitracen 0.601 (0.525, 0.688) 1.300 (1.097, 1.540)




Yes vs. No 1.060 (1.003, 1.120) 1.292 (1.178, 1.417)
Chronic obstructive pulmonary disease
Yes vs. No 1.080 (1.017, 1.147) 1.120 (1.010, 1.241)
Renal disease
Yes vs. No 0.741 (0.667, 0.824) e
Cancer
Yes vs. No 0.773 (0.685, 0.873) e
Baseline painful physical symptoms
Headache/migraine/dizziness
Yes vs. No 1.062 (1.016, 1.109) 1.125 (1.046, 1.211)
Baseline mental illnesses
Schizophrenia
Yes vs. No 4.271 (4.010, 4.548) 2.971 (2.688, 3.283)
Other psychotic disorder
Yes vs. No 1.776 (1.616, 1.953) 1.594 (1.374, 1.848)
Substance related
Yes vs. No 2.277 (2.099, 2.471) 1.982 (1.742, 2.255)
Alcohol related
Yes vs. No 3.526 (3.112, 3.995) 2.014 (1.656, 2.449)
Drugs related
Yes vs. No 1.257 (1.051, 1.502) 1.328 (1.038, 1.699)
Bipolar spectrum disorder
Yes vs. No 2.453 (2.236, 2.691) 2.655 (2.321, 3.037)
Dementia
Yes vs. No 1.817 (1.638, 2.015) 1.440 (1.172, 1.770)
Generalized anxiety disorder
Yes vs. No 0.840 (0.759, 0.929) e
Obsessive-compulsive disorder
Yes vs. No 0.864 (0.757, 0.987) 1.278 (1.068, 1.529)
Panic disorder
Yes vs. No 0.825 (0.736, 0.924) 1.478 (1.271, 1.718)
Total 12-month costs prior to
index date (1000 USD)
1.059 (1.052, 1.067) 1.033 (1.021, 1.045)
OR ¼ odds ratio; CI ¼ conﬁdence interval; AD ¼ antidepressant; SNRI ¼ serotonin
norepinephrine reuptake inhibitor; TCA ¼ tricyclic antidepressant; SSRI ¼ selective
serotonin reuptake inhibitor; other newer AD: bupropion and mirtazapine; other
older AD: maprotiline, moclobemide, and trazodone.
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components of pain (Giesecke et al., 2005). High prevalence of pain
complaints has been reported in patients with depression (Bair
et al., 2003; Husain et al., 2007; Ohayon and Schatzberg, 2003).
Our results added to this evidence in ﬁnding a high percentage of
comorbid PPS in patients with newly-diagnosed depression, which
supports ﬁndings from previous studies that pain usually appears
before the development of MDD (Ohayon and Schatzberg, 2010).
On the other hand, increasing pain interference has been reported
to be associated not only with higher odds of having depressive
disorders (Barry et al., 2012), but also with adverse impact on poor
treatment response (Bair et al., 2004). Pain complaints seem to be
characteristic of depression that is more severe and refractory to
antidepressant treatments, as evidenced by higher healthcare
utilization, and higher costs (Gameroff and Olfson, 2006).
As most previous studies were based on highly selective
samples and did not consider many comorbidities, it is unclear
whether these results could be generalized to larger samples of
patients in a real-world setting, and to what extent other factors
such as comorbid mental/physical illnesses would contribute to
the possible association between PPS, healthcare utilization, and
treatment outcome. In the current study, we concurred with
previous studies in suggesting that the presence of PPS was
associated with higher total healthcare costs in the following year;
this remained true for those with newly-diagnosed depression. In
addition, analyses based on origins of pain complaints found that
the co-existence of PPS was generally associated with higher non-
psychiatric costs but lower psychiatric costs, with headache being
the only exception: unlike pain complaints over other somatic
systems, having headache was associated with higher psychiatric
costs and greater odds of using psychiatric emergency and inpa-
tient services. A recent study suggested the existence of differ-
ences in separate pain modalities in relation to depression, and
that a closer relationship may exist between MDD and neuro-
pathic pain than non-neuropathic pain (Ohayon and Stingl, 2012).
It seems possible that a more direct relationship might exist
between depression and pain complaints over the central nervous
system than PPS from other somatic systems as our data might
suggest.
4.4. Antidepressant choice
The current study showed that initial choice of antidepressants
appears to be associated with total healthcare costs in the following
year. Compared to patients prescribed SSRIs, those prescribed older
antidepressants had lower total and psychiatric costs, whilst
patients prescribed SNRIs, and other newer antidepressants had
higher total and psychiatric costs. However, to a large extent these
differences may be attributed to physician selection: patients
prescribed older antidepressants were more likely to suffer minor
depression, to be older, and to have more PPS and physical
comorbidities at baseline. Contrarily, patients prescribed newer
antidepressants were more likely to have MDD, to be younger, and
to have fewer baseline physical comorbidities (not shown in this
paper). These distinctive characteristics suggest the existence of
physician selection based on patients’ clinical characteristics that
unfortunately could not be fully accounted for by the adjustment
factors in our analyses.
Further support could be drawn from the comparisons between
cost models: as seen in Table 4, patients prescribed SNRIs and other
newer antidepressants were similar to those prescribed SSRIs in
non-psychiatric costs, whilst patients prescribed TCAs and other
older antidepressants generally had higher non-psychiatric costs.
These results could be interpreted as showing that there were
differences especially in physical comorbidities between these two
groups of depressed patients. Previous database analyses have also
suggested that SSRI users may have higher depression-related
service expenditures but lower non-depression-related service
expenditures than TCA users (Pan et al., 2012). Along with these
previous ﬁndings, our results suggest that depressed patients
prescribed older antidepressants may be different from those
prescribed SSRIs, SNRIs, and other newer antidepressants in terms
of clinical features of depression and comorbidities.
4.5. Limitations and conclusions
As service use data contained in the NHIRD includes only health
services provided by the NHI system in Taiwan, the perspective of
the current analysis was relatively limited, and we were not able to
analyze wider economic impacts. Confounding or selection bias
due to the nonrandomized study design should be borne in mind
while interpreting the results, although the real-world context and
whole-country coverage are strengths, especially when analyzing
the inherent heterogeneity of clinical presentations and patient
characteristics and their inﬂuences on help-seeking behaviors,
clinical outcomes, and costs.
In conclusion, the current studydbased on a large national
databasedsuggests a set of signiﬁcant correlates of healthcare
costs for depressed patients. Male gender and a diagnosis of MDD
were signiﬁcantly associated with higher total healthcare costs. The
baseline comorbidities of CVD and headache were associated not
only with higher non-psychiatric but also with higher psychiatric
costs; moreover, these comorbidities were related to increased use
of psychiatric emergency and inpatient services in the following
year.
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Impact of initial treatment outcome on long-term
costs of depression: a 3-year nationwide follow-up
study in Taiwan
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Background. The impact of initial treatment outcome on long-term healthcare costs in depression remains to be deter-
mined. We aimed to identify demographic and clinical characteristics associated with initial treatment outcomes and to
test whether and how these outcomes inﬂuence total healthcare costs over the subsequent 3 years.
Method. In this secondary analysis of a large healthcare database, a national cohort of adult patients (n=126471) who
received antidepressant treatment for depression was identiﬁed and factors associated with initial outcomes were exam-
ined. Potential predictors of total healthcare costs in the subsequent years were assessed using generalized linear
modeling, with a particular focus on initial outcome status after antidepressant treatment and co-morbidities.
Results. Depression type and co-morbid painful physical symptoms (PPS) or mental illnesses were found to be associ-
ated with initial outcome status. Having sustained treatment-free status after initial treatment was shown to be associ-
ated with a 22–33% reduction in total healthcare costs in the second and third years (compared to those with late
recontacts). Although the presence of co-morbid PPS was associated with higher healthcare costs, having certain
co-morbid anxiety disorders was associated with lower costs over the 3 years.
Conclusions. Initial outcome status after antidepressant treatment has a sustained impact on individuals’ total health-
care costs over the following 3 years. Future efforts to improve initial treatment outcome of depression are warranted.
Received 5 January 2013; Revised 16 April 2013; Accepted 5 June 2013; First published online 18 July 2013
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Introduction
Depressive disorders are a leading cause of burden
among all diseases globally, accounting for 9.6% of
all years lived with disability (YLDs) (Vos et al. 2012).
To promote individual and population health and to
reduce YLDs, it is crucial to improve patients’ treat-
ment outcomes and health states during and after
treatment for depression. Moreover, given the high
prevalence and chronic/relapsing course of depression,
healthcare costs can pose a great barrier to its treat-
ment. An association between depression and
increased levels of health-service use and costs has
been demonstrated (Simon et al. 1995; Katon, 2003),
but much less is known about how this relationship
is inﬂuenced by treatment outcomes. Data from longi-
tudinal studies suggest that costs are signiﬁcantly
lower for patients who experience remission after the
acute treatment phase than for those with less favor-
able outcomes (Simon et al. 2006; Sobocki et al. 2006;
Sicras-Mainar et al. 2010a). However, the existing
literature is limited in several ways. First, ﬁndings
were based on relatively small samples (Simon et al.
2006; Sobocki et al. 2006). Second, the duration over
which study subjects were followed up was limited
to 6 to 12 months, and so the impact of initial treat-
ment outcome on service use and costs beyond this
point is unknown. Third, many of the studies tested
for outcome (e.g. remission) at a point when a large
proportion of participants would still be receiving anti-
depressants, thus leaving the impacts after cessation of
antidepressant treatments largely undetermined.
In this study, we aimed to assess the longer-term
economic impacts of outcome status following initial
treatment for depression using claims data from
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Goldberg Centre, De Crespigny Park, Denmark Hill, London SE5 8AF,
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a large national cohort of patients with depression
from the National Health Insurance Research Data-
base (NHIRD) in Taiwan. Type of depression, past
treatment history, co-morbid mental/physical illness-
es, painful physical symptoms (PPS) and choice of
initial antidepressants have been found to be associ-
ated with healthcare costs and service use for patients
treated for depression in Taiwan (Pan et al. 2013a),
hence the cost analysis conducted in the current
study has taken these factors into account. Speciﬁc
objectives of this study were to explore factors associ-
ated with initial outcome status and to examine health-




Data were extracted from the NHIRD in Taiwan. On
1 March 1995, Taiwan launched the compulsory single-
payer NHI program to centralize the disbursement of
healthcare funds and guarantee equal access to health
care for all citizens; since 2000, the NHI coverage rate
has exceeded 96%. Patients can enjoy free choice of
providers and have direct access to specialist care with-
out going through a gatekeeper or referral system.
There is also no limit to the number of visits a patient
can have (Chen et al. 2007). The NHI program uses the
NHIRD, which consists of data ﬁles characterizing
healthcare utilization of insured residents in Taiwan,
including expenditures, medical procedures/treat-
ments and basic characteristics of patients, providers
and physicians. The NHIRD uses the ICD, 9th revision,
clinical modiﬁcation (ICD-9-CM) diagnoses. The index
date for our study was deﬁned as the date on which
the subject was ﬁrst prescribed an antidepressant for
a diagnosis of depressive disorders in 2003. Data
regarding service use and costs for the 3 years follow-
ing the index date were extracted.
Participants
All insured subjects of the NHI system in Taiwan meet-
ing the following criteria were included: (a) age 518
years on the index date; (b) at least one prescription
for an antidepressant for treatment of major depressive
disorder (MDD: ICD-9-CM codes 296.2x and 296.3x) or
other depressive disorders (ICD-9-CM codes 300.4x
and 311.xx) in 2003; (c) at least three antidepressant
prescriptions within the ﬁrst 3 months of the index
date; and (d) data available for a minimum of
12 months before and a minimum of 36 months after
the index date.
Deﬁnition of initial outcome status
In this study, proxy criteria of treatment outcomes
were operationally deﬁned, which focused on the ces-
sation of antidepressant treatment. This proxy measure
has been validated by evaluating the concordance
between remission as deﬁned by antidepressant
cessation for at least 6 months and remission deter-
mined by clinical criteria; the level of concordance
between the two approaches was considered accepta-
ble [Cronbach’s α=90.6%, 95% conﬁdence interval
(CI) 85.6–95.6] (Sicras-Mainar et al. 2010b). This proxy
measure of remission was also used in a recent econ-
omic evaluation for patients with depression (Byford
et al. 2011).
However, to prevent confusion from actual re-
mission deﬁned by clinical rating scales, in this study
we adopted the more descriptive term ‘treatment-free
status’ instead of ‘remission’. Additionally, in our
recent study addressing attrition and treatment out-
comes, ‘sustained treatment-free status’ was deﬁned
as further requiring no restart of antidepressant treat-
ments (late recontacts) during the 18-month follow-up
period (Pan et al. 2013b). We also speciﬁed that only
participants who had at least three antidepressant pre-
scriptions in the ﬁrst 3 months were included to ensure
that we were identifying a group of depressed patients
with initial presentation that justiﬁed antidepressant
treatment.
Study participants were therefore grouped accord-
ing to three treatment outcomes:
(1) Sustained treatment-free status: patients who had
antidepressant cessation for at least 6 months and
had not restarted antidepressant use by the end
of the 18-month observation period.
(2) Continuous treatment: patients who had not had
cessation of antidepressant use for at least 6 months
by the end of the 18-month observation period.
(3) Late recontacts: patients who had achieved anti-
depressant cessation for at least 6 months but
later restarted antidepressant use during the 18-
month period of observation.
Observation period for treatment outcome status
For each individual, the observation period started
on the index date and continued for 18 months after
this index date. The additional 6 months after the
ﬁrst 12 months was included to ensure there was ad-
equate time to assess whether treatment-free status
had been achieved, given the deﬁnition described
earlier. The treatment-free period (i.e. cessation of anti-
depressant treatment) could start at any point during
the 12 months after the index date, but a participant
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needed to remain off antidepressants for a minimum of
6 months to meet the deﬁnition. Hence, an observation
period of 18 months was required.
Demographic and clinical information
Demographic and clinical data, including age, gender,
index diagnosis of depressive disorders and initial
choice of antidepressants, were extracted. Provider
information and clinical setting at the initial visit
were also extracted. Participants were grouped accord-
ing to past treatment history: newly diagnosed
depression (deﬁned as people who had not received
antidepressant treatment or a depression diagnosis in
the 12 months before the index date) and non-newly
diagnosed depression.
Baseline characteristics were collected regarding
co-morbid mental disorders, physical illnesses (cardio-
vascular disease, diabetes mellitus, chronic obstructive
pulmonary disease, renal diseases and cancer), PPS
(headache, backache, musculoskeletal and gastrointes-
tinal pain and others) and also healthcare utilization/
expenditure during the 12 months prior to the index
visit.
Service use and costs
Service use data extracted from the NHIRD included
contacts with out-patient services, emergency attend-
ances and in-patient stays (for all reasons). The percent-
age of patients with at least one unit of service use and
the mean number of service contacts were reported in
this study. Annual service costs were calculated from
the actual claims data, were converted by purchasing
power parity (PPP) conversion rates (IMF, 2013) and
are expressed in international dollars.
Statistical analyses
Sociodemographic data, clinical characteristics, base-
line co-morbidities and initial choice of antidepressants
were described and compared between groups by
initial outcome status. Service use and costs of groups
based on outcome status were also described by
service categories and compared for the next 3 years
after the index date.
To identify characteristics predictive of initial out-
come status, a multinomial logistic regression analysis
was performed, with outcome status as the dependent
variable. The independent variables included age,
sex, depression type, past treatment history, physician
specialty, clinical settings at index visit, initial choice of
antidepressants, baseline co-morbid mental/physical
disorders and baseline PPS.
A multivariate generalized linear model regression
with a log link and gamma variance function
was used (McCullagh & Nelder, 1989) to examine the
effects of outcome status on total healthcare costs
while adjusting for other independent factors. Besides
the regression model for the ﬁrst year, separate models
were run for the second-year and third-year total
healthcare costs respectively, to further explore im-
pacts of initial outcome status on future healthcare
costs over the longer-term follow-up. Considering
potential issues of multiple comparisons, a stringent
signiﬁcance criterion of p<0.01 was adopted for all
statistical analyses, which were performed using Stata
version 11.1 (StataCorp LP, USA).
Results
A total of 126471 adult individuals met the inclusion
criteria. Of these, 34.1% (n=43065) were classiﬁed as
achieving sustained treatment-free status after initial
treatment, 56.6% (n=71543) were continuously on anti-
depressant treatment, and another 9.4% (n=11863) had
cessation of antidepressants for 6 months and later
recontacts during the 18-month observation period.
Table 1(for a full version of this table see Table S1 in
the online supplementary material) reveals notable
differences between groups by initial outcome status,
with the largest difference noted for past treatment his-
tory. Table 2 shows that there were signiﬁcant differ-
ences in the use services and costs between the three
groups; these differences remained robust until the
end of the 3-year follow-up. Although service use
and costs in the ﬁrst year were comparable between
the groups, these measures for patients initially achiev-
ing sustained treatment-free status decreased sharply
in the second and third years and were much lower
than the other groups. Those initially not achieving
sustained treatment-free status contributed to 67.2%
of the total costs for the whole study cohort, and to
77.6% and 76.8% in the second and third years re-
spectively.
Factors associated with initial outcome status
Table 3 shows that patients who had MDD were more
likely to be continuously on antidepressant treatment
whereas newly diagnosed depression was associated
with the other outcomes. Patients with a history of
both antidepressant treatment and a diagnosis of
depression were the most likely to be on continuous
treatment. Being diagnosed with MDD and being pre-
scribed antidepressant treatment by a psychiatrist
(compared to other physicians) were also associated
with higher odds of being continuously on anti-
depressant treatment.
Having certain kinds of PPS (i.e. backache, musculo-
skeletal or gastrointestinal pain) were each associated
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with higher odds of having late recontacts. The pres-
ence of co-morbid mental illnesses tended to be asso-
ciated with higher odds of being on continuous
treatment, with dementia being the only exception
(associated with higher odds of sustained cessation of
antidepressant treatment).
Factors associated with total costs in the
subsequent years
Models for total healthcare costs over the subsequent
3 years (Table 4) revealed that patients who experi-
enced sustained treatment-free status after initial treat-
ment had 33% lower costs in the second year and 22%
lower costs in the third year compared to patients who
experienced late recontacts.
In these models, patients who were diagnosed by
non-psychiatrists on the index date had higher total
costs for the subsequent 3 years, as were those diag-
nosed when they were in-patients. It is notable that,
in the second and third years, total healthcare costs
did not differ between patients prescribed selective
serotonin reuptake inhibitors (SSRIs) and older-
generation antidepressants. The presence of physical
co-morbidities and PPS were associated with higher
costs for all 3 years. Having co-morbid mental illnesses
was generally associated with higher total costs, with
exceptions being generalized anxiety disorder (GAD),
panic disorder and phobic disorder, which were
associated with lower costs.
Discussion
This study has added to the evidence base that initial
treatment outcomes can impact total healthcare costs
over the longer term. Speciﬁcally, patients who experi-
enced sustained treatment-free status from initial treat-
ment were found to have lower costs in the second and
third years, compared to those with less favorable out-
comes. In addition, treatment outcomes and total costs
over time differed by initial choice of antidepressants
in addition to the presence of co-morbid mental
disorders and PPS.
The impact of initial outcome status
The focus in this study on sustained treatment-free
status is relevant in assessing the impacts of initial out-
come status over a longer-term follow-up given a high
relapse/recurrence rate within the ﬁrst 6 to 12 months
of follow-up (Shapiro & Keller, 1981; Lin et al. 1998;
Paykel, 1998). Only 30% of recovered patients were










Male 17129 (39.8) 28326 (39.6) 4316 (36.4)
MDD diagnosis (depression type) 15321 (35.6) 30682 (42.9) 4524 (38.1)
Psychiatrist (physician type) 33658 (78.2) 59224 (82.8) 9599 (80.9)
Clinical setting
Out-patient 41317 (95.9) 69339 (96.9) 11483 (96.8)
Emergency service 220 (0.5) 221 (0.3) 51 (0.4)
In-patient 1528 (3.5) 1983 (2.8) 329 (2.8)
Index AD treatment
SNRI 3899 (9.1) 6465 (9.0) 1027 (8.7)
Other newer ADb 1538 (3.6) 2308 (3.2) 365 (3.1)
TCA 3411 (7.9) 6729 (9.4) 1031 (8.7)
Other older ADc 7708 (17.9) 13919 (19.5) 2091 (17.6)
Flupentixol/melitracen 2233 (5.2) 2716 (3.8) 601 (5.1)
Use of multiple ADs 3971 (9.2) 9573 (13.4) 1175 (9.9)
SSRI 20305 (47.1) 29833 (41.7) 5573 (47.0)
MDD, Major depressive disorder; AD, antidepressant; SNRI, serotonin norepinephrine reuptake inhibitor; TCA, tricyclic
antidepressant; SSRI, selective serotonin reuptake inhibitor.
a The χ2 test was used: all comparisons between groups by initial outcome statuses were statistically signiﬁcant at a
p<0.001.
b Bupropion and mirtazapine.
c Maprotiline, moclobemide and trazodone.
Values given as n (%).
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(n=71543) Late recontact (n=11863)
% using Mean (S.D.)b % using Mean (S.D.)b % using Mean (S.D.)b
The ﬁrst year
Psychiatric out-patient 84.6 6.63 (6.27) 89.2 12.79 (8.52) 87.5 7.43 (6.71)
Psychiatric in-patient 5.9 0.09 (0.43) 7.3 0.13 (0.60) 6.0 0.10 (0.46)
Psychiatric emergency 2.2 0.04 (0.50) 2.2 0.04 (0.47) 2.1 0.04 (0.72)
Non-psychiatric out-patient 98.0 26.42 (24.10) 98.2 30.46 (28.16) 98.6 30.56 (27.55)
Non-psychiatric in-patient 21.3 0.42 (1.15) 18.3 0.32 (0.95) 19.7 0.35 (0.98)
Non-psychiatric emergency 35.2 0.79 (2.53) 33.6 0.88 (4.37) 35.5 0.85 (2.33)
The second year
Psychiatric out-patient 27.1 2.00 (5.06) 85.4 10.37 (8.56) 78.4 6.60 (7.55)
Psychiatric in-patient 1.5 0.02 (0.23) 5.0 0.09 (0.51) 4.9 0.08 (0.42)
Psychiatric emergency 0.7 0.01 (0.33) 1.6 0.03 (0.53) 1.6 0.03 (0.45)
Non-psychiatric out-patient 90.3 24.26 (24.62) 97.8 31.60 (29.28) 98.3 32.02 (28.83)
Non-psychiatric in-patient 14.2 0.24 (0.81) 18.7 0.33 (0.96) 19.2 0.35 (1.00)
Non-psychiatric emergency 25.6 0.49 (1.38) 33.5 0.87 (4.00) 35.4 0.89 (2.72)
The third year
Psychiatric out-patient 28.2 2.33 (5.46) 76.4 9.13 (8.89) 59.6 5.32 (7.28)
Psychiatric in-patient 1.7 0.03 (0.24) 4.6 0.08 (0.46) 3.4 0.06 (0.37)
Psychiatric emergency 0.7 0.02 (0.33) 1.5 0.03 (0.42) 1.4 0.03 (0.37)
Non-psychiatric out-patient 88.0 22.70 (23.42) 95.3 30.14 (28.15) 95.7 29.07 (26.95)
Non-psychiatric in-patient 12.8 0.22 (0.80) 17.4 0.30 (0.92) 16.3 0.29 (0.92)
Non-psychiatric emergency 23.6 0.46 (1.50) 31.3 0.79 (3.23) 30.4 0.72 (2.67)
Healthcare costsc Mean (S.D.) Mean (S.D.) Mean (S.D.)
The ﬁrst year
Psychiatric out-patient 464.99 (553.93) 1139.45 (947.58) 524.62 (568.87)
Psychiatric in-patient 255.33 (1588.13) 364.86 (1956.39) 290.05 (1811.71)
Psychiatric emergency 1.74 (17.15) 1.99 (20.01) 1.91 (21.26)
Non-psychiatric out-patient 1236.20 (2491.82) 1469.44 (4440.36) 1331.53 (2456.17)
Non-psychiatric in-patient 1236.20 (6086.22) 526.14 (2403.05) 589.58 (2747.11)
Non-psychiatric emergency 87.59 (258.85) 79.74 (364.09) 79.97 (240.80)
Total 3282.04 (7143.48) 3581.62 (5886.44) 2817.67 (4585.09)
The second year
Psychiatric out-patient 126.63 (424.18) 940.46 (952.99) 494.09 (684.41)
Psychiatric in-patient 95.32 (1102.80) 287.67 (1821.63) 257.01 (1761.05)
Psychiatric emergency 0.73 (12.33) 2.06 (25.10) 1.76 (21.50)
Non-psychiatric out-patient 1040.82 (2395.60) 1481.47 (4861.05) 1374.46 (2432.50)
Non-psychiatric in-patient 652.49 (4090.22) 791.01 (4416.81) 823.52 (5106.10)
Non-psychiatric emergency 49.90 (190.85) 83.60 (278.42) 84.52 (244.86)
Total 1965.89 (5175.87) 3586.28 (7327.98) 3035.37 (6277.77)
The third year
Psychiatric out-patient 172.36 (517.78) 861.70 (1046.36) 452.90 (779.66)
Psychiatric in-patient 110.64 (1226.52) 291.75 (1943.95) 216.26 (1721.74)
Psychiatric emergency 0.92 (14.80) 2.08 (26.67) 1.86 (23.35)
Non-psychiatric out-patient 1051.93 (2525.14) 1470.94 (2843.33) 1345.12 (2705.43)
Non-psychiatric in-patient 613.92 (4084.97 824.14 (4565.86) 688.09 (3427.75)
Non-psychiatric emergency 53.28 (199.43) 87.98 (293.08) 81.06 (290.45)
Total 2003.07 (5305.59) 3538.61 (6159.07) 2785.30 (5142.88)
S.D., Standard deviation.
a The χ2 test was used for categorical variables and ANOVA for continuous variables: all comparisons between groups
by initial outcome status were statistically signiﬁcant at p<0.001 with the exceptions being percentage using, mean number
of use, and costs for the ﬁrst-year psychiatric emergency services.
b Number of contacts.
c Healthcare costs are expressed in international dollars: the ﬁrst year in 2003–2004 international dollars; the second year
in 2004–2005 international dollars; and the third year in 2005–2006 international dollars.
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Table 3. Multinomial logistic analysis for sustained treatment-free status and late recontact (versus continuous treatment)
Sustained treatment-free status Late recontact
Age group (years) (v. 18–24)
585 0.601 (0.500–0.723)** 0.458 (0.325–0.644)**
75–84 0.402 (0.367–0.441)** 0.423 (0.365–0.492)**
65–74 0.337 (0.311–0.365)** 0.440 (0.388–0.499)**
55–64 0.354 (0.327–0.382)** 0.490 (0.435–0.552)**
45–54 0.381 (0.355–0.408)** 0.508 (0.456–0.566)**
35–44 0.428 (0.400–0.459)** 0.576 (0.518–0.640)**
25–34 0.634 (0.591–0.681)** 0.750 (0.672–0.837)**
Sex
Male v. Female 1.014 (0.979–1.050) 0.897 (0.849–0.948)**
Depression type
Major depression v. Other depression 0.809 (0.781–0.839)** 0.870 (0.823–0.919)**
Past treatment historya
Newly diagnosed depression 3.336 (3.212–3.465)** 2.114 (1.992–2.243)**
Non-newly diagnosed depression with
history of both AD treatment and
depression diagnosis
0.794 (0.750–0.840)** 0.833 (0.764–0.909)**
Physician type
Non-psychiatrist v. Psychiatrist 1.448 (1.383–1.515)** 1.199 (1.116–1.289)**
Clinical setting (v. In-patient)
Out-patient 0.889 (0.806–0.981)* 1.023 (0.871–1.203)
Emergency service 0.969 (0.732–1.282) 1.099 (0.712–1.697)
Index AD treatment (v. SSRI)
SNRI 0.906 (0.853–0.963)** 0.854 (0.777–0.940)**
Other newer ADb 0.947 (0.862–1.040) 0.815 (0.700–0.948)**
TCA 0.851 (0.799–0.907)** 0.885 (0.804–0.975)*
Other older ADc 0.889 (0.848–0.932)** 0.854 (0.793–0.919)**
Flupentixol/melitracen 1.271 (1.170–1.381)** 1.208 (1.065–1.369)**
Use of multiple ADs 0.649 (0.612–0.687)** 0.671 (0.614–0.733)**
Presence of baseline physical illnesses
Chronic obstructive pulmonary disease 1.009 (0.962–1.058) 1.043 (0.969–1.122)
Diabetes mellitus 1.035 (0.980–1.093) 1.002 (0.919–1.091)
Renal disease 1.170 (1.088–1.259)** 1.055 (0.940–1.184)
Cancer 1.232 (1.136–1.336)** 1.106 (0.972–1.258)
Cardiovascular disease 0.990 (0.949–1.033) 1.012 (0.948–1.080)
Presence of baseline PPS
Headache/migraine/dizziness 0.973 (0.939–1.010) 1.030 (0.974–1.089)
Back 1.000 (0.962–1.040) 1.116 (1.052–1.184)**
Musculoskeletal 1.040 (1.003–1.078)* 1.063 (1.005–1.125)*
Gastrointestinal 1.022 (0.986–1.058) 1.068 (1.011–1.128)*
Others 1.025 (0.962–1.091) 1.053 (0.959–1.157)
Presence of baseline mental illnesses
Schizophrenia 0.719 (0.660–0.783)** 0.744 (0.651–0.850)**
Other psychotic disorders 0.917 (0.822–1.023) 0.885 (0.744–1.052)
Substance related 0.874 (0.786–0.972)* 1.003 (0.857–1.175)
Alcohol related 1.153 (0.956–1.390) 1.270 (0.963–1.674)
Drugs related 1.107 (0.884–1.387) 0.978 (0.682–1.403)
Bipolar spectrum disorder 0.784 (0.694–0.887)** 0.843 (0.701–1.013)
Dementia 1.166 (1.069–1.272)** 0.864 (0.740–1.008)
GAD 0.904 (0.840–0.973)** 0.938 (0.840–1.046)
Obsessive–compulsive disorder 0.688 (0.606–0.781)** 0.998 (0.841–1.186)
Panic disorder 0.689 (0.626–0.758)** 0.881 (0.771–1.006)
Phobic disorder 0.741 (0.615–0.893)** 0.784 (0.592–1.038)
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reported to remain in recovery during a previous 1-
year follow-up (Keller & Shapiro, 1981). Rather than
having a sustained recovery, a recent study also
emphasized that 85% of out-patients with MDD have
a chronic and/or recurrent course (Rush et al. 2012). It
is thus important to evaluate the effect of sustained
treatment-free status while taking into account both
early relapses/recurrences and chronic depression
under continuous treatment.
Based on the same proxy measure of outcomes, pre-
vious studies have shown that 12-month costs were
signiﬁcantly lower for remitters than non-remitters
(Sicras-Mainar et al. 2010a; Byford et al. 2011), but
beyond this point, the impact of outcome status on
healthcare costs has remained less clear. In the current
study, patients who achieved sustained treatment-free
status had lower total costs in the second and third
years compared to those with other initial outcomes,
indicating an effect of initial outcome on total health-
care costs over a prolonged period of time. In addition,
the evidence from previous studies has been limited
to examining service use and costs in the ﬁrst 6 or
12 months following initial treatment, and these are
likely to be linked to the treatment that may have
led to the outcomes. We found that ﬁrst-year costs
were higher for those patients achieving sustained
treatment-free status than for those who experienced
late recontacts (Table 2). An interpretation of this result
could be that the higher total ﬁrst-year costs for those
achieving sustained treatment-free status may be due
to the treatment required to achieve the outcome
status, which then reduces costs in subsequent years.
On the contrary, patients with insufﬁcient treatment
in the ﬁrst year may then have higher costs sub-
sequently as a result of not experiencing sustained
treatment-free status. As shown in Table 2, those not
achieving sustained treatment-free status contributed
to 67.2% of the total costs for the whole study cohort
in the ﬁrst year, and this increased to 77.6% and
76.8% in the second and third years respectively.
Depression type, choice of initial antidepressants
and other clinical characteristics
Our results suggest that the nature of depressive dis-
orders is important for determining treatment out-
comes (Sobocki et al. 2006). For instance, a diagnosis
of MDD, being diagnosed by a psychiatrist, or the
presence of a prior history of treatment/or a diagnosis
can be indicators of greater disease severity or chronic/
relapsing course and thus poorer outcome. However,
non-psychiatric medical conditions constitute an im-
portant driver of total healthcare costs. Patients
initially diagnosed in in-patient settings or diagnosed
by a non-psychiatrist, possibly implying the presence
of medical conditions, had higher total healthcare
costs for each of the 3 years during the follow-up,
along with increased age and co-morbidities.
Among initial antidepressants, ﬂupentixol/melitra-
cen was shown to be associated with higher odds of
achieving sustained treatment-free status than SSRIs;
this can be better understood in the context that only
15.9% of the patients initially prescribed ﬂupentixol/
melitracen in this study were cases with MDD. The
ﬁnding that patients with depressive disorders not
fulﬁlling the criteria for MDD were more likely to be
prescribed ﬂupentixol/melitracen is particularly rel-
evant because a substantial proportion of out-patients
in real-world settings were reported not to meet the
criteria of minimum baseline severity for antidepress-
ant efﬁcacy trials and those with less severe depressive
symptoms were associated with better outcomes
(van der Lem et al. 2011).
Compared to patients prescribed SSRIs, those pre-
scribed tricyclic antidepressants (TCAs) or other older-
generation antidepressants had costs that did not differ
Table 3 (cont.)
Sustained treatment-free status Late recontact
Post-traumatic stress disorder 0.891 (0.614–1.291) 0.787 (0.440–1.409)
Sleep disorder 0.918 (0.882–0.955)** 1.038 (0.977–1.102)
Attention deﬁcit hyperactivity disorder 0.884 (0.461–1.696) 0.594 (0.176–2.007)
AD, Antidepressant; SNRI, serotonin norepinephrine reuptake inhibitor; TCA, tricyclic antidepressant; SSRI, selective
serotonin reuptake inhibitor; PPS, painful physical symptoms; GAD, generalized anxiety disorder.
a Reference group is non-newly diagnosed depression with history of either AD treatment or depression diagnosis.
b Bupropion and mirtazapine.
c Maprotiline, moclobemide and trazodone.
Values given as odds ratio (99% conﬁdence interval).
* p<0.01, ** p<0.001.
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Table 4. Multivariate analysis of total healthcare costs for the consecutive 3 years
First-year costs Second-year costs Third-year costs
Outcome status (v. late recontact)
Sustained treatment-free status 1.051 (1.030–1.072)** 0.668 (0.652–0.684)** 0.777 (0.757–0.798)**
Continuous treatment 1.222 (1.199–1.246)** 1.087 (1.062–1.112)** 1.176 (1.147–1.206)**
Age group (years) (v. 18–24)
5 85 1.723 (1.619–1.834)** 2.737 (2.518–2.975)** 2.964 (2.694–3.261)**
75–84 1.469 (1.426–1.514)** 2.278 (2.194–2.365)** 2.409 (2.312–2.509)**
65–74 1.250 (1.218–1.283)** 1.892 (1.832–1.955)** 2.027 (1.957–2.099)**
55–64 1.080 (1.053–1.108)** 1.577 (1.528–1.626)** 1.699 (1.643–1.757)**
45–54 0.968 (0.946–0.990)** 1.339 (1.302–1.378)** 1.405 (1.363–1.448)**
35–44 0.935 (0.915–0.957)** 1.235 (1.202–1.270)** 1.295 (1.257–1.334)**
25–34 0.932 (0.910–0.954)** 1.191 (1.157–1.226)** 1.226 (1.188–1.265)**
Sex
Male v. Female 1.090 (1.077–1.102)** 1.046 (1.031–1.060)** 1.067 (1.051–1.083)**
Depression type
Major depression v. Other depression 1.079 (1.067–1.092)** 1.065 (1.050–1.080)** 1.074 (1.058–1.091)**
Past treatment historya
Newly diagnosed depression 1.045 (1.031–1.058)** 0.980 (0.965–0.996)* 0.982 (0.966–1.000)*
Non-newly diagnosed depression with
history of both AD treatment and
depression diagnosis
1.079 (1.061–1.098)** 1.061 (1.038–1.084)** 1.061 (1.036–1.086)**
Physician type
Non-psychiatrist v. Psychiatrist 1.035 (1.020–1.051)** 1.029 (1.010–1.049)** 1.028 (1.008–1.049)**
Clinical setting (v. In-patient)
Out-patient 0.450 (0.436–0.465)** 0.671 (0.644–0.699)** 0.684 (0.654–0.716)**
Emergency service 0.672 (0.613–0.737)** 0.816 (0.728–0.915)** 0.779 (0.688–0.881)**
Index AD treatment (v. SSRI)
SNRI 1.176 (1.153–1.199)** 1.079 (1.053–1.105)** 1.069 (1.041–1.097)**
Other newer ADb 1.119 (1.085–1.154)** 1.076 (1.036–1.118)** 1.024 (0.983–1.067)
TCA 0.906 (0.888–0.924)** 1.011 (0.986–1.037) 0.982 (0.956–1.009)
Other older ADc 0.950 (0.936–0.965)** 1.003 (0.984–1.022) 1.020 (0.999–1.041)
Flupentixol/melitracen 0.880 (0.856–0.905)** 1.007 (0.973–1.041) 0.978 (0.943–1.014)
Use of multiple ADs 1.120 (1.100–1.140)** 1.089 (1.065–1.113)** 1.082 (1.056–1.108)**
Presence of baseline physical illnesses
Chronic obstructive pulmonary disease 1.093 (1.076–1.109)** 1.089 (1.069–1.110)** 1.131 (1.108–1.154)**
Diabetes mellitus 1.220 (1.199–1.242)** 1.278 (1.250–1.306)** 1.288 (1.258–1.319)**
Renal disease 1.178 (1.150–1.207)** 1.235 (1.198–1.273)** 1.251 (1.210–1.293)**
Cancer 1.291 (1.257–1.326)** 1.214 (1.173–1.257)** 1.259 (1.212–1.307)**
Cardiovascular disease 1.128 (1.113–1.143)** 1.117 (1.099–1.136)** 1.068 (1.049–1.087)**
Presence of baseline PPS
Headache/migraine/dizziness 1.028 (1.016–1.040)** 1.031 (1.016–1.045)** 1.049 (1.032–1.065)**
Back 1.056 (1.043–1.069)** 1.029 (1.013–1.045)** 1.037 (1.020–1.054)**
Musculoskeletal 1.060 (1.048–1.073)** 1.076 (1.061–1.092)** 1.074 (1.058–1.091)**
Gastrointestinal 1.048 (1.036–1.060)** 1.029 (1.015–1.044)** 1.039 (1.024–1.055)**
Others 1.078 (1.056–1.099)** 1.049 (1.024–1.076)** 1.061 (1.033–1.090)**
Presence of baseline mental illnesses
Schizophrenia 1.571 (1.530–1.613)** 1.745 (1.689–1.803)** 1.785 (1.723–1.848)**
Other psychotic disorders 1.074 (1.038–1.111)** 1.068 (1.024–1.114)** 1.155 (1.104–1.209)**
Substance related 1.224 (1.184–1.265)** 1.287 (1.235–1.341)** 1.328 (1.270–1.388)**
Alcohol related 1.369 (1.291–1.452)** 1.469 (1.364–1.582)** 1.553 (1.431–1.686)**
Drugs related 1.088 (1.012–1.170)** 1.033 (0.943–1.131) 1.070 (0.969–1.182)
Bipolar spectrum disorder 1.151 (1.111–1.194)** 1.176 (1.124–1.230)** 1.177 (1.122–1.235)**
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signiﬁcantly in the second and third years whereas
initial prescription of multiple antidepressants was
associated with higher total costs in each of the
3 years. This is consistent with a previous systematic
review that patients using TCAs generally had health-
care costs comparable to those using SSRIs in database
studies (Pan et al. 2012). Our ﬁndings add to the
evidence base by showing that, after taking into
account initial outcome status, total healthcare costs
do not differ between patients prescribed SSRIs and
older-generation antidepressants over a longer-term
follow-up but initial prescription of multiple anti-
depressants is associated with higher costs.
PPS
Patients with PPS have been shown to be less likely
to achieve remission following acute treatment for
depression (Fava et al. 2004), and our study concurs
with these studies in ﬁnding that having certain PPS
is associated with late recontacts even after a 6-month
treatment-free status. Moreover, we previously found
that the presence of baseline PPS consistently predicts
higher 12-month healthcare costs of patients with
depression (Pan et al. 2013a), consistent with prior
studies that patients with PPS and depression had
higher service utilization and costs (Gameroff &
Olfson, 2006). The current ﬁndings also showed that
the presence of each kind of PPS at baseline is associated
with an increase in total healthcare costs, not only in the
ﬁrst year but also in the second and third years.
Co-morbid mental disorders
The presence of most co-morbid mental disorders was
associated with decreased odds of having sustained
treatment-free status and increased odds of staying
on continuous treatment, with dementia being the
only exception. Depressive symptoms in dementia
rarely persist over a longer-term follow-up, for
example 2 years (Aalten et al. 2005; Savva et al. 2009;
Wetzels et al. 2010). Over time, depression has tended
to decrease with a high resolution rate (Bergh et al.
2011) whereas apathy has increased in these patients
(Aalten et al. 2005; Wetzels et al. 2010). Therefore, one
possible interpretation of our results could be that
depression occurs over certain stages in the course of
dementia and disappears later when the illness pro-
gresses.
The presence of co-morbid mental disorders
increased costs in the following years with the excep-
tions of GAD, panic and phobic disorder. Patients
with anxiety disorders have been shown to be less
likely to use services compared to those with mood
disorders, and also to have reduced perceived need
for help (Mojtabai et al. 2002; Alonso et al. 2004).
Despite potential confounding from differences in cod-
ing systems, it seems probable that the lower service
use and costs of these patients as seen in our study
may be inﬂuenced by the nature of their co-morbid
anxiety disorders. The extent to which the co-morbid
anxiety disorders inﬂuences health-service use and
costs of patients with depression warrants further
research.
Table 4 (cont.)
First-year costs Second-year costs Third-year costs
Dementia 1.199 (1.166–1.234)** 1.226 (1.183–1.271)** 1.257 (1.208–1.308)**
GAD 0.983 (0.961–1.005) 0.957 (0.930–0.984)** 0.966 (0.937–0.995)*
Obsessive–compulsive disorder 1.031 (0.993–1.070) 1.034 (0.988–1.082) 1.084 (1.032–1.138)**
Panic disorder 0.923 (0.898–0.949)** 0.910 (0.880–0.942)** 0.957 (0.923–0.993)*
Phobic disorder 0.943 (0.892–0.997)* 0.974 (0.910–1.044) 0.936 (0.870–1.008)
Post-traumatic stress disorder 1.067 (0.954–1.193) 1.157 (1.009–1.326)* 1.295 (1.119–1.499)**
Sleep disorder 1.029 (1.016–1.042)** 1.047 (1.030–1.063)** 1.042 (1.025–1.060)**
Attention deﬁcit hyperactivity disorder 0.890 (0.717–1.104) 0.978 (0.750–1.275) 1.024 (0.771–1.361)
Baseline total healthcare expenditures
(in 1000 international dollars)
1.159 (1.155–1.162)** 1.161 (1.156–1.166)** 1.157 (1.151–1.162)**
AD, Antidepressant; SNRI, serotonin norepinephrine reuptake inhibitor; TCA, tricyclic antidepressant; SSRI, selective
serotonin reuptake inhibitor; PPS, painful physical symptoms; GAD, generalized anxiety disorder.
a Reference group is non-newly diagnosed depression with history of either AD treatment or depression diagnosis.
b Bupropion and mirtazapine.
c Maprotiline, moclobemide and trazodone.
Values given as relative risk (99% conﬁdence interval).
* p<0.01, ** p<0.001.
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Implications and policy recommendations
Choice of index antidepressants between SSRIs and
older-generation antidepressants did not show any
signiﬁcant differences in healthcare costs in the second
and third years whereas prescription of multiple anti-
depressants at the index visit, although possibly
inﬂuenced by physician preferences and the nature of
the depressive disorders, was associated with higher
total healthcare costs in the following years, implying
that initial prescription of a single antidepressant
may be preferable to constrain costs.
Patients not achieving sustained treatment-free
status were found to have higher healthcare costs in
the subsequent years in this study. As shown in a
recent study (Pan et al. 2013b), patients remaining
engaged with antidepressant treatment within the
ﬁrst 3 months after the index visit have higher odds
of achieving sustained treatment-free status and
lower odds of having late recontacts over the
18-month period. It seems that endeavors to reduce
early attrition, probably through shared decision mak-
ing and good patient–physician communication, and
to improve initial treatment outcome of depression
should be emphasized so to reduce total healthcare
costs in the subsequent years.
Limitations
There are limitations to this study. As service-use data
contained in the NHIRD include only information
from health services provided by the NHI system in
Taiwan, the perspective of the current analysis was
limited, and we were not able to analyze wider econ-
omic impacts outside the health system. The lack of
information on clinical symptoms and the use of a
proxy deﬁnition are also limitations. We are aware
that stopping a psychopharmacological therapy may
have complex reasons other than achieving good clini-
cal response, for example experiences of side-effects of
medications. However, with the 18-month observation
period in this study, the sustained treatment-free status
seems likely to indicate initial treatment effectiveness
without later clinical ﬂuctuations sufﬁcient to trigger
a medical contact when simultaneously specifying
another subgroup of subjects who have later recon-
tacts, which may reﬂect changes in clinical conditions
in which help-seeking is considered beneﬁcial (Pan
et al. 2013b).
Moreover, as this was a secondary analysis of a large
healthcare database, we are aware that the analysis
of the pattern of care and related costs of individual
outcomes over time may require combining further
information from other sources, such as bottom-up
longitudinal studies of treated prevalence and prior
expert knowledge, to give ﬁrmer conclusions. A re-
plication study with a more recent cohort in Taiwan
may also be warranted to reﬂect changes in health-
care systems over time, along with its associated im-
pacts on subjects’ service use and healthcare costs.
Additionally, future research adopting a cost–inci-
dence design may help to enhance our understanding
of the impact of course of depression on service use
and costs.
Factors that may further limit generalizability of the
current ﬁndings include differences in the insurance
system and the role of private health insurance
between countries. In this study most patients with
depression received specialized treatment from psy-
chiatrists, and this is very different from countries in
which the referral system is emphasized. Within the
NHI system in Taiwan, patients can easily have access
to specialists without referrals from general prac-
titioners and with affordable co-payments. Therefore,
this unique medical environment of Taiwan should
be borne in mind when interpreting the current results.
Conclusions
This study, based on a large national cohort, indicates
that the outcome status of initial treatment exerts an
impact on total healthcare costs in the second and
third years after the index date. Furthermore, the pres-
ence of co-morbid anxiety disorders and PPS had an
impact on the total healthcare costs of patients with
depression over the longer-term follow-up. It is impor-
tant to both physicians and policy makers to further
improve initial treatment outcomes of depression
through effective strategies. Future endeavors to ex-
plore the impacts of co-morbid anxiety disorders and
PPS on health service use and treatment of depres-
sion are warranted.
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